Pr ot oc ol I 8 F- M C- G P G K( b) 
A Ra n d o mize d, D o u ble- bli n d, Place b o- C o ntr olle d Trial C o m pari n g t he Efficac y a n d Safet y of T hree 
Tirze pati de D oses Vers us Place b o i n Patie nts Wit h T y pe 2 Dia betes, I na de q uatel y C o ntr olle d Wit h Diet a n d 
E xercise Al o ne 
N C T 0 3 9 5 4 8 3 4  
A p pr o val Date: 1 5- A pr- 2 0 2 0 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e 1
L Y 3 2 9 8 1 7 6 Pr ot o c ol I 8 F -M C -G P G K ( b) 
A R a n d o mi z e d, D o u bl e -bli n d, Pl a c e b o -C o ntr oll e d Tri al 
C o m p ari n g t h e Effi c a c y  a n d S af et y of T hr e e Tir z e p ati d e 
D o s e s v er s u s Pl a c e b o i n P ati e nt s wit h T y p e 2 Di a b et e s ,
I n a d e q u at el y C o ntr ol l e d wit h Di et a n d E x er ci s e A l o n e 
( S U R P A S S -1) 
C o nfi d e nti al I nf or m ati o n 
T h e i nf or m ati o n c o nt ai n e d i n t hi s d o c u m e nt i s c o nfi d e nti al a n d i s i nt e n d e d f or t h e u s e of 
cli ni c al i n v e sti g at or s.  It i s t h e pr o p ert y of Eli Lill y a n d C o m p a n y or it s s u b si di ari e s a n d 
s h o ul d n ot b e c o pi e d b y or di stri b ut e d t o p er s o n s n ot i n v ol v e d i n t h e cli ni c al i n v e sti g ati o n of 
tir z e p ati d e ( L Y 3 2 9 8 1 7 6) , u nl e s s s u c h p er s o n s ar e b o u n d b y a c o nfi d e nti alit y a gr e e m e nt 
wit h Eli Lill y a n d C o m p a n y or it s s u b si di ari e s .  
N ot e t o R e g ul at or y A ut h oriti e s:   T hi s d o c u m e nt m a y c o nt ai n pr ot e ct e d p er s o n al d at a 
a n d/ or c o m m er ci all y c o nfi d e nti al i nf or m ati o n e x e m pt fr o m p u bli c di s cl o s ur e. Eli Lill y a n d 
C o m p a n y r e q u e st s c o n s ult ati o n r e g ar di n g r el e a s e/r e d a cti o n pri or t o a n y p u bli c r el e a s e. I n 
t h e U nit e d St at e s, t hi s d o c u m e nt i s s u bj e ct t o Fr e e d o m of I nf or m ati o n A ct ( F OI A) 
E x e m pti o n 4 a n d m a y n ot b e r e pr o d u c e d or ot h er wi s e di s s e mi n at e d wit h o u t t h e writt e n 
a p pr o v al of Eli Lill y a n d C o m p a n y or it s s u b si di ari e s. 
Tir z e p ati d e ( L Y 3 2 9 8 1 7 6) 
Eli Lill y a n d C o m p a n y 
I n di a n a p oli s, I n di a n a U S A 4 6 2 8 5 
Pr ot o c ol El e ctr o ni c all y Si g n e d a n d A p pr o v e d b y Lill y : 1 3 -D e c -2 0 1 8
A m e n d m e nt ( a) El e ctr o ni c all y Si g n e d a n d A p pr o v e d b y Lill y : 0 3 -M a y -2 0 1 9 
A m e n d m e nt ( b) El e ctr o ni c all y Si g n e d a n d A p pr o v e d b y Lill y 
o n a p pr o v al d at e pr o vi d e d b el o w. 
A p pr o v al D at e: 1 5- A pr- 2 0 2 0 G M T 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e 2
L Y 3 2 9 8 1 7 6 T a bl e of C o nt e nt s 
S e cti o n P a g e 
Pr ot oc ol  I 8 F -M C -G P G K( b) A Ra n d o mize d, D o u ble -bli n d, Place b o -
C o ntr olle d Trial C o m par i n g t he Efficac y a n d Safet y o f T hree 
Ti rze pati de D oses vers us Pl ace b o i n Pati e nts wi t h  T y pe 2 Di a betes, 
I na de q uatel y C o ntr olle d wit h Diet a n d E xercise Al o ne ( S U R P A S S - 1) ................................ [ADDRESS_1239650] u d y  Rati o nale ............................................................................................................ 2 1 
3. 2. Bac k gr o u n d .................................................................................................................. 2 1 
3. 3. Be nefit/ Ris k Assess me nt .............................................................................................. [ADDRESS_1239651] u gs ......................................................................................................... 3 7 
7. 4. 2. I ni ti at i o n of Ne w A nt i h y per gl yce mic Me dicat i o n................................................. 3 7 
7. 5. Pre parati o n/ Ha n dli n g/ St ora ge/ Acc o u nta bilit y............................................................... 3 7 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239652] ......................................................................... 4 9 
9. 2. 2. 1. H y p o gl yce mia ................................................................................................ 4 9 
9. 2. 2. 2. Se vere, Persiste nt H y per gl yce mia ................................................................... 5 0 
9. 2. 2. 3. Pa ncreat itis ..................................................................................................... 5 1 
9. 2. 2. 4. T h y r oi d Mali g na ncies a n d C -Cell H y per plasia ................................................ 5 2 
9. 2. 2. 5. Maj or A d verse Car di o vasc ular E ve nts ............................................................ 5 2 
9. 2. 2. 6. S u pra ve ntric ular Arr h yt h mias a n d Car diac C o n d ucti o n 
Di s or ders ........................................................................................................ 5 2 
9. 2. 2. 7. H y perse nsi ti vi t y  E ve nts .................................................................................. 5 3 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239653] u g A nt i b o dies ............................................................................... 5 3 
9. 2. 2. 8. Di a bet ic Ret i n o pat h y  C o m plicat i o ns ............................................................... 5 3 
9. 2. 2. 9. He pat o biliar y  Dis or ders .................................................................................. 5 3 
9. 2. 2. 1 0. Se vere Gastr oi ntesti nal A d verse E ve nts .......................................................... 5 3 
9. 2. 2. 1 1. Ac ute Re nal E ve nts ........................................................................................ 5 3 
9. 2. 2. 1 2. Meta b o lic Aci d osis, I ncl u di n g Dia betic Ket oaci d osis ..................................... 5 4 
9. 2. 2. 1 3. A m p utati o n/ Peri p heral Re vasc ularizat i o n....................................................... 5 4 
9. 2. 2. 1 4. Maj or De pressi ve Dis or der/ S uici dal I deat i o n.................................................. 5 4 
9. 2. 3. C o m plai nt Ha n dli n g ............................................................................................. 5 4 
9. 3. Treat me nt of O ver d ose ................................................................................................ . 5 4 
9. 4. S af et y........................................................................................................................... 5 4 
9. 4. 1. Electr ocar di o gra ms .............................................................................................. 5 4 
9. 4. 2. Vi t al  Si g ns........................................................................................................... 5 5 
9. 4. 3. La b orat or y  Tests .................................................................................................. 5 5 
9. 4. 4. I m m u n o ge nicit y Assess me nts .............................................................................. 5 5 
9. 4. 5. S af et y M o ni t ori n g ................................................................................................ 5 6 
9. 4. 5. 1. He pati c Safet y M o ni t ori n g .............................................................................. 5 6 
9. 5. P har mac o ki net ics ......................................................................................................... 5 7 
9. 6. P har mac o d y na mics ...................................................................................................... 5 7 
9. 7. P har mac o ge n o mics ...................................................................................................... 5 7 
9. 7. 1. W h o le Bl o o d Sa m ple(s) f or P har mac o ge net ic Researc h ....................................... [ADDRESS_1239654] ics .................................................................................... 6 3 
1 0. 3. 2. 3. C o nc o mita nt T hera p y ..................................................................................... 6 3 
1 0. 3. 2. 4. Treat me nt C o m plia nce .................................................................................... 6 3 
1 0. 3. 3. Efficac y A nal yses ................................................................................................ 6 3 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e 5
L Y 3 2 9 8 1 7 6 1 0. 3. 3. 1 .Pri mar y A nal yses ........................................................................................... 6 3 
1 0. 3. 3. 2. Sec o n dar y  A nal yses ........................................................................................ 6 4 
1 0. 3. 3. 3. Terti ar y/ E x pl orat or y  A nal yses ........................................................................ 6 5 
1 0. 3. 4. S af et y A nal yses .................................................................................................... 6 5 
1 0. 3. 4. 1. H y p o gl yce mic E ve nts ..................................................................................... 6 5 
1 0. 3. 4. 2. Gastr oi ntesti nal E ve nts ................................................................................... 6 5 
1 0. 3. 4. 3. A d j u dicate d Car di o vasc ular E ve nts ................................................................ 6 5 
1 0. 3. 4. 4. Ce ntral  La b orat or y  Meas ures, Vi t al  Si g ns, a n d 
Electr ocar di o gra ms ......................................................................................... 6 5 
1 0. 3. 5. P har mac o ki net ic/ P har mac o d y na mic A nal yses ...................................................... 6 6 
1 0. 3. 6. E val uat i o n of I m m u n o ge nicit y............................................................................. 6 6 
1 0. 3. 7. Ot her A nal yses ..................................................................................................... 6 6 
1 0. 3. 7. 1. Heal t h  Ec o n o mics ........................................................................................... 6 6 
1 0. 3. 7. 2. S u b gr o u p A nal yses ......................................................................................... 6 6 
1 0. 3. 8. I nteri m A nal yses .................................................................................................. 6 7 
1 1. Refere nces ........................................................................................................................ 6 8 
1 2. A p pe n dices ....................................................................................................................... 7 0 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239655] i ves a n d E n d p o i nt s............................................................................... 2 3 
Ta ble G P G K. 3. Treat me nt Re gi me ns ...................................................................................... 3 5 
Ta ble G P G K. 4. Descri pt i o n of A nal ysis P o p ulat i o n a n d Data Sets .......................................... 6 1 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239656] u d y  desi g n f or Cli nical Pr ot oc ol I 8 F -M C -G P G K. .................. 2 5 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239657] u d y  Pr oce d ures d ue t o t he C O VI D -1 9 Pa n de mic ...................... 8 7 
A p pe n di x 9. Pr ot oc ol  A me n d me nt I 8 F -M C -G P G K( b) 
A Ra n d o mize d, D o u ble -bli n d, Pl ace b o C o ntr olle d Trial C o m par i n g t he 
Efficac y a n d Safet y of  T hree Ti rze pati de D ose s vers us Pl ace b o i n 
P ati e nts wi t h  T y pe 2 Di a betes, I na de q uatel y  C o ntr olle d wi t h  Diet a n d 
E xercise Al o ne ( S U R P A S S - 1) ....................................................................... 8 8 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239658] u d y: 
A Ra n d o mize d, D o u ble -bli n d, Pl ace b o -C o ntr olle d Trial C o m par i n g t he Efficac y a n d Safet yof  
T hree Ti rze pati d e D oses vers us Pl ace b o i n Pati e nts wi t h  T y pe 2 Di a betes ,I na de q uatel y 
C o ntr ol le d wi t h  Diet a n d E xercise Al o ne ( S U R P A S S - 1) 
R ati o n ale: 
T y pe 2 di a betes m elli t us ( T 2 D M) is a m eta b o lic c o n dit i o n c haracterize d b y i m paire d gl yce mic 
c o ntr ol  ca use d b y  i ncrease d i ns uli n resista nce a n d pr o gressi ve beta -cell fail ure a n d c o nse q ue nt l y 
i na de q uate i ns uli n secret i o n.  I n a d dit i o n t o lifest yle i nter ve nt io n i ncl u di n g m e dical n utri ti o n 
t h era p y  a n d p h ysical t hera p y, gl uc ose -l o weri n g me di cat i o ns are us uall y  re q uire d f or i m pr o vi n g 
gl yce mic c o ntr ol  i n pat ie nt s wi t h  T 2 D M ( A D A 2 0 1 8; Da vies et al. 2 0 1 8 ). 
Ti rze pati d e is a 3 9 -a mi n o aci d s y nt het ic pe pti de wit h a g o nis t a cti vit y at b ot h t he 
gl uc ose - de pe n de nt i ns uli n otr o pic p ol y pe pti de ( GI P ) a n d gl uca g o n -li ke pe pti de - 1 ( G L P) rece pt ors.  
Its  str uct ure is base d o n t he GI P se q ue nce a n d i ncl u des a C 2 0 fatt y  di -a ci d m oi et y t h at  
It is a d mi niste re d o nce wee kl y ( Q W) b y s u bc uta ne o us i nject i o n. 
St u d y  I 8 F -M C -G P G K ( St u d y  G P G K ) is a P hase 3, m ul ti ce nter, ra n d o mize d, d o u ble- bli n d , 
parallel , i nter nati o n al , place b o -c o ntr olle d, [ADDRESS_1239659] u d y .
O bjecti ve(s)/ E n d p oi nts: 
O bjecti ves E n d p oi nts 
Pri m ar y 
T o de m o nstrate t hat tirze pati de Q W 5m g , 
a n d/ o r 1 0 m g, a n d / o r1 [ADDRESS_1239660] b o i n H b A 1c c ha n ge fr o m baseli ne t o 4 0 
wee ks Mea n c ha n ge i n H b A 1c 
Ke y Sec o n d ar y (c o ntr olle d f o r t y pe 1 err or) 
T o de m o nstrate s u peri orit y of tirze pati de Q W 
5 m g, a n d/ or 1 0 m g, a n d / or [ADDRESS_1239661] b o 
at 4 0 wee ks f or: Mea n c ha n ge i n b o d y wei g ht 
Pr o p orti o n of patie nts wit h H b A 1c tar get 
val ues of < 7. 0 % ( <5 3 m m ol/ m ol) 
Mea n c ha n ge i n fasti n g ser u m gl uc ose (ce ntral 
la b orat o r y ) 
Pr o p orti o n of patie nts wit h H b A 1c tar get 
val ues of < 5. 7 % ( < 3 9 m m ol/ m ol) C CI 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e 1 0 
L Y 3 2 9 8 1 7 6 O bjecti ves E n d p oi nts 
A d diti o n al Sec o n d ar y ( n ot c o ntr olle d f or t y pe 1 
err or) 
T o c o m pare tirze pati de Q W [ADDRESS_1239662] b o at 4 0 wee ks f or: Pr o p orti o n of patie nts wit h H b A 1c tar get of 
≤ 6. 5 % ( ≤4 8 m m ol/ m ol) 
Mea n c ha n ge i n dail y a vera ge 7-p oi nt self -
m o nit ore d bl o o d gl uc ose pr ofiles fr o m 
baseli ne 
Pr o p orti o n of patie nts w h o ac hie ve d wei g ht 
l oss of ≥ 5 % , ≥ 1 0 % ,a n d ≥ 1 5 % 
S afet y 
T o c o m pare t he safet y of tirze pati de Q W 
5m g, [ADDRESS_1239663] b o f or: Treat me nt -e mer ge nt a d verse e ve nts ( T E A Es) 
Earl y  disc o nti n uati o n of st u d y dr u g d ue t o 
a d verse e ve nts ( A Es )
A dj u dicate d pa ncreatic A Es 
Ser u m calcit o ni n 
Inci de nce of aller gic a n d h y perse nsiti vit y 
reacti o ns 
I nci de nce of treat me nt -e mer ge nt a nti -dr u g 
a nti b o dies t o tirze pati de 
Mea n c ha n ge i n s yst olic a n d diast olic bl o o d 
press ure a n d heart rate fr o m baseli ne 
Occ urre nce of h y p o gl yce mic e pis o des 
Ti me t o i nitiati o n of resc ue t hera p y f or se vere 
persiste nt h y per gl yce mia 
P h ar m ac o ki netics 
T o c haracterize t he p har mac o ki netics of 
tirze pati de Q W 5 m g, 1 0 m g, a n d 1 5 m g a n d 
t he relati o ns hi ps bet wee n tirze pati de e x p os ure 
a n d safet y, t olera bilit y, a n d efficac y meas ures P o p ulati o n p har mac o ki netic a n d 
p har mac o d y na mic para meters 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239664] u d y Desi g n:   
St u d y  G P G K is a m ul ti ce nter, ra n d o mize d, d o u ble- bli n d, parallel, i nter nat i o nal, 
pl ace b o -c o ntr olle d, [ADDRESS_1239665] u d y .
Tre at me nt Ar ms a n d D ur ati o n:   
St u d y  G P G K will c o nsist of 3 peri o ds:  a n a p pr o xi matel y 3 -wee k scree ni n g/lea d -i n peri o d, 
f o ll o we d b y a 4 0 -wee k treat m e nt peri o d ,a n d a 4 -wee k safet y f o ll o w- u p p eri o d .  Patie nts will be 
ra n d o mize d i n a 1: 1: 1: 1 rati o (tirze pat i de [ADDRESS_1239666] ace b o).  Patie nts will be stratifie d base d o n c o u ntr y , baseli ne H b A 1c [ ≤ 8. 5 % ( ≤ 6 9 m m o l/ m o l) 
or >8. 5 % ( > 6 9 m m o l/ m o l)] ,a n d a n y  p ast pri or us e ( Yes or N o) of a n y oral a nt i d ia bet ic 
me dicat i o n). 
N u m ber of P atie nts :
A t otal o f a p pr o xi matel y  4 7 2 p ati e nts ( 1 1 8 pati e nts per treat m e nt gr o u p) will be ra n d o mize d .
St atistic al A n al ysis: 
Effic ac y A n al yses 
Efficac y will be assesse d usi n g t he m o difie d i nte nt -t o -treat p o p ulati o n, w hic h c o nsists of all 
ra n d o ml y assi g ne d partici pa nts w h o are e x p ose d t o at least [ADDRESS_1239667] b o rel at i ve t o t he 
pri mar y  m eas ure of mea n c ha n ge i n H b A 1c val ues fr o m baseli ne t o 4 0- wee k visit.  T he 
“efficac y” est i ma n d, re prese nts efficac y pri or t o disc o nti n uati o n o f st u d y  dr u g wi t h o ut 
c o nf o u n di n g effects of resc ue t hera p y  f or p ersi ste nt se vere h y per gl yce mia.  T he “treat me nt -
re gi me n” est i ma n d, re prese nts t he efficac y irres pecti ve of a d here nce t o i n vest i gat i o nal pr o d uct or 
i nt r o d ucti o n of  resc ue t hera p y  f or p ersi ste nt se vere h y per gl yce mia.  
F or t he F D A a n d p ossi bl y ot her re g ulat or y  a ge n cies , t he pri mar y  efficac y  assess me nt will  b e 
g ui de d b y  t he “treat m e nt -re gi me n” est i ma n d.  T his assess me nt will a nal yze c ha n ge i n H b A 1c 
val ues fr o m baseli ne t o 4 0- wee k visit usi n g a n a nal ysis o f c o vari a nce ( A N C O V A )wi t h  t er m s: 
treat m e nt, c o u ntr y, a n y past pri or use ( Yes or N o) of a n y oral a nt i d ia bet ic me dicat i o n, a n d 
baseli ne H b A 1c as a c o variate .  T he A N C O V A a nal ysis will be c o n d ucte d usi n g t h e f ull anal ysis 
set at [ADDRESS_1239668] u g a n d/ or i nit iat i o n of resc ue me dicat i o n (retrie ve d dr o p o uts).  
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239669] ical i nfere nce o ver m ult i ple 
i m p utati o ns will be g ui de d b y t he met h o d pr o p ose d b y  R u bi n ( 1 9 8 7). 
F or all ot her p ur p oses, t he pri mar y efficac y assess me nt, g ui de d b y t he “efficac y” est i ma n d, will 
use efficac y a nal ysis se t w hi c h c o nsists of data o b tai ne d bef ore t he i nit iat i o n of a n y  resc ue 
t h era p y  a n d bef ore pre m at ure treat m e nt di sc o nt i n uati o n.  T he a nal ysis m o del f or c ha n ge i n 
H b A 1c val ues fr o m baseli ne assesse d o ver ti me will  b e a mi xe d m o d el  f or re peate d m eas ures 
( M M R M) wi t h  ter ms :  treat m e nt, visit, treat me nt -b y -visit i nteracti o n ,c o u ntr y , a n y past pri or use 
( Yes or N o) of a n y  or al  a nti dia betic m e dicat i o nas fi xe d effects, baseli ne H b A 1c as a c o variate, 
a n d pat ie nt as a ra n d o m effect.   A n u nstr uct ure d c o varia nce str uct ure will m o del relat i o ns hi p of 
wi t hi n -patie nt err ors.  
Si nce t he y  are i nte n de d f or differe nt p ur p oses, eac h of t he [ADDRESS_1239670] ical a nal ysis pla n ( S A P). 
S afet y A n al yses 
S af et y assess me nt will be base d o n all a vaila ble data t h r o u g h safet y f o ll o w u p visit , i rres pect i ve 
of  w het her t he y  were o btai ne d af t er st u d y  dr u g disc o nti n uat i o nor w het her t he partici pa nt 
recei ve d resc ue me dicat i o n. S u m mar y statis ti cs will  b e pr o vi d e d f or i nci de nce o f T E A Es, 
seri o us A E s, a n d st u d y  disc o nt i n uat i o n d ue t o A Es or deat hs fr o m first d ose t o e n d of safet y 
f o ll o w- u p.  C o u nts a n d pr o p orti o ns of pat ie nt s e x peri e nci n g A Es will be re p orte d f or eac h 
treat m e nt gr o u p, a n d Fis her’s e xact test will be use d t o c o m pare t he treat me nt gr o u ps.  F or 
c o nti n u o us la b orat or y  a nal y tes, s u m mar y  st ati st ics will be pr o vi de d b y visit, wit h statist ical 
c o m paris o ns a m o n g treat m e nt at eac h visit c o n d ucte d usi n g a n M M R M a nal ysis. A d dit i o nal 
details, i ncl u di n g a nal ysis o f A Es of s pecial i nterest, will be pr o vi de d i n t he S A P .
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239671] o m e c or o na vi r us 2 ( S A R S -C o V -2), t he vir us t hat ca uses t he n o vel 
C or o na vir us Disease 2 0 1 9 ( C O VI D- 1 9), please refer t o A p pe n di x 8 f o r a d di ti o nal  i nstr ucti o ns. 
   
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239672] u d y 
P eri o d III 
Scr e e ni n g/ 
Le a d i n Tr e at m e nt P eri o d S af et y 
F/ U 
Visit [ADDRESS_1239673] e n d 
of t x 
All o w a bl e 
D e vi ati o n ( d a ys) c ± 3 ± 7 ± 3 - ± 3 ± 3 - ± 3 ± 3 - ± 3 ± 7 ± 7 ± [ADDRESS_1239674] 
circ u mf er e nc e X X X X X X X X X X X 
El ectr oc ar di o gr a m hX X X X 
Vit al si g ns ( 2 sitti n g 
B P a n d H R) i X X X X X X X X X X X X X X X 
Dil at e d fu n d osc o pic 
Ex a m i n ati o n j X
A d v ers e e v e nts X X X X X X X X X X X X X X X X 
C o nc o mit a nt 
m e dic ati o ns X X X X X X X X X X X X X X X X 
R e vi e w 
hy p o glyc e mic 
ev e nts c oll ect e d i n 
t h e di ari es X X X X X X X X X X X 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239675] u d y 
P eri o d III 
Scr e e ni n g/ 
Le a d i n Tr e at m e nt P eri o d S af et y 
F/ U 
Visit [ADDRESS_1239676] e n d 
of t x 
All o w a bl e 
D e vi ati o n ( d a ys) c ± 3 ± 7 ± 3 - ± 3 ± 3 - ± 3 ± 3 - ± 3 ± 7 ± 7 ± 7 
F asti n g Visit dX X X X X X X X X X X
P K s p ecific Visit eX X X
Di a b et es 
e d uc ati o n k,l X
B G m et er, S M B G 
tr ai ni n g m X
Dis p e ns e B G 
m et er/s u p pli es as 
n e e d e d X X X X X X X X X X X 
St u dy dr u g i nj ecti o n 
tr ai ni n g wit h d e m o 
d evic e lX
H a n d o ut di ari es , 
i nstr uct i n us e l X X X X 
R e mi n d p ati e nts 
a b o ut [ADDRESS_1239677] e d i n t h e 
di ari es X X X X
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239678] u d y P eri o d 
III 
Scr e e ni n g/ 
Le a d i n Tr e at m e nt P e ri o d S af et y F/ U 
Visit [ADDRESS_1239679] 
e n d of t x 
All o w a bl e D e vi ati o n 
( d a ys) c ± 3 ± 7 ± 3 - ± 3 ± 3 - ± 3 ± 3 - ± 3 ± 7 ± 7 ± [ADDRESS_1239680] u g 
c o m pli a nc e X X X X X X X X X 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239681] u d y 
P eri o d III 
Scr e e ni n g/ 
L e a d i n Tr e at m e nt P eri o d S af et y F/ U 
Visit [ADDRESS_1239682] e n d of 
t x 
All o w a bl e D e vi ati o n 
( d a ys) c - ± 3 ± 7 ± 3 - ± 3 ± 3 - ± 3 ± 3 - ± 3 ± 7 ± 7 ± [ADDRESS_1239683] ,estr a di ol q X
C h e mistry p a n el XrX X X X X 
F asti n g s er u m gl uc os e X X X X X X X X X X X 
F asti n g i ns uli n X X X X X X
F asti n g gl uc a g o n X X X X X X
F asti n g C -p e pti d e X X X X X X
Li pi d p a n el X X X X X X X 
Uri n ary al b u mi n/cr e ati ni n e 
r ati o XrX X X 
S er u m cr e ati ni n e, e G F R 
( C K D -E PI) s XrX X X X X 
C alcit o ni n XrX X X X X 
H e m at ol o g y XrX X X X X 
H b A 1c X X X X X X X X X X X X 
P a ncr e atic a myl as e, li p as e XrX X X X X 
I m m u n o g e nicit y tX X X X X X X 
P K s a m pl e f or 
i m m u n o g e nicit y u X X X X X X X 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239684] u d y 
P eri o d III 
Scr e e ni n g/ 
L e a d i n Tr e at m e nt P eri o d S af et y F/ U 
Visit [ADDRESS_1239685] e n d of 
t x 
All o w a bl e D e vi ati o n 
( d a ys) c - ± 3 ± 7 ± 3 - ± 3 ± 3 - ± 3 ± 3 - ± 3 ± 7 ± 7 ± [ADDRESS_1239686] as m a -2. 0 mL X X X X X 
P ati e nt -R e p ort e d O utc o m es y
A P P A DL X X X 
E Q -5 D -5L X X X 
I W -S P X X X 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e 1 9 
L Y 3 2 9 8 1 7 6 A b bre viati o ns:  A D A = a nti -dr u g a nti b o d y; A P P A D L = A bilit y t o Perf or m P h ysical Acti vities of Dail y Li vi n g; B G = bl o o d gl uc ose; B P = bl o o d press ure; C K D -
E PI = C hr o ni c  Ki d ne y Disease -E pi [INVESTIGATOR_32450] o g y; E C G = electr ocar di o gra m; e C R F = electr o nic case re p ort f or m; e G F R = esti mate d gl o mer ular filtrati o n r ate; 
E Q - 5 D- 5 L = E ur o pea n Q ual it y  of Life -di me nsi o ns; E T = earl y ter mi nati o n; F/ U = f oll o w - u p; H b A 1c = he m o gl o bi n A 1c; H R = heart rate; I W -S P = I m pact of 
Wei g ht o n Self -Perce pti o n; P K = p har mac o ki netics; P R O = patie nt -re p orte d o utc o me; S M B G = self -m o nit o ri n g of bl o o d gl uc ose ;T x = treat me nt .
aBaseli ne assess me nts m ust be c o m plete d bef ore pr ocessi n g i n t he i nteracti ve we b -res p o nse s y ste m (I W R S). 
bPatie nts w h o are u na ble or u n willi n g t o c o nti n ue i n t he st u d y f or a n y reas o n will perf or m a n E T visit.  If t he p atie nt is disc o nti n ui n g d uri n g a n u nsc he d ule d 
visit, t hat visit s h o ul d be perf or me d as t he E T visit.  If t he patie nt is disc o nti n ui n g d uri n g a sc he d ule d visit, t hat visit s h o ul d be perf or me d as a n E T visit.  
Visit 8 0 1 ( safet y  f oll o w - u p v isit) s h o ul d be per f or me d [ADDRESS_1239687] he visit date is deter mi ne d i n relati o n t o t he date of t he ra n d o mizati o n visit ( ± t he all o we d visit wi n d o w). 
dO n visits 3, 4, 6, 7, 9, 1 0, 1 2, 1 3, 1 4 , E T , a n d at f oll o w -u p, patie nts s h o ul d be re mi n de d t o re p ort t o t he site i n a fasti n g c o n diti o n, after a peri o d of 
a p pr o xi matel y 8 h o urs wit h o ut eati n g, dri n ki n g (e xce pt water), or a n y si g nifica nt p h ysical acti vit y a n d bef ore ta ki n g st u d y d r u g. 
eVisit is f or tirze pati de P K bl o o d dra ws 
fMe dical hist or y  i ncl u des assess me nt of pree xisti n g c o n diti o ns (i ncl u di n g hist or y of gall bla d der disease, car di o vasc ular disease, a n d me d ullar y t h yr oi d 
carci n o ma) a n d s u bsta nce usa ge (s uc h as alc o h ol a n d t o bacc o) .
gWei g ht meas ure me nts m ust be i n kil o gra ms. 
hElec tr ocar di o gra ms occ urri n g o n visits wit h tirze pati de P K c ollecti o n s h o ul d be c ollecte d at least 3 0 mi n utes pri or t o o btai ni n g t he sa m ple f or tirze pati de P K 
meas ure me nt. 
iVital si g n meas ure me nts s h o ul d be ta ke n bef ore o btai ni n g a n E C G traci n g a n d bef ore c ol lecti o n of bl o o d sa m ples f or la b orat or y testi n g, at visits w here 
re q uire d.  T he partici pa nt s h o ul d sit q uietl y f or 5 mi n utes bef ore vital si g n meas ure me nts are ta ke n.  F or eac h para meter, 2 meas ure me nts will be ta ke n usi n g 
t he sa me ar m; t he rec or di n gs s h o u l d be ta ke n at least [ADDRESS_1239688] be ta ke n wit h a n a ut o mate d bl o o d press ure mac hi ne. 
jDilate d f u n d osc o pic e xa m i nati o n will be perf or me d b y a ne ye care pr ofessi o nal ( o p ht hal m ol o gist or o pt o metrist) f or all patie nts bet wee n Visit [ADDRESS_1239689] u g(s) f or w o me n of 
c hil d beari n g p ote ntial o nl y.  A d diti o nal pre g na nc y tests will be perf or me d at Visits 7, 1 2, a n d 1 4. Pre g na nc y  t e sts ma y  be perf or me d at t he i n vesti gat or’s 
discreti o n d uri n g t he st u d y.  If re q uire d per l ocal re g ulati o ns a n d/ or i nstit uti o nal g ui deli nes, pre g na nc y testi n g ca n als o o cc ur at ot her ti mes d uri n g t he st u d y 
treat me nt peri o d. 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e 2 0 
L Y 3 2 9 8 1 7 6 qF ollicle -sti m ulati n g h or m o ne ( F S H) test perf or me d at Visit [ADDRESS_1239690] uter us, n ot o n h or m o ne 
t hera p y , a n d w h o ha ve ha d s p o nta ne o us a me n orr hea f or m ore t ha n 6 m o nt hs a n d less t ha n 1 2 m o nt hs a n d estra di ol le vels c o nsiste nt wit h a p os t me n o pa usal 
state ( F S H ≥ 4 0 mI U/ m L a n d estra d i ol < 3 0 p g/ m L). 
rScree ni n g visit assess me nt will ser ve as baseli ne .
sT he C K D -E PI e q uati o n will be use d b y t he ce ntral la b t o esti mate a n d re p ort e G F R. 
tI n t he e ve nt of s yste mic dr u g h y perse nsiti vit y reacti o ns (i m me diate or n o ni m me diate), a d diti o nal bl o o d sa m ples will be c ollec te d i ncl u di n g A D A , P K, a n d 
e x pl orat or y i m m u ne safet y sa m ple. 
uP K sa m ples f or i m m u n o ge nicit y m ust be ta ke n pri or t o dr u g a d mi nistra ti o n. 
vP K sa m ples will be c ollecte d at t hese visits e xce pt f or Visit [ADDRESS_1239691] d ose a d mi nistere d a t Wee k 3 9 will be c ollecte d at Visit 1 4 ( Wee k 4 0) . 
yAll P R Os s h o ul d be c o m plete d bef ore a n y ot her st u d y pr oce d ures if t he patie nt is n ot a d versel y affecte d b y t he fasti n g c o n dit i o n or c o m plete d after t he patie nt 
has s ufficie ntl y rec o vere d fr o m t he pr ece di n g visit pr oce d ures. 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239692] u d y R ati o n al e 
T y pe 2 di a betes m elli t us ( T 2 D M) is a m eta b o lic c o n dit i o n c haracterize d b y i m paire d gl yce mic 
c o ntr ol  ca use d b y  i ncrease d i ns uli n resista nce a n d pr o gressi ve beta -cell fail ure a n d c o nse q ue nt l y 
i na de q uate i ns uli n secret i o n.  T y pe 2 di a betes mellit us is ass ociate d wit h c o m o r bi di ti es s uc h as 
i ncrease d wei g ht or o besit y,  h y perte nsi o n, i ncrease d bl o o d li p o pr otei n c o nce ntr ati o ns, a n d a 
hi g her ri s k f or macr o -a n d micr o vasc ular c o m plicati o ns.  T o pre ve nt t hese c o m plicati o ns, ti g ht 
gl yce mic c o ntr ol is rec o m me n de d ( A D A 2 0 1 8; Da vies et al . 2 0 1 8 ). 
I njecta ble i ncreti n -base d treat me nts ( f o r e xa m ple , gl uca g o n -li ke pe pti de - 1 [ G L P - 1 ]rece pt or 
a g o nists) are c o m m o nl y use d i n c o m bi nat i o n wi t h or al  a nt i h y per gl yce mic me dicat i o n ( O A Ms )t o 
ac hie ve a n d mai ntai n gl uc ose c o ntr ol ( I nz ucc hi et al . 2 0 1 5 ; A D A 2 0 1 8).  W hile ass ociate d wit h 
l o w er ri s k f or h y p o gl yce mia a n d eit her wei g ht ne utral or wei g ht l oss effects, c urre nt pre parati o ns 
are directe d at a si n gle m o lec ular tar get ( G L P -1 rece pt ors) a n d pr o vi de d ose -de pe n de nt 
gl uc ose -l o weri n g effects, w hic h ca n be li mite d b y gastr oi ntesti nal ( GI) t olera bilit y ( Na uc k 2 0 1 6). 
T he m eta b o lic effects of G L P - 1 rece pt or a g o nists ca n be e n ha nce d b y c o m bi ni n g t he m wit h t he 
acti o ns of  ot her e nter o pa ncreat ic h or m o nes.  Gl uc ose -de pe n de nt i ns uli n otr o pic p ol y pe pti de 
( GI P) sti m ulates i ns uli n secret i o n i n a gl uc ose -de pe n de nt m a n ner a n d ma y  e x ert s o m e ot her 
acti o ns be y o n d it s r ol e as a n i ncreti n t hat c o ul d p ote nt ia ll y  i m pr o ve t hera pe utic efficac y i n 
c o m bi nat i o n wi t h  G L P -1 rece pt or a g o ni sts al o ne (f or e xa m ple, i m pr o ve d li pi d h o m e ostasi s a n d 
w h o le -b o d y  e ner g y  m eta b o lis m) ( As mar et al . 2 0 1 6 ; Na uc k a n d Meier 2 0 1 8 ). 
Ti rze pati d e (L Y 3 2 9 8 1 7 6 )is a [ADDRESS_1239693] ure is base d o n t he GI P se q ue nce a n d i ncl u des a C 2 0 fatt y  
di -aci d m oi et y t h at   It is a d mi nistere d as o nc e- wee kl y ( Q W) 
s u bc uta ne o us ( S C) i nject i o n( C os k u n et al. 2 0 1 8) .  
St u d y  I 8 F -M C -G P G K ( St u d y  G P G K ) is a P hase 3, m ul ti ce nter, ra n d o mize d, d o u ble- bli n d , 
parallel , i nter nati o n al , place b o -c o ntr olle d, [ADDRESS_1239694] u dies ha ve c o m plete d d osi n g a n d a nal ysis:  a P hase [ADDRESS_1239695] u d y I 8 F -M C -G P G A ( St u d y  G P G A), a n d t w o P hase [ADDRESS_1239696] u d ie sI 8 F -M C -G P G B ( St u d y  
G P G B) a n d I 8 F -M C -G P G F (St u d y  G P G F).   
P hase 1 St u d y  G P G A was a c o m bi nat i o n of si n gle asce n di n g d ose ( S A D) a n d m ult i ple asce n di n g 
d ose st u d y  i n heal t h y s u bjects f o ll o we d b y  a m ul ti pl e d ose st u d y  i n pat ie nt s wi t h  T [ADDRESS_1239697] i gate d safet y,  t ol era bili t y , p har mac o ki net ic s ( P K), a n d p har mac o d y na mics 
( P D ) of ti rze pat i de a d mi nistere d as S C i nject i o ns.  A t otal o f 1 4 2 s u bjects ( 8 9 healt h y s u bjects 
a n d 5 3 pati e nts wi t h  T 2 D M) recei ve d at least 1 d ose of treat me nt.  D o ses of ti rze pat i de ra n ge d C CI 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e 2 2 
L Y 3 2 9 8 1 7 6 fr o m 0. 2 5 m g t o 8 m g i n t he S A D ( wi t h  m a xi m u m  t ol erate d d ose ac hie ve d at 5 m g) i n healt h y 
s u bjects ;m ult i ple d oses fr o m 0. 5 m g t o 4. 5 m g Q W a n d titrate d d oses u p t o 1 0 m g Q W  f or 4 
wee ks i n healt h y s u bjects ;a n d m ul ti ples d oses ra n ge d fr o m 0. 5 m g t o 5 m g Q W a n d titrate d 
d oses u p t o 1 5 m g Q W f or 4 wee ks i n patie nts wit h T 2 D M.  T he safet y,  t ol era bilit y, a n d P K/ P D 
pr ofiles of ti rze pat i de at d oses a n d escalat i o n re gi me ns a d mi nistere d i n t his P hase [ADDRESS_1239698] u d y  ( St u d y  G P G B) assesse d t he efficac y , t ol era bili t y , a n d safet y of  4 d oses 
( 1 m g , 5m g , 1 0 m g,a n d 1 5 m g) of  ti rze pat i de vers us place b o a n d a n acti ve c o m parat or 
( d ul a gl uti d e 1. 5 m g) i n 3 1 8 pati e nts wi t h  T 2 D M wit h i na de q uate gl yce mic c o ntr ol o n diet a n d 
e xercise al o ne or o n a sta ble d ose of metf or mi n m o n ot hera p y .  T he d oses of 1 0 m g a n d 1 5m g 
were attai ne d b y t it rati o n ( Frias et al. 2 0 1 8) .  
St u d y  G P G B de m o nstrate d t h at ti rze pat i de 5-m g , 1 0 -m g ,a n d 1 5 -m g d oses si g nifica nt l y l o were d 
he m o gl o bi n A 1 c ( H b A 1c) a n d b o d y  wei g ht i n a d ose -de pe n de nt ma n ner i n pat ie nt s wi t h  T [ADDRESS_1239699] of  t he ti rze pati d e a d verse e ve nts ( A Es ) were GI 
r el ate d, c o nsist i n g ma i nl y of na usea, v o mit i n g, a n d diarr hea a n d were d ose - de pe n de nt.  T he GI 
A Es were us uall y  mil d t o m o derate i n i nte nsit y.   S eri o us A Es ( S A Es) were bala nce d acr oss t he 
treat m e nt gr o u ps ,a n d n o ne of t he gr o u ps i n eit her st u d y  re p orte d se v ere h y p o gl yce mia 
( Fri as et al. 2 0 1 8) . 
As i t was rec o g nize d t hat t he titrati o n sc he me e m pl o ye d i n St u d y  G P G B was u nli kel y t o be 
o pti mal f or t he re d ucti o n of  GI -relate d A Es e x pecte d wit h tirze pat i de , St u d y  G P G F was desi g ne d 
t o e x pl ore alter nat i ve titrati o n sc he mes (l o n ger ti me i nter vals bet wee n d ose escalati o ns a n d 
differe nt d ose escalat i o ns) t o s u p p ort e val uati o n of o pti mize d d osi n g re gi me n(s) i n P hase 3. T his 
was a [ADDRESS_1239700] u d y  t o assess t he efficac y a n d 3 differe nt titrati o n sc he mes 
t o attai n d oses as hi g h as 1 5 m g of tirze pat i de i n patie nts wit h T 2 D M. 
T hese data s u p p ort c o nti n ue d de vel o p me nt of ti rze pati de as a t hera p y  f or T 2 D M.  
3. 3. B e n e fit/ Ri s k A s s e s s m e nt 
M ore i nf or mat i o n a b o ut t he k n o w n a n d e x pecte d be nefits, ris ks, S A Es ,a n d reas o na bl y 
a nt ic i pate d A Es of ti rze pati de are t o be f o u n d i n t he I n vest i gat or’s Br oc h ure (I B). 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239701] u d y .
T a bl e G P G K . 2. O bj e cti v e s a n d E n d p oi nt s 
O bjecti ves E n d p oi nts 
Pri m ar y 
T o de m o nstrate t hat tirze pati de Q W 5m g ,
a n d/ o r1 0 m g, a n d/ o r [ADDRESS_1239702] b o i n H b A 1c c ha n ge fr o m baseli ne t o 4 0 
wee ks Mea n c ha n ge i n H b A 1c 
Ke y Sec o n d ar y (c o ntr olle d f or t y pe 1 err or) 
T o de m o nstrate s u peri orit y of tirze pati de Q W 
5 m g ,a n d/ or 10 m g, a n d/ or [ADDRESS_1239703] b o 
at 4 0 wee ks f or: Mea n c ha n ge i n b o d y wei g ht 
Pr o p orti o n of patie nts wit h H b A 1c tar get 
val ues of < 7. 0 % ( <5 3 m m ol/ m ol) 
Mea n c ha n ge i n fasti n g ser u m gl uc ose ( F S G) 
(ce ntral la b orat or y) 
Pr o p orti o n of patie nts wit h H b A 1c tar get 
val ues of < 5. 7 % ( < 3 9 m m ol/ m ol) 
A d diti o n al Sec o n d ar y ( n ot c o ntr olle d f or t y pe 1 
err or) 
T o c o m pare tirze pati de Q W [ADDRESS_1239704] b o at 4 0 wee ks f or: Pr o p orti o n of patie nts wit h H b A 1c tar get of 
≤ 6. 5 % ( ≤4 8 m m ol/ m ol) 
Mea n c ha n ge i n dail y a vera ge 7-p oi nt self -
m o nit ore d bl o o d gl uc ose pr ofiles fr o m 
baseli ne 
Pr o p orti o n of patie nts w h o ac hie ve d wei g ht 
l oss of ≥ 5 % , ≥ 1 0 % ,a n d ≥ 1 5 % 
S afet y 
T o c o m pare t he safet y of tirze pati de Q W 
5m g, [ADDRESS_1239705] b o f or: Treat me nt -e mer ge nt a d verse e ve nts ( T E A Es) 
Earl y  disc o nti n uati o n of st u d y dr u g d ue t o 
a d verse e ve nts ( A Es) 
A dj u dicate d pa ncreatic A Es 
Ser u m calcit o ni n 
Inci de nce of aller gic a n d h y perse nsiti vit y 
reacti o ns 
I nci de nce of treat me nt -e mer ge nt a nti -dr u g 
a nti b o dies t o tirze pati de 
Mea n c ha n ge i n s yst olic a n d diast olic bl o o d 
press ure a n d heart rate fr o m baseli ne 
Occ urre nce of h y p o gl yce mic e pis o des 
Ti me t o i nitiati o n of resc ue t hera p y f or se vere 
persiste nt h y per gl yce mia 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e 2 4 
L Y 3 2 9 8 1 7 6 O bjecti ves E n d p oi nts 
P h ar m ac o ki netics 
T o c haracterize t he p har mac o ki netics ( P K) of 
tirze pati de Q W 5 m g, 1 0 m g, a n d 1 5 m g a n d 
t he relati o ns hi ps bet wee n tirze pati de e x p os ure 
a n d safet y, t olera bilit y, a n d efficac y meas ures P o p ulati o n P K a n d P D para meters 
Terti ar y / E x pl or at or y 
T o c o m pare tirze pati de Q W [ADDRESS_1239706] f or t he 
f oll o wi n g :C ha n ge i n fasti n g gl uca g o n, C- pe pti de, a n d 
i ns uli n le vel 
Mea n c ha n ge i n li pi [INVESTIGATOR_805] (t otal c h olester ol, H D L, 
L D L, V L D L, a n d T G )
Mea n c ha n ge i n waist circ u mfere nce 
C ha n ges fr o m baseli ne i n mea n b o d y mass 
i n de x 
Bi o mar kers 
Patie nt- re p o rte d o utc o mes 
oA bilit y t o Perf or m P h ysical 
Acti vities of Dail y Li vi n g 
oE ur o pea n Q ualit y of 
Life - D i me nsi o ns ( E Q - 5 D- 5 L) sc ores 
oI m pact of Wei g ht o n Self -Perce pti o n 
A b bre viati o ns:  H D L = hi g h -de nsit y li p o pr otei n; L D L = l o w -de nsit y li p o pr otei n; P D =p har mac o d y na mics; Q W = 
o nce wee kl y; T G = tri gl yceri des; V L D L = ver y l o w -de nsit y  li p o pr otei n. 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239707] of 3 peri o ds:  a n a p pr o xi matel y 3 -wee k scree ni n g/lea d -i n peri o d, 
f o ll o we d b y a 4 0 -wee k treat m e nt peri o d ,a n d a 4 -wee k safet y f o ll o w- u p peri o d .  Patie nts will be 
ra n d o mize d i n a 1: 1: 1: 1 rati o ( ti rze pat i de 5m g Q W , [ADDRESS_1239708] ace b o).  Patie nts will be stratifie d base d o n c o u ntr y , baseli ne H b A 1c [ ≤ 8. 5 % ( ≤ 6 9 m m o l/ m o l) 
or >8. 5 % ( > 6 9 m m o l/ m o l) ], a n d a n y  p ast pri or use ( Yes or N o) of a n y O A M .
St u d y  g o ver na nce c o nsi derati o ns a re descri be d i n detail i n A p pe n di x [ADDRESS_1239709] u d y  d esi g n .
A b bre viati o n :  Q W = o nce wee kl y .
Fi g ur e G P G K . 1. Ill u str ati o n of st u d y d e si g n f or Cli ni c al Pr ot o c ol I 8 F -M C -G P G K .
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239710] u d y Peri o d I ( scree ni n g a n d le a d -i n) 
Scree ni n g ( Visit 1) 
T he p ur p ose of scree ni n g pr oce d ures at Visit 1 is t o esta blis h i nit ial eli gi bilit y a n d t o o btai n 
bl o o d sa m ples f or l a b orat or y  assess me nts nee de d t o c o nfir m eli gi bilit y at Vi si t 2. T he patie nt 
will si g n t he i nf or me d c o nse nt f or m (I C F) bef ore a n y st u d y pr oce d ures are perf or me d. 
Pr oce d ures at t his visit will be perf or me d as s h o w n i n t he Sc he d ule of Acti vit ies (Secti o n 2). 
Le a d -i n ( Visit 2 t o Visit 3) 
At  Visit 2, t he scree ni n g la b orat or y  res ul ts will  b e re vie we d. F or t h ose patie nts meet i n g all ot her 
eli gi bilit y re q ui re me nts, a dilate d f u n d osc o pic e xa mi nat i o n, perf or m e d b y a n o p ht hal m o l o gist or 
o pt o m etrist, m ust be c o m plete d bet wee n Visit 2 a n d Visit 3 t o e ns ure t h at patie nts wit h 
pr oliferat i ve dia bet ic reti n o pat h y, dia bet ic mac ul o pat h y ,or n o n pr oliferat i ve dia bet ic reti n o pat h y 
w h o re q uire ac ute treat me nt, are i de nt ifie d a n d e xcl u de d . A d dit i o nall y, at Vi si t2, pati e nts a n d 
t h ei r care gi ver(s), if a p plica ble, will recei ve a gl uc o meter a n d trai ni n g o n h o w t o perf or m self -
m o nit ori n g of bl o o d gl uc ose ( S M B G).  Patie nts will be as ke d t o m o nit or fa st i n g bl o o d gl uc ose 
(F B G) 4 ti mes a wee k a n d t w o 7 -p oi nt S M B G pr ofiles d o ne o n 2 n o nc o nsec uti ve da ys i n t he 2-
wee k peri o d pri or t o Visit 3 (ra n d o mizat i o n), Visit 7 ( Wee k 1 2), Visit 1 4( Wee k 4 0 ), a n d Visit 
8 0 1 ( Wee k 4 4) .  Patie nts will be pr o vi de d diaries a n d will be trai ne d as a p pr o pri ate t o rec or d 
bl o o d gl uc ose ( B G )val ues a n d h y p o gl yce mic e ve nts .  D uri n g t his peri o d, patie nts will als o be 
trai ne d o n disease ma na ge me nt (s y m pt o ms of h y p o gl yce mia a n d h y per gl yce mia) a n d st u d y  
pr oce d ures; t his trai ni n g ca n be re peate d at s u bse q ue n t visi ts as dee me d a p pr o pri ate. Patie nts 
s h o ul d m o ni t or B G a n y  ti me a h y p o gl yce mic e ve nt is s us pecte d. D uri n g t he lea d -i n p eri o d, 
pati e nts s h o ul d c o nt i n ue t heir diet a n d e xercise r o uti ne a n d m ust n ot a d d a n y  O A Ms i n or der t o 
all o w relia ble assess me nt of H b A 1c at baseli ne ( Visit 3).  
St u d y Peri o d II ( 4 0 -wee k tre at me nt peri o d) 
R a n d o miz ati o n ( Visit 3) 
At  Visit 3, eli gi ble pat ie nt s will perf or m all re q uire d baseli ne st u d y pr oce d ures (i ncl u di n g t he 
c ollect i o n of all  b aseli ne la b orat or y  m eas ures a n d el ectr ocar di o gr a m  [ E C G ]) pri or t o 
ra n d o mizat i o n a n d pri or t o ta ki n g t he first d ose of st u d y dr u g e xce pt f or P K sa m ple c ollecti o n 
w hic h will be c o llecte d a n yt i me o n t he sa me da y after a d mi nistrati o n at t he site (see S ect i o n 2).  
P ati e nt s h o ul d arri ve t o t he cli nic i n t he fast i n g state; t he fast i n g state s h o ul d ha ve laste d at least 
8 h o urs .T he q uesti o n naires ( E ur o pea n Q ualit y of Life - D i me nsi o ns [ E Q - 5 D- 5 L] , A bilit y t o 
Perf or m  P h ysical  Acti vi ti es of  Dail y Li vi n g [A P P A D L ], I m p a ct of  Wei g ht o n Self -Perce pt i o n
[I W -S P ]) s h o ul d be c o m plete d bef ore a n y ot her st u d y pr oce d ures if t he pat ie nt  is n ot a d versel y 
affecte d b y  t h e f asti n g c o n di ti o n or c o m plete d after t he patie nt has s ufficie nt l y rec o vere d fr o m 
t h e prece di n g visit pr oce d ures.  
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e 2 7 
L Y 3 2 9 8 1 7 6 P ati e nts will  b e i nstr ucte d o n h o w t o use t he si n gle - d ose pe n ( S D P) a n d will i nject t heir first d ose 
of  st u d y  dr u g w hile i n t he cli nic f or Vi si t 3.  T he date a n d ti me of t he first d ose of st u d y dr u g 
s h o ul d be rec or de d o n t he el e ctr o ni c case re p ort f or m  ( e C R F). 
F o ll o wi n g ra n d o mizat i o n, p ati e nts will  p arti ci pate i n a 4 0 - wee k treat me nt peri o d.   
P ostr a n d o miz ati o n peri o d (e n d of Visit 3 t o Visit 1 4 ): 
T he starti n g d ose of st u d y  dr u g will be 2. [ADDRESS_1239711] u g will be 2. 5 m g Q W f o r 4 wee ks, t he n t he d os e will be i ncrease d b y 2. 5 m g e ver y 4 
wee ks ( 2. 5 m g t o 5 m g t o 7. 5 m g t o 1 0 m g) u nt il t he [ADDRESS_1239712] u g will be 2. 5 m g 
Q W f o r 4 wee ks, t he n t he d ose will be i ncrease d b y 2. 5 m g e ver y 4 wee ks ( 2. 5 m g t o 5 m g t o 
7. 5 m g t o 1 0 m g t o 1 2. 5 m g t o 1 5 m g) u nt il t he [ADDRESS_1239713] u d y Peri o d I II (s afet y f oll o w -u p peri o d) 
S afety foll o w - u p ( Visit 8 0 1) v isits: 
All patie nts w h o c o m plete t he treat me nt peri o d are re q uire d t o c o m plete Visit [ADDRESS_1239714] u d y  earl y  a n d perf or mi n g a n earl y  ter mi nat i o n ( E T) vi si t will als o be as ke d t o perf or m t he 
safet y f o ll o w- u p visi t, s o t hat t he safet y f o ll o w- u p visit will be t heir fi nal visit.  D uri n g t he safet y 
f o ll o w- u p peri o d, patie nt s will n ot recei ve st u d y  dr u g or i ni ti ate a n y ne w a nti h y per gl yce mic 
t h era p y .  I n t he e ve nt a pati e nt has persiste nt ,se vere h y per gl yce mia ,defi ne d as a n y F B G val ues 
wi t hi n 1 wee k f or 2 c o nsec ut i ve wee ks is > 2 0 0 m g/ d L ( >1 1. 1 m m o l/ L) or H b A 1c ≥ 8. 5 % 
(≥ 6 9 m m o l/ m o l) ,ne w a nt i h y per gl yce mic me dicati o n ca n be i nit iate d at t he discret i o n of t he 
i n vesti gat or as descri be d i n Sect i o n 7. 4. [ADDRESS_1239715] u d y  pr oce d ures liste d i n t he Sc he d ule of Acti vit ies ( Secti o n 2). 
P ati e nts will  b e per mitte d t o use c o nc o mita nt me dicati o ns t hat t h e y  r e q ui re d uri n g t he st u d y , 
e xce pt certai n me dicat i o ns t hat ma y i nterfere wit h t he assess me nt of efficac y a n d safet y 
c haracterist ic s of t he st u d y  tr e at m e nts.  A nt i h y per gl yce mic me dicat i o ns ot her t ha n st u d y  dr u gs 
are n ot all o we d at a n y  ti me d uri n g t he st u d y e xce pt as all o we d f or resc ue t hera p y, after earl y 
st u d y  dr u g di sc o nt i n uat i o n, or s h ort -t er m  i ns uli n use.  Resc ue t hera p y  wi t h  ot her 
gl uc ose -l o weri n g a ge nts ma y  b e m e dicall y i n dicate d i n certai n sit uat i o ns after ra n d o mizat i o n d ue 
t o se vere, persiste nt h y per gl yce mia or earl y disc o nti n uat i o n of st u d y  treat m e nt .  Metf or mi n will 
be t he first c h oice of t h era p y  u nless c o ntrai n dicate d .  Gl uca g o n -li ke pe pt i de -1 rece pt or a g o ni sts, 
di pe pt i d yl pe pt i dase -4 ( D P P -4) i n hi bit ors, a n d pra mli nt i d e are pr o hi bite d me dicat i o ns a n d are n ot 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e 2 8 
L Y 3 2 9 8 1 7 6 all o we d as resc ue t hera pi[INVESTIGATOR_014].  S h ort -t er m  i ns uli n use f or u p t o 1 4 da y s is all o w e d f or certai n 
cli nical sit uat i o ns (f or e xa m p le, elect i ve s ur ger y, d uri n g h os pi[INVESTIGATOR_1314] o n, h y per os m olar states).  If 
i ns uli n is prescri be d as a resc ue t hera p y , i t m ust be differe ntiate d fr o m s h ort -t e r m  use of i ns uli n 
t h era p y  f or m e dical  e mer ge ncies w he n re p orte d i n t he e C R F. 
P ati e nts w h o de vel o p se ve re, persi ste nt h y per gl yce mia base d o n pre s pecifie d t hres h o l d s (see 
Secti o n s7. 8. 2. 3 a n d 9. 2. 2. 2 ) will recei ve a ne w gl uc ose -l o weri n g i nter ve nt i o n (“resc ue t hera p y”) 
a n d will als o c o nti n ue t o a d mi nister st u d y  dr u g.  Pati e nts w h o nee d h y per gl yce mic resc ue 
t h era p y  will c o nt i n ue i n t he trial u nt il t h e y  c o m plete all  st u d y  visi ts .  
St u d y  g o ver na nce c o nsi derati o ns are descri be d i n detail i n A p pe n di x 3 .
5. 2. N u m b er of P arti ci p a nt s 
A t otal o f a p pr o xi matel y  4 7 2 p ati e nts ( 1 1 8 pati e nts per treat m e nt gr o u p) will be ra n d o mize d. 
5. 3. E n d of St u d y D efi niti o n 
E n d of t he st u d y is t he date of t he last visit or last sc he d ule d pr oce d ure s h o w n i n t he Sc he d ule o f 
Act i vit ies ( Secti o n 2)f o r t he last patie nt .
5. 4. S ci e ntifi c R ati o n a l e f or St u d y D e si g n 
St u d y  G P G K is desi g ne d t o assess t h eefficac y, safet y ,a n d P K of  ti rze pat i de Q W (5 m g, 1 0 m g, 
a n d 1 5 m g) as m o n ot hera p y vers us place b o i n patie nts wit h T [ADDRESS_1239716] u d y .T he pla n ne d treat me nt d urati o n of  4 0 wee ks is c o nsi dere d 
a p pr o priate t o assess t he f ull effects a n d be nefit/ris k of eac h mai nte na nce d ose of tirze pat i de o n 
b ot h gl yce mic c o ntr ol a n d b o d y  wei g ht as re q ueste d b y t h e F D A .
T he parallel -gr o u p desi g n f or treat me nt c o m paris o n was c h ose n t o a v oi d a n y i nteracti o n bet wee n 
treat m e nts t hat m a y i nterfere wit h t he i nter pretati o n of t he trial o utc o me.  T o mi ni mize t he 
p ote nti al  c o nf o u n di n g effect of c ha n ges t o c o nc o mita nt me dicati o ns, pati e nts will  b e per mitte d t o 
use c o nc o mita nt me dicat i o ns t hat t he y  r e q ui re d uri n g t he st u d y .  Me dicat i o ns t hat ma y i nterfere 
wi t h  t he assess me nt of efficac y  a n d safet y c haracteri st ics o f t h e st u d y  treat m e nts will  n ot be 
all o we d (see Sect i o n 7. 7 ). 
5. 5. J u stifi c ati o n f or D o s e 
Ti rze pati d e d oses of  [ADDRESS_1239717] u d y . 
T hese d oses a n d ass oci ate d escalat i o n sc he mes were selecte d base d o n assess me nt of safet y,  
efficac y  ( gl yce mic a n d wei g ht l oss be nefit), a n d GI t olera bilit y data f o ll o we d b y  e x p os ure -
res p o nse m o deli n g of data i n pati e nts wi t h  T [ADDRESS_1239718] u dies. D osi n g al g orit h ms 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239719] u di es. 
T he selecte d d ose a n d escalati o n sc he me w o ul d e na ble f urt her e val uat i o n of be nefit/ris k 
c o nsi derati o ns f or 5 -m g, 1 0 -m g, a n d 1 5 -m g d oses of ti rze pat i de .
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239720] u d y  o nl y  if t h e y  m eet all  of  t h e f oll o wi n g criteria at 
scree ni n g :
T y pe of P atie nt a n d Dise ase C h ar acteristics 
[ 1] Ha ve bee n dia g n ose d wit h T 2 D M base d o n t he W orl d H eal t h  O r ga nizat i o n
cl assificat i o n or ot her l ocall y a p p lica ble dia g n ostic sta n dar ds ,are naï ve of 
di a betes i njecta ble t hera pi[INVESTIGATOR_014] , a n d ha ve n ot use d a n y  O A M d uri n g t he 3 m o nt hs 
prece di n g Visi t 1 
P atie nt C h ar acteristics 
[ 2] Ha ve H b A 1c ≥ 7. 0 % ( ≥5 3 m m o l/ m o l)  t o ≤9. 5 % ( ≤8 0 m m o l/ m o l) d es pi t e di et a n d 
e xercise treat m e nt , as deter mi ne d b y  t he ce ntral  l a b orat or y  at Visi t 1 ( N ote: 
H b A 1c val ue as deter mi ne d b y t he ce ntral la b at Visit 1) 
[ 3 ]Are of sta ble wei g ht ( ± 5 %) d uri n g t he 3 m o nt hs pr ece di n g Visi t 1 a n d a gree t o 
n ot i nit iate a diet a n d/ or e xercise pr o gra m d u ri n g t he st u d y  wi t h  t he i nte nt of 
re d uci n g b o d y  wei g ht ot her t ha n t he lifest yle a n d dietar y meas ures f or dia betes 
treat m e nt 
[ 4 ]Ha ve b o d y  m ass i n de x ( B MI) ≥ 2 3 k g/ m 2at Visi t 1 
[ 5 ]Are 1 8 y e ars ol d or of a n acce pta ble a ge t o pr o vi de i nf or me d c o nse nt acc or d i n g t o 
l o cal re g ulati o ns, w hic he ver is ol der 
Male patie nts ( See A p pe n di x 6 f o r m ore details) :
oMale patie nts s h o ul d be willi n g t o use relia ble c o ntrace pti ve met h o ds t hr o u g h o ut 
t h e st u d y  a n d f or at least [ADDRESS_1239721] i o n 
Fe male pat ie nt s: 
oFe male pat ie nt s n ot of c hil d beari n g p ote ntial d ue t o s ur gical sterilizat i o n 
( h ysterect o m y or bilater al  o o p h orect o m y  or t u bal  li gat i o n) , c o n ge nital a n o ma l y 
(t h at i s, M ulleria n a ge nesis) ,or m e n o pa use 
oW o me n wi t h  a n i ntact uter us are dee me d p ost me n o pa usal if t he y are at 
least 4 5 years ol d a n d 
ha ve n ot ta ke n h or m o nes or oral c o ntrace pti ves wit hi n t he last 
ye ar a n d ha d cessat i o n of me nses f or at least 1 year 
O R 
ha ve ha d at least [ADDRESS_1239722] i m ulat i n g h or m o ne 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e 3 1 
L Y 3 2 9 8 1 7 6 ( F S H) a n d estra di o l le vels c o nsiste nt wit h a p ost me n o pa usal 
state ( F S H ≥4 0 m I U/ m L a n d estra di o l <3 0 p g/ m L). 
oFe male pat ie nt s of c hil d beari n g p ote ntial ( n ot s ur gicall y sterilize d a n d 
bet wee n m e narc he a n d [ADDRESS_1239723] m e n o pa usal ) m ust 
test ne gati ve f or pre g na nc y  at Vi si t [ADDRESS_1239724] ,
if se x uall y  acti ve, a gree t o use 2f o r ms of effect i ve 
c o ntrace pti o n, w here at least 1 f o r m  i s hi g hl y effecti ve f or t he 
d urati o n of  t he tri al a n d f or 3 0 da y s t hereafter ,
A N D 
n ot be breastfee di n g 
[ 6 ]I n t he i n vest i gat or’s o pi [INVESTIGATOR_9384] o n, are well m o ti vate d, ca pa ble, a n d willi n g t o 
(a) perf or m  f i n ger -st ic k B G m o nit ori n g, i ncl u di n g sc he d ule d B G pr ofiles wit h u p t o 7 
meas ure me nts i n 1 da y  
( b) lear n h o w t o self- i nject st u d y  dr u gs ,as re q ui r e d f or t his pr ot oc ol ( vis uall y i m paire d 
pers o ns w h o are n ot a ble t o perf or m t he i nject i o ns m ust ha ve t he assista nce of a 
si g hte d i n di vi d ual trai ne d t o i nject t he st u d y  dr u g; pers o ns wi t h  p h ysical li mitat i o ns 
w h o are n ot a ble t o perf or m t he i nject i o ns m u st ha ve t he assista nce of a n i n di vi d ual 
trai ne d t o i nject t he st u d y  dr u g) 
(c) are willi n g a n d a ble t o i nject st u d y dr u gs 
( d ) m ai ntai n st u d y  di aries , as re q uire d f or t his pr ot oc ol 
(e) ha ve a s ufficie nt u n dersta n di n g of o ne of t he pr o vi de d la n g ua ges of t he c o u ntr y  
s uc h t hat t he y  will  be a ble t o c o m plete t he pati e nt q uesti o n naires 
I nf or me d C o nse nt 
[ 7 ]Ha ve gi ve n writte n i nf or me d c o nse nt t o partici pate i n t his st u d y  i n acc or da nce 
wi t h  l o c al  re g ulat i o ns a n d t he et hi cal r e vie w boar d ( E R B) g o ver ni n g t he st u d y  
si t e 
6. 2. E x cl u si o n Crit eri a 
P ati e nts will be e xcl u de d fr o m st u d y  e nr o ll me nt if t he y meet a n y o f t h e f ol l o wi n g cri t eri a at 
scree ni n g :
Me dic al C o n diti o ns 
[ 8 ]Ha ve t y pe 1 dia betes mellit us ( T 1 D M) 
[ 9 ]Ha ve a hist or y  of c hr o nic or ac ute pa ncreatit is a n y ti me pri or t o st u d y  e ntr y  
( Vi si t 1) 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e 3 2 
L Y 3 2 9 8 1 7 6 [ 1 0]Ha ve hist or y  of 
pr oliferat i ve dia bet ic reti n o pat h y ,
or 
di a bet ic mac ul o pat h y ,
or 
n o n pr o liferat i ve dia bet ic reti n o pat h y t hat re q uires ac ute treat me nt 
( a dilate d f u n d osc o pic e xa mi nat i o n perf or me d b y a n o p ht hal m o l o gist or 
o pt o m etrist bet wee n Visit 2 a n d Visit 3 is re q uire d t o c o nfir m eli gi bilit y)  
[ 1 1]Ha ve a hist or y  of  ket oaci d osi s or h y p er os m ol ar state/c o m a
[ 1 2]Ha ve a k n o w n cli nicall y si g nifica nt gastric e m pt yi n g a b n or malit y (f or 
e xa m ple, se vere dia bet ic gastr o paresis or gastric o utlet o bstr ucti o n), ha ve 
u n der g o ne or pla n t o ha ve d uri n g t he c o urse of t he st u d y :  gastri c b y pass 
( bariatric) s ur ger y  or restri ct i ve bariatric s ur ger y (f or e xa m ple, La p -Ba n d ®), 
or c hr o ni call y ta ke dr u gs t hat direct l y affect GI m o tilit y
[ 1 3]Ha ve a n y of t he f o ll o wi n g car di o vasc ular ( C V )c o n dit i o ns wit hi n 2 m o nt hs 
pri or t o Visit 1:  ac ute m y ocar dial  i nfarcti o n, cere br o vasc ular acci de nt 
(str o ke), or h os pi[INVESTIGATOR_90730] i o n d ue t o c o n gesti ve heart fail ure ( C H F) 
[ 1 4]Ha ve a hist or y  of  Ne w Y or k Heart Ass ociat i o n F u nct i o nal Classificati o n I V 
C H F 
[ 1 5]Ha ve ac ute or c hr o nic he pat it is, si g ns a n d s y m pt o ms of a n y li ver disease 
ot her t ha n n o nalc o h o lic fat t y  l i ver disease ( N A F L D), or ala ni ne 
a mi n otra nsferase ( A L T) le vel > 3. 0 ti mes t he u p per li mit of n or mal ( U L N) f o r 
t h e refere nce ra n ge, as deter mi ne d b y t he ce ntral la b orat or y  at st u d y  e ntr y .  
P ati e nts wi t h  N A F L D are eli gi ble t o partici pate i n t his trial if t heir A L T le vel 
is ≤3. 0 ti mes t he U L N f o r t he refere nce ra n ge 
[ 1 6]Ha ve a n est i mate d gl o mer ular filtrati o n rate < 3 0 m L/ mi n/ 1. 7 3 m 2, c al c ulate d 
b y C hr o nic Ki d ne y Disease -E pi [INVESTIGATOR_32450] o g y as deter mi ne d b y ce ntral  
la b orat or y  at Vi si t 1 
[ 1 7]Ha ve e vi de nce of a si g nifica nt, u nc o ntr olle d e n d ocri ne a b n or malit y (f or 
e xa m ple, t h y r ot o xi c osis or a dre nal crises), i n t he o pi [INVESTIGATOR_9384] o n of t he i n vesti gat or 
[ 1 8]Ha ve fa mil y or pers o nal hist or y  of  me d ullar y t h yr oi d carci n o ma ( M T C) or 
Mul ti ple E n d ocri ne Ne o pl asia t y pe 2 ( M E N 2) 
[ 1 9 ]Ha ve a ser u m  c al ci t o ni n le vel of ≥ 3 5 n g/ L , as deter mi ne d b y ce ntral 
la b orat or y  at Vi si t 1 
[ 2 0]K n o w n or s us pecte d h y perse nsi ti vit y t o trial pr o d uct(s) or relate d pr o d ucts 
[ 2 1]Ha ve e vi de nce of a si g nifica nt, a ct i ve a ut oi m m u ne a b n or malit y (f or e xa m ple, 
l u p us or r he u mat oi d art hrit is) t hat, i n t he o pi [INVESTIGATOR_9384] o n of t he i n vest i gat or, is li kel y 
t o re q uire c o nc urre nt treat me nt wit h s yste mic gl uc oc ortic o i ds i n t he ne xt 1 2 
m o nt hs 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e 3 3 
L Y 3 2 9 8 1 7 6 [ 2 2]Ha ve ha d a tra ns pla nte d or ga n (c or neal tr a ns pla nts [ kerat o plast y] all o we d) or 
a wai ti n g a n or ga n tra ns pla nt 
[ 2 3]Ha ve a hist or y  of  a n act i ve or u ntreate d mali g na nc y or are i n re missi o n fr o m 
a cli nicall y  si g nifica nt m ali g na nc y  ( ot her t ha n basal  or s q u a m o us cell s ki n 
ca ncer, i n sit u carci n o mas of t h e cer vi x, or i n sit u pr ostate ca ncer) f or less 
t h a n 5 y ears 
[ 2 4]Ha ve a hist or y  of  a n y ot her c o n dit i o n (s uc h as k n o w n dr u g, alc o h o l a b use, or 
ps yc hiatric dis or der) t hat, i n t he o pi [INVESTIGATOR_9384] o n o f t h e i n vesti gat or, ma y precl u de t he 
pati e nt f r o m  f ol l o wi n g a n d c o m p le ti n g t he pr ot oc ol 
[ 2 5]Ha ve a n y he mat ol o gical c o n dit i o n t hat m a y i nterfere wit h H b A 1c 
meas ure me nt (f or e xa m ple, he m o l y ti c a ne mias, sic kl e cell  disease) 
Pri or/ C o nc o mit a nt T her a p y 
[ 2 6 ]Use of a n y  O A M d uri n g t he 3 m o nt hs prece di n g t o Visit 1 
[ 2 7]Ha ve a hist or y  of  use of a n y  i njecta ble t hera p y  f or T 2 D M treat m e nt e xce pt 
f o r t he use of i ns uli n f or treat me nt of gestati o nal dia betes, or s h ort -t e r m  use 
(1 4 da y s) f or ac ute c o n di ti o ns s uc h as ac ute ill ness, h os pi[INVESTIGATOR_90730] i o n, or 
el ect i ve s ur ger y 
[ 2 8]Ha ve bee n tr eate d wit h prescri pti o n dr u gs t hat pr o m ote wei g ht l oss (f or 
e xa m ple, Sa xe n da [lira gl ut i de 3. 0 m g], Xe nical ®[ orlistat], Meri dia ®
[si b utra mi ne], Ac utri m ®[ p he n yl pr o pa n o la mi ne], Sa n ore x ®[ m azi n d o l] , 
A di p e x ®[ p he nter mi ne], B E L VI Q ®[l orcaseri n], Qs y mia ™
[ p he nt er mi ne/t o pi[INVESTIGATOR_77333] c o m bi nat i o n], C o n tra ve ®[ naltre x o ne/ b u pr o pi o n], or 
si milar ot her b o d y  w ei g ht l oss me dicat i o ns i ncl u di n g o ver -t h e- c o u nter [ O T C] 
me dicat i o ns [f or e xa m ple, allī ®]) wi t hi n 3 m o nt hs pri or t o Visit 1 a n d/ or 
bet wee n st u d y  e ntr y  ( Vi si t 1) a n d ra n d o mizat i o n ( Vi si t 3 )
[ 2 9]Are recei vi n g c hr o nic ( > 2 wee ks or 1 4 da y s) s yste mic gl uc oc ortic o i d t hera p y 
(e xcl u di n g t o pi[INVESTIGATOR_2855], i ntra oc ular, i ntra nasal, or i n hale d pre parati o ns) or ha ve 
recei ve d s uc h t hera p y  wi t h i n 1 m o nt h of Visit 1 or bet wee n Visit s 1 a n d 3 
Pri or/ C o nc urre nt Cli nic al Tri al E x perie nce 
[ 3 0 ] Are c urre nt l y e nr olle d i n a n y ot her cli nical st u d y  i n v o l vi n g a n i n vest i gat i o nal 
pr o d uct or a n y  ot her t y pe of me dical researc h j u d ge d n ot t o be scie nt ificall y 
or m e dicall y c o m pat i ble wit h t his st u d y 
[ 3 1 ] H a ve part ic i pate d, wit hi n t he last [ADDRESS_1239725] has 5 half -
li ves or 3 0 da y s( w hic he ver i s l o n ger) ,s h o ul d ha ve passe d pri or t o scree ni n g 
[ 3 2 ] H a ve pre vi o usl y c o m p lete d or wi t h dra w n fr o m  t his st u d y  or a n y  ot her st u d y  
i n vesti gat i n g ti rze pat i de 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e 3 4 
L Y 3 2 9 8 1 7 6 Ot her E xcl usi o ns 
[ 3 3 ] A re i n vest i gat or site pers o n nel directl y affiliate d wit h t his st u d y  a n d/ or t hei r 
i m me diate fa milies.  I m me diate fa mil y is defi ne d as a s p o use, pare nt, c hil d, 
or si bli n g, w het her bi o l o gical  or l e gall y a d o pte d 
[ 3 4] A re Lill y  e m pl o y ees 
[ 3 5] A re u n willi n g or u na ble t o c o m pl y  wi t h  t he use of a data c ollect i o n de vice t o 
di rect l y rec or d d at a fr o m t he patie nt 
6. 3. Lif e st yl e Re stri cti o n s 
Per t he Sc he d ule of Act i vit ies ( Sect i o n2), q ualifie d me dical staff will pr o vi de dia betes 
ma na ge me nt c o u nseli n g, w hic h will i ncl u de i nstr ucti o ns o n diet a n d e xercise a n d e d ucat i o n 
a b o ut t he si g ns, s y m pt o ms, a n d treat me nt of h y p o gl yce mia , s h o ul d i t occ ur .  
P ati e nts s h o ul d c o nt i n ue t heir us ual e xercise ha bits a n d ge nerall y f o ll o w a heal t h y meal pla n 
( wi t h  c o nsiste nt meal size a n d ti me of da y ) t hr o u g h o ut t he c o urse of t he st u d y .  Dietar y  
c o u nseli n g ma y be re vie we d t hr o u g h o ut t he st u d y , as nee de d.  Per Incl usi o n Cri t eri o n [ 4 ] 
(Secti o n 6. 1 ), patie nts s h o ul d n ot i nit iate a n or ga nize d diet a n d/ or e xercise (wei g ht re d ucti o n )
pr o gra m d uri n g t he st u d y  ot her t ha n t he lifest yle a n d dietar y meas ures f or dia betes treat me nt. 
St u d y  p arti ci pa nts s h o ul d be i nstr ucte d n ot t o d o nate bl o o d or bl o o d pr o d ucts d uri n g t he st u d y .
6. 4. S cr e e n F ail ur e s 
I n di vi d uals w h o d o n ot meet t he criteria f or partici pati o n i n t his st u d y  (scree n fail ure) m ust n ot 
be rescree ne d .
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239726] er e d 
P ati e nt swill be ra n d o mize d i n a 1: 1: 1: [ADDRESS_1239727] u d y  f or t he 5 -m g gr o u p.  F or t he 1 0 -m g gr o u p, t he starti n g d ose of 
ti rze pat i de will be 2. 5 m g Q W f or 4 wee ks, t he n t he d ose will be i ncrease d b y 2. 5 m g e ver y 4 
wee ks ( 2. 5 m g t o 5 m g t o 7. 5 m g t o 1 0 m g) u nt il t he [ADDRESS_1239728] u d y .  F or t he 1 5 -m g ar m, t he starti n g d ose of ti rze pat i de will be 2. 5 m g Q W 
f o r 4 wee ks, t he n t he d ose will be i ncrease d b y  2. 5 m g e ver y  4 wee ks ( 2. 5 m g t o 5 m g t o 7. 5 m g 
t o 1 0 m g t o 1 2. 5 m g t o 1 5 m g) u nt il t he [ADDRESS_1239729] b o Q W Si n gle -d ose pe n S C 
A b bre viati o ns: Q W =o nce wee kl y; S C =s u bc uta ne o us .
T he i n vest igat or or his or her desi g nee is res p o nsi ble f or t he f oll o wi n g: 
e x plai ni n g t he c orrect use of t he i n vesti gati o nal a ge nt(s) t o t h e patie nt . F or S D P, 
a de m o nstrati o n de vice will be use d 
verif yi n g t hat i nstr ucti o ns are f o ll o we d pr o perl y 
mai ntai ni n g acc urate rec or ds of i n vesti gati o nal pr o d uct dis pe nsi n g a n d c o llect i o n
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239730] i vit ies 
(Secti o n 2).  Patie nts s h o ul d be i nstr ucte d t o discar d all use d S D Ps i n a cl osea ble, 
p u nct ure -resi sta nt c o ntai ner acc or di n g t o l ocal r e g ul at i o ns. 
7. 1. 1. P a c k a gi n g a n d L a b elli n g 
T he s p o ns o r will pr o vi de t ir ze pat i de a n d place b o i n S D Ps.   T hese will be dis pe nse d via a n 
i nt eract i ve we b -res p o nse s yste m (I W R S).  Si n gle -d ose pe ns will be pac ka ge d i n cart o ns t o be 
di s pe nse d.  Cli nical st u d y  m at eri als will  b e la bele d acc or di n g t o t he c o u ntr y ’s re g ul at or y  
re q ui re me nts. 
7. 1. 2. M e di c al D e vi c e s 
T he c o m bi nat i o n pr o d ucts pr o vi de d f o r use i n t he st u d y  are ti rze pat i de i n vest i gat i o nal S D P a n d 
pl ace b o S D P .
7. 2. Met h o d of Tr e at m e nt A s si g n m e nt 
P ati e nts w h o m eet all cri t eri a f or e nr oll me nt will be ra n d o mize d t o [ADDRESS_1239731] u d y  treat m e nt 
gr o u ps at Visit 3.  Assi g n me nt t o treat me nt gr o u ps will be deter mi ne d b y a c o m p uter -ge nerate d 
ra n d o m se q ue nce usi n g a n I W R S.  Patie nts will be ra n d o mize d i n a 1: 1: 1: [ADDRESS_1239732] u g s 
Assi g n me nt t o ti rze pat i de ( 3 d oses) or place b o will occ ur at ra n d o mizati o n .  
T here are n o restrict i o ns o n t he ti me of da y  eac h wee kl y d ose of st u d y  dr u g is gi ve n, b ut it is 
a d visa ble t o a d mi nister t he S C i njecti o ns o n t he sa me da y a n d sa me ti me eac h wee k , wi t h  or 
wi t h o ut m eals .  T he act ual  date a n d ti me of all d ose a d mi nistrati o ns will be rec or de d b y  t he 
pati e nt .  If a d ose of st u d y  dr u g is misse d, t he patie nt s h o ul d ta ke it as s o o n as p ossi ble u nless it 
is wit hi n [ADDRESS_1239733] i o n 
s u p plies pr o vi de d; a care gi ver ma y  a d mi nister t he i nject i o n i n t he patie nt’s u p per ar m. A ne w 
S D P will be use d f or eac h i nject i o n. If st u d y  dr u g is t o al wa ys be i njecte d i n t he sa me b o d y  
r e gi o n, pati e nts s h o ul d be a d vise d t o use a differe nt i njecti o n site eac h wee k. 
7. 3. Bli n di n g 
T his is a d o u ble -bli n d st u d y .I n vest i gat ors, site staff, cli nical m o nit ors ,a n d patie nts will re mai n 
bli n de d t o t he treat me nt  assi g n me nts u ntil t he st u d y  i s c o m plete. 
E mer ge nc y  u n bli ndi n g f or A Es m a y  b e perf or m e d t hr o u g h t h e I W R S, w hic h ma y s u p ple me nt or 
ta ke t he place of e mer ge nc y  c o des ge nerate d b y  a c o m p uter dr u g -la beli n g s yste m. T hi s o pti o n 
ma y be use d O N L Y if t he pati e nt ’s well -bei n g re q uires k n o wle d ge of t he patie nt ’s treat m e nt 
assi g n me nt. All act i o ns res ult i n g i n a n u n bli n di n g e ve nt are rec or de d a n d re p orte d b y  t he I W R S. 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239734] i gat or has t he s ole res p o nsi bilit y f o r deter mi ni n g if u n b li n di n g 
of  a pati e nt ’s treat m e nt assi g n me nt is warra nte d f o r m e dical ma na ge me nt of t he e ve nt.  T he 
pati e nt’s safet y m u st al wa ys be t he first c o nsi derati o n i n ma ki n g s uc h a deter mi nat i o n.  If a 
pati e nt’s treat me nt assi g n me nt is u n bli n de d, Lill y m ust be n oti fie d i m me diatel y. If t he 
i n vesti gat or deci des t hat u n bli n di n g is warra nte d, it is t he res p o nsi bilit y of  t he i n vesti gat or t o 
pr o m ptl y d oc u m e nt t he decisi o n a n d rati o nale a n d n otif y Lill y as s o o n as p ossi ble. 
If a n i n vest i gat or, site pers o n nel perf or mi n g a ssess me nts, or patie nt is u n bli n de d, t he patie nt will 
c o nti n ue o n t he assi g ne d t hera p y  t hr o u g h t he e n d of t he st u d y , if  m e dicall y a p pr o priate. St u d y 
si te pers o n nel a n d t he s p o ns or will d oc u me nt a n y  u n bli n di n g e ve nts. 
7. 4. D o s a g e M o difi c ati o n 
7. 4. 1. St u d y Dr u g s 
N o a dj ust me nt  i n st u d y  dr u g d oses will be all o we d. Details a b o ut d ose a d mi nistrati o n of 
ti rze pat i de d uri n g t he st u d y  are descri be d i n Sect i o ns 7. 2. [ADDRESS_1239735] u d y o nl y i n t he 
f o ll o wi n g sit uat i o ns: 
As a n a nt i h y per gl yce mic i nter ve nt i o n f o r se vere, persiste nt h y per gl yce mia ( “resc ue 
t h era p y ”), as defi ne d i n Sect i o n 9. 2. 2. 2 .
I n t h ose patie nts w h o re q uire per ma ne nt disc o nt i n uati o n of st u d y  dr u g, b ut re m ai n i n t he 
st u d y  ( Secti o n 8. 1. 1 )
D uri n g t he saf et y fol l o w- u p p eri o d ( bet wee n Visi t 1 4[ Wee k 4 0 ] or E T a n d Visit 8 0 1) ,
o nl y  if  t he pat ie nt  nee ds a d dit i o nal gl yce mic c o ntr ol as o utli ne d i n Sect i o n 5. [ADDRESS_1239736] u d y  P eri o d III (safet y f o ll o w- u p peri o d) disc ussi o n .
If a ne w a nt i h y per gl yce mic me dic at i o n is i nt r o d uce d, met f o r mi n will be t he first c h oice of 
t h era p y  u nless c o ntrai n dicate d. Gl uca g o n -li ke p e pti de- [ADDRESS_1239737] resc ue i nter ve nt i o n f o r h y per gl yce mia 
s h o ul d be reser ve d f or patie nts wit h se vere, persiste nt h y per gl yce mia wit h a n a vera ge F S G ≥ 3 0 0 
m g/ d L ( ≥ 1 6. 7 m m ol / L) or i n ot her cli nical sit uat i o ns w here t he i n vesti gat or belie ves m ore ra pi d 
gl yce mic c o ntr ol is warra nte d. 
7. 5. Pr e p ar ati o n/ H a n dli n g/ St or a g e/ A c c o u nt a bilit y 
T he i n vest i gat or or h is or her desi g nee is res p o nsi ble f or t he f oll o wi n g: 
c o nfir mi n g a p pr o priate t e m perat ure c o n di ti o ns ha ve bee n mai ntai ne d d uri n g 
tra nsi t f or all st u d y  treat m e nt recei ve d a n d a n y discre pa ncies are re p orte d a n d 
res ol ve d bef ore use of t he st u d y  tr e at m e nt. 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e 3 8 
L Y 3 2 9 8 1 7 6 e ns uri n g t hat o nl y partici pa nts e nr o lle d i n t he st u d y ma y recei ve st u d y treat me n t 
a n d o nl y  a ut h ori ze d si te staff ma y  s u p pl y  or a d mi nister st u d y  treat m e nt. All st u d y 
treat m e nts m ust be st ore d i n a sec ure, e n vir o n me ntall y  c o ntr olle d, a n d m o ni t or e d 
( m a n ual  or a ut o m ate d) area i n acc or da nce wit h t he la bele d st ora ge c o n dit i o ns 
wi t h  access li mite d t o t he i n vest i gat or a n d a ut h orize d site staff .
the i n vest i gat or, i nst it ut i o n, or t he hea d of t he me dical i nst it uti o n ( w here 
a p plica ble) is res p o nsi ble f or st u d y  treat m e nt acc o u nta bilit y,  rec o nciliat i o n, a n d 
rec or d m ai nte na nce (s uc h as recei pt, rec o nciliat i o n,a n d fi nal dis p osit i o n rec or ds). 
T he st u d y  si t e m ust st ore t he st u d y  dr u g i n a l oc ke d a n d sec ure e n vir o n me nt. Pl ease refer t o t he 
st u d y  dr u g l a bel f or s pecific st ora ge c o n dit i o ns.  Pati e nts will  recei ve i ns ulate d ba gs wit h c o oli n g 
g el  pac ks f or use i n tra ns p orti n g t he st u d y  dr u g cart o n fr o m  t he si te t o h o m e. 
St u d y  si te staff m ust re g ul arl y  assess w het her t he patie nt is c orrectl y a d mi nisteri n g t he assi g ne d 
st u d y  dr u g a n d st ori n g t he st u d y  dr u g acc or di n g t o t he pr o vi de d i nstr ucti o ns. 
7. 6. Tr e at m e nt C o m pli a n c e 
St u d y  dr u g c o m plia nce will  be deter mi ne d b y  t he f oll o wi n g: 
St u d y  dr u g a d mi nistrati o n data will be rec or de d b y t he patie nt a n d re vie we d b y  
t h e i n vest i gat or at eac h st u d y visit. 
T h e pati e nts will  be i nstr ucte d t o ret ur n a n y  u n use d st u d y  dr u g a n d/ or e m pt y 
cart o ns at t he ne xt visit t o t he st u d y  si t e f or t he p ur p ose of perf or mi n g dr u g 
acc o u nta bilit y. 
I n t h e3 ti rze pat i de treat me nt gr o u ps, as well as t he place b o gr o u p , treat me nt c o m plia nce f or eac h 
visit i nter val is defi ne d as ta ki n g at least 7 5 % of t he re q uire d d oses of st u d y  dr u g.  Si milarl y , a 
pati e nt will be c o nsi dere d si g nifica ntl y n o nc o m p lia nt if he or s he is j u d ge d b y  t he i n vesti gat or t o 
ha ve i nte nt i o nall y  or re peate dl y ta ke n m ore t ha n t he prescri be d a m o u nt of me dicat i o n.  
I n a d dit i o n t o t he as sess me nt of a patie nt’s c o m p lia nce wit h t he st u d y dr u g a d mi nistrati o n, ot her 
as pects of c o m plia nce wit h t he st u d y  treat me nts will be assesse d at eac h visit base d o n t he 
pati e nt’s a d here nce t o t he visit sc he d ule, c o m plet i o n of st u d y  di ari es, t he res ul ts of  h o me B G 
m o nit ori n g, a n d a n y ot her para meters t he i n vesti gat or c o nsi ders necessar y .
P ati e nts c o nsi dere d t o be p o orl y  c o m plia nt wi t h  t h ei r m e dicati o n a n d/ or t he st u d y  pr oce d ures 
will recei ve a d dit i o nal trai ni n g a n d i nstr ucti o n, as re q uire d, a n d will be re mi n de d of t he 
i m p orta nce of c o m p l yi n g wit h t he pr ot oc ol. 
7. 7. C o n c o mit a nt T h er a p y 
P ati e nts will  b e per mitte d t o use c o nc o mita nt me dicati o ns t hat t he y  r e q ui re d uri n g t he st u d y , 
e xce pt certai n me dicat i o ns t hat ma y i nterfere wit h t he assess me nt of efficac y a n d safet y 
c haracterist ic s of t he st u d y  tr e at m e nts. 
I n vest i gat i ve site staff will i nf or m pat ie nt s t hat t he y m ust c o ns ult wit h t he i n vesti gat or or a 
desi g nate d site staff me m ber u p o n bei n g prescri be d a n y ne w me dicat i o ns d uri n g t he st u d y .  T hi s 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239738] u d y  (i ncl u di n g O T C dr u gs, s u c h as 
paraceta m o l or as pi [INVESTIGATOR_27969] n) m ust be d oc u m e nte d, a n d t he na me of t he dr u g a n d t he date(s) of 
a d mi nistrati o n m ust be rec or de d o n t he “ C o nc o mit a nt Me dicat i o ns” sect i o n of t he e C R F. 
A nt i h y per gl yce mic me dicat i o ns ot her t ha n st u d y  dr u gs are n ot all o we d at a n y ti me d uri n g t he 
st u d y  e xce pt as all o we d f or t h ose pati e nts w h o re q ui re per m a ne nt di sc o nt i n uat i o n of st u d y  dr u g, 
b ut re m ai n i n t he st u d y ; resc ue t h era p y af ter ra n d o mizat i o n d ue t o se vere, persiste nt 
h y per gl yce mia ;or d uri n g t he safet y f o ll o w- u p peri o d (see Secti o n 7. 4. 2 ).   S h ort -t er m i ns uli n use 
f o r u p t o 1 4 da ys is all o we d f or certai n cli nical sit uati o ns (f or e xa m ple, elect i ve s ur ger y, d uri n g 
h os pi [INVESTIGATOR_1314] o n, h y per os m ol ar states) a n d m ust be differe nt iat e d fr o m i ns uli n use as resc ue 
t h era p y w he n re p orte d i n t he e C R F .  
All n o n st u d y  m e dicati o ns will be rec or de d o n t h e e C R F at all  visi ts .
N o nst u d y me dicat i o ns ta ke n b y  pat ie nt s w h o are scree ne d b ut n ot ra n d o mize d will n ot be 
re p orte d t o Lill y  u nless a n S A E or A E occ urs t h at t he i n vest i gat or belie ves ma y ha ve bee n 
ca use d b y  a st u d y  pr oce d u re. 
7. 8. Tr e at m e nt aft er t h e E n d of t h e St u d y 
7. 8. 1. Tr e at m e nt aft er St u d y C o m pl eti o n 
St u d y  c o m pl et i o n will occ ur after all pat ie nt s c o m pl ete t he f oll o w -u p visit.   I n vest i gat ors will 
c o nti n ue t o f o ll o w Sc he d ule of Act i vit ies ( Secti o n 2) f or all  patie nts u ntil n otifie d b y Lill y t hat 
st u d y  c o m plet i o n ha socc urre d. 
Ti rze pati d e will n ot be ma de a vaila ble after c o nc l u si o n of  t he st u d y  t o pati e nts. 
7. 8. 2. S p e ci al Tr e at m e nt C o n si d er ati o n s 
T his sect i o n pr o vi des g ui da nce o n ma na ge me nt of e pis o des of h y p o gl yc e mic e ve nts ;se vere, 
persiste nt h y per gl yce mia d uri n g t he treat me nt peri o d ;patie nts w h o per ma ne nt l y disc o nt i n ue 
st u d y  dr u g pri or t o Vi si t 1 4 ;a n d pat ie nt s wi t h  GI s y m pt o m s.   F or effect i ve i m ple me ntati o n of 
meas ures descri b e d here, i t i s i m p orta nt t hat patie nts, a n d t heir care gi vers, if a p plica ble, be well 
e d ucate d a b o ut t he si g ns a n d s y m pt o ms of h y per gl yce mia ( f o r e xa m ple , se vere t hirst, dr y  m o ut h, 
fre q ue nt mict urit i o n, or dr y  s ki n) a n d h y p o gl yce mia ( f o r e xa m ple , i nte nse h u n ger, s weati n g, 
tr e m or, restless ness, ir ri ta bili t y , de pressi o n , hea dac hes, di st ur be d slee p, or tra nsie nt ne ur ol o gical 
di s or ders).  Patie nts s h o ul d be i nstr ucte d t o c o ntact t he i n vesti gati ve site i n t he e ve nt of se vere, 
persiste nt h y per gl yce mia or se vere h y p o gl yce mia bet wee n st u d y  visi ts or i n t he e ve nt w he n a 
pati e nt i nte n ds t o per m a ne nt l y disc o nti n ue st u d y  dr u g. 
7. 8. 2. 1. St a n d ar d s of M e di c al C ar e 
I n vest i gat ors a n d ot her st u d y  t e a m  m e m bers are e x pecte d t o treat patie nts acc or di n g t o t he 
nat i o nall y  esta blis he d sta n da r ds of care f or dia betes ma na ge me nt i n res pect i ve partici pat i n g 
c o u ntri es, e xce pt w here t hat treat me nt w o ul d be i n c o nflict wit h t h e pr ot oc ol -pr o vi de d treat m e nt 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239739] u d y  of  Dia betes ( Da vies et al. 2 0 1 8) d uri n g t heir patie nts ’part ic i pat i o n i n t his 
st u d y .
7. 8. 2. 2. M a n a g e m e nt of H y p o gl y c e mi a Ri s k 
I n t hi s st u d y , i ncrease d ris k o f h y p o gl yce mia is defi ne d as ha vi n g a si n gle e pis o de of se vere 
h y p o gl yce mia or ha vi n g m ore t ha n [ADDRESS_1239740] e ns ure t hat 
t h e pati e nt has bee n f ull y  c o m plia nt wi t h  t he assi g ne d t h era pe ut ic re gi me n a n d als o t hat t here is 
n o e vi de nce of ot her p ossi ble ca uses of h y p o gl yce mia (f o r e xa m ple , o missi o n  of  m eal , 
u ne x pecte d i ncrease i n e xercise). If t he p ati e nts f ulfill t he defi nit i o n of i ncrease d ris k of 
h y p o gl yce mia, t h e i n vest i gat or s h o ul d di sc o nti n ue t he pati e nt f r o m  st u d y  treat m e nt a n d f o ll o w 
t h e g ui da nce f or ma na ge me nt of pati ent s t o per ma ne nt l y disc o nt i n u e t h est u d y  dr u gs as o utli ne d 
i n S e cti o n 8. 1. [ADDRESS_1239741] i gat ors will be trai ne d o n t he a p plicat i o n of cri t eri a f or d e ci di n g w he n a n d h o w t o i nter ve ne 
wi t h  patie nts w h o d o n ot reac h gl yce mic tar gets.  If a n y of t he F B G val ues wi t hi n 1 wee k f or 2 
c o nsec ut i ve wee ks e xcee d t he li m it s o utli ne d bel o w a n d n o i nterc urre nt ca use of t he 
h y per gl yce mia c o ul d be i de nt ifie d (i n vest i gat ors s h o ul d first c o nfir m t hat t he patie nt is f ull y 
c o m plia nt wi t h  t he assi g ne d t hera pe utic re gi me n a n d t hat he or s he d oes n ot ha ve a n ac ute 
c o n di ti o n ca usi n g se vere h y per gl yce mia), r esc ue me dicat i o n will be prescri be d as a n a d d -o n t o 
ra n d o mize d treat me nt . P at ie nt s will c o nt i n ue t o f oll o w t he pr ot oc ol -s pecifie d visit sc he d ule as 
descri be d i n Secti o n 7. 4. 2 .
>2 7 0 m g/ d L ( >1 5. 0 m m o l/ L) fr o m baseli ne t o Wee k 6 ( 4 val ues/ wee k) 
>2 4 0 m g/ d L ( >1 3. 3 m m o l/ L) fr o m Wee k 6 t o Wee k 1 2 ( 4 val ues/ wee k) 
>2 0 0 m g/ d L ( >1 1. 1 m m o l/ L) fr o m Wee k 1 2 t o e n d of trial ( 4 val ues/ wee k) 
O R 
H b A 1c ≥ 8. 5 % ( ≥ 6 9 mm o l/ m ol)  b y a n d after Wee k [ADDRESS_1239742] all pla n ne d effica c y  a n d safet y meas ure me nts a n d 
s h o ul d recei ve a n ot her gl uc ose -l o weri n g i nter ve nt i o n ( Secti o n 7. 4. 2 ). T he ne w gl uc ose -l o weri n g 
i nt er ve nt i o n will be rec or de d o n t he e C R F s pecifie d f or c ollecti n g a nt i h y per gl yce mic 
me dicat i o ns. 
T o ass ure ti mel y i nit iat i o n of a n ot her a nti h y per gl yce mic me dicat io n after per m a ne nt 
di sc o nti n uat i o n of st u d y  dr u g, patie nts s h o ul d be a d vise d t o pr o m pt l y n otif y  t he si te w he n t his 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239743] i gat or s h o ul d e val uate t he nee d f or a d di ti o nal a nt i h y per gl yce mic 
me dicat i o n at t hi s t i me (as o utli ne d i n Sect i o n7. 4. 2 ) a n d i nit iate t he a d dit i o nal i nt er ve nt i o n
acc or di n gl y. A n u nsc he d ule d visit s h o ul d be use d as nee de d f or m ore ti mel y  i ni ti at i o n if 
warra nte d base d o n t he i n vest i gat or ’s cli nical j u d g me nt. 
7. 8. 2. 5. M a n a g e m e nt of P ati e nt s wit h G a str oi nt e sti n al S y m pt o m s 
I n t he P hase [ADDRESS_1239744] c o m m o nl y  re p orte d treat me nt -e mer ge nt A Es ( T E A Es) f or 
pati e nts recei vi n g tirze pat i de were na usea, v o mit i n g, a n d di arr hea. 
T he ti rze pat i de d ose escalat i o n sc he me has bee n desi g ne d t o mi ni mize t he de vel o p me nt of 
i nt ol era ble GI s y m pt o m s.  T he escalat i o n peri o d is c o nsi dere d t o be [ADDRESS_1239745] u g d osa ge. 
T o mit i gate GI s y m pt o ms a n d ma na ge patie nts wit h i nt ole ra ble GI A Es d uri n g t he escalat i o n 
p eri o d ( Wee k 0 t o 2 4) , t he i n vesti gat or s h o ul d 
ad vise patie nts t o eat s maller meals, f or e xa m ple, s plitti n g [ADDRESS_1239746] o p eati n g w he n t he y  f e el  f ull. 
prescri be s y m pt o mat ic me dicat i o n (f or e xa m ple, a nt ie met ic or a nti diarr heal 
me dicat i o n) per l ocal c o u ntr y  a vaila bilit y a n d i n di vi d ual patie nt nee ds. Use of 
s y m pt o m at ic me dicat i o n s h o ul d be ca pt ure d as c o nc o mita nt me dicat i o n i n t he 
e C R F. 
te m p oraril y i nterr u pt tirze pat i de ( o mit 1 d ose, t he patie nt will ta ke 3 of 4 d os es at 
t h at d ose le vel).  After t he i nterr u pti o n, restart at t he sa me d ose wit h t he patie nt 
ta ki n g me dicat i o n t o alle viate t heir GI s y m pt o ms .T he data relate d t o te m p orar y  
i nt err u pti o n of  st u d y  treat m e nt s h o ul d be d oc u me nte d i n s o urce d oc u me nts a n d 
e ntere d o n t he e C R F.  
If i nt olera ble GI s y m pt o ms or e ve nts persist des pi[INVESTIGATOR_040] t he a b o ve meas ures, t he 
i n vesti gat or ma y  deci de t o disc o nt i n ue st u d y  dr u gs . De- escalati o n of st u d y  dr u gs 
will n ot be all o we d . Patie nts w h o st o p t he st u d y dr u g per ma ne ntl y will recei ve 
an ot her gl uc ose -l o weri n g i nter ve nt i o n( Secti o n 7. 4. 2 ) a n d will c o nt i n ue 
parti ci pat i n g i n t he st u d y acc or di n g t o t he pr ot oc ol t o c ollect all pla n ne d efficac y  
a n d safet y meas ure me nts. T he ne w gl uc ose -l o weri n g i nt er ve nt i o n will be 
rec or de d o n t he e C R F s pecifie d f or c ollecti n g a nt i h y per gl yce mic me dicat i o ns .
I n t he e ve nt of i nt ol era ble persiste nt GI s y m pt o ms t h at occ ur after t h e escalati o n peri o d ( af t er 
Wee k 2 4) , t he i n vest i gat or s h o ul d ta ke t he a b o ve meas ures t o kee p t he patie nt o n st u d y  treat m e nt 
bef ore st o p pi n g t he st u d y  dr u g per m a ne ntl y a n d i niti ate a n ot her gl uc ose -l o weri n g i nter ve nt i o n. 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239747] :
P atie nt Decisi o n 
oThe patie nt re q uests t o disc o nt i n ue i n vest i gat i o nal pr o d uct. 
Disc o nti n u ati o n d ue t o i ncre ase d ris k of h y p o gl yce mi a 
Pl ease refer t o S ecti o n 7. 8. 2. 2 f o r details .
Disc o nti n u ati o n d ue t o a he p atic e ve nt or li ver test a b n or m alit y 
P ati e nts w h o are disc o nt in ue d fr o m i n vest i gat i o nal pr o d uct d ue t o a he pat ic e ve nt or li ver 
test a b n or m ali t y  s h o ul d ha ve a d di ti o n al  h e pat ic safet y  data c oll ecte d vi aa n eC R F. 
Di sc o nti n uati o n of  t he i n vest i gat i o nal pr o d uct f or a b n or mal li ver tests s h o ul d be 
c o nsi dere d b y t he i n vesti gat or w he n a patie nt meets o ne of t he f o ll o wi n g c o n di ti o ns af t er 
c o ns ultati o n wit h t he Lill y -desi g nate d m e dical m o ni t or: 
A L T or as partate a mi n otra nsferase ( A S T) > 8XU L N 
A L T or A S T > 5XU L N f or m ore t ha n 2 wee ks 
A L T or A S T > 3XU L N a n d t otal bilir u bi n le vel ( T B L) > 2XU L N or 
i nt er nat i o nal n or m alize d rati o > 1. 5 
A L T or A S T > 3XU L N wit h t he a p peara nce of fat i g ue, na usea, v o mit i n g, 
ri g ht u p per q ua dra nt pai n or te n der ness, fe ver, ras h, a n d/ or e osi n o p hilia 
( > 5 %) 
al kali ne p h os p hatase ( A L P) > 3XU L N 
A L P > 2. 5XU L N a n d T B L > 2XU L N 
A L P > 2. 5XU L N wit h t he a p peara nce of fati g ue, na usea, v o mit i n g, ri g ht 
q ua dra nt pai n or te n der ness, fe ver, ras h, a n d/ or e osi n o p hilia ( > 5 %) 
I n a d dit i o n, patie nts will be disc o nt i n ue d fr o m t h e i n vesti gat i o nal pr o d uct i n t he 
f o ll o wi n g circ u msta nces :
If a patie nt is i na d verte nt l y e nr o lle d a n d it is deter mi ne d t hat c o nti n ue d treat me nt 
wi t h  st u d y  dr u g w o ul d n ot be m e dicall y  a p pr o pri ate, see Secti o n 8. 1. 3 
Ac ute or c hr o nic p a ncreat it is 
If a patie nt is dia g n ose d wit h M T C after ra n d o mizati o n or has a p ostra n d o mizat i o n 
cal ci t o ni n val ue ≥ 3 5 ng/ L t h at has i ncrease d at least 5 0 % o ver baseli ne 
If a patie nt i s dia g n ose d wi t h  a n acti ve or u ntreate d mali g na nc y  ( ot her t ha n basal or 
s q ua m o us cell s ki n ca ncer, i n sit u carci n o mas of t he cer vi x, or i n sit u pr ostate ca ncer) 
af ter ra n d o mizat i o n
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e 4 3 
L Y 3 2 9 8 1 7 6 A n y si g nifica nt st u d y  dr u g -r el ate d h y perse nsit i vit y reacti o n 
A n y o t h er T E A E, S A E, or cli nicall y si g nifica nt la b orat or y  v al ue f or w hic h t he 
i n vesti gat or belie ves t hat per ma ne nt st u d y  dr u g di sc o nti n uat i o n is t he a p pr o priate 
meas ure t o be ta ke n 
If fe male patie nt bec o me s pre g na nt 
If a patie nt is dia g n ose d wit h T [ADDRESS_1239748] pre mat urel y f or a n y reas o n s h o ul d 
c o m plete a d verse e ve nt a n d ot her f o ll o w- u p pr oce d ures per Secti o n 2( Sc he d ule of Act i vit ies), 
Secti o n 9. 2 ( A d verse E ve nts ), a n d Secti o n 9. 4 ( Safet y) of t his pr ot oc ol. 
8. 1. 2. T e m p or ar y Di s c o nti n u ati o n fr o m St u d y Tr e at m e nt 
I n certai n sit uat i o ns after ra n d o mizat i o n, t he i n vesti gat or ma y nee d t o te m p oraril y i nterr u pt st u d y  
dr u g (f or e xa m pl e, A E) .  If st u d y  dr u g i nterr u pti o n is d ue t o a n A E, t he e ve nt is t o be 
d oc u m e nte d a n d f o ll o we d acc or di n g t o t he pr oce d ures i n Secti o n 9. [ADDRESS_1239749] u g after a n y  t e m p orar y  i nt err u pti o n, as s o o n as i t is safe t o d o s o. 
If t he n u m ber of c o nsec ut i ve misse d d oses i s ≤ 2, t he treat me nt ca n be restarte d at t he 
sa me d ose, if t he dr u g was well t ol erate d pri or t o disc o nti n uat i o n, 
If t he n u m ber of c o nsec ut i ve misse d d oses is ≥ 3, t he n t he treat me nt s h o ul d be restarte d at 
[ADDRESS_1239750] i ve of t he d ose t he pat ie nt  was recei vi n g bef ore t he 
i nt err u pti o n a n d s u bse q ue nt l y escalate d as re q uire d b y pr ot oc ol .
If t he a b o ve sit uati o ns occ ur a gai n d uri n g t he c o urse of t he st u d y ,t h e i n vest i gat or i n 
c o ns ultati o n wit h s p o ns or or desi g nee will d isc uss t he ne xt treat me nt o pti o n .
The i n vest i gat or will use t he I W R S t o recei ve t he a p pr o priate st u d y dr u g dis pe nsi n g 
i nf or m at i o n t o preser ve bli n di n g o f t h e st u d y dr u g 
If t he st u d y  dr u g i nterr u pti o n is d ue t o i nt olera ble persiste nt GI A E (f or e xa m ple, na usea, 
v o mit i n g, or diarr hea), t he patie nts s h o ul d be treate d as s u g geste d i n Sect i o n 7. 8. 2. [ADDRESS_1239751] u d y  treat m e nt u nless t here 
are e xte n uat i n g circ u msta nces t hat ma ke it me dicall y necessar y f or t he patie nt t o c o nti n ue o n 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239752] i o n 2
( Sc he d ule of Act i vit ie s), Secti o n 9. 2 ( A d verse E ve nts), a n d Secti o n 9. 4 ( Safet y) of t he pr ot oc o l. 
8. 2. Di s c o nti n u ati o n fr o m t h e St u d y 
I n or der t o mi ni mize t he a m o u nt of missi n g data a n d t o e na ble assess me nt of st u d y  o bjecti ves as 
pl a n ne d i n t he st u d y  pr ot oc ol , e ver y  att e m pt will  b e m a de t o kee p pati e nts i n t he st u d y  
irres pect i ve of t h e f ol l o wi n g: 
a d here n ce t o st u d y  dr u g ,
a d here nce t o visit sc he d ule ,
missi n g assess me nts ,
st u d y  dr u g di sc o nt i n uat i o n d ue t o a n A E ,
de vel o p me nt of c o m or bi dit ies , a n d 
de vel o p me nt of cli nical o utc o mes .
T he ci rc u msta nces liste d a b o ve are n ot vali d reas o ns f or disc o nt i n uat i o n fr o m t h e st u d y . 
P ati e nts will be disc o nt i n ue d i n t he f o ll o wi n g ci rc u msta nces: 
Enr oll me nt i n a n y ot her cli nical st u d y  i n v o l vi n g a n i n vest i gat i o nal pr o d uct or 
e nr o ll me nt i n a n y ot her t y p e of  m e dical researc h j u d ge d n ot t o be 
scie ntificall y or me dicall y c o m pati ble wit h t his st u d y 
Parti ci p ati o n i n t he st u d y  n ee ds t o be st o p pe d f or me dical, safet y,  re g ul at or y , 
or ot her reas o ns c o nsiste nt wit h a p plica ble la ws, re g ulat i o ns, a n d g o o d cli nica l 
practi ce 
If a fe male pat ie nt  bec o mes pre g na nt 
If a patie nt is dia g n ose d wit h T 1 D M 
Pati e nt re q uests t o be wit h dra w n fr o m t he st u d y 
P ati e nts w h o a gree t o pr o vi de i nf or mat i o n rel e va nt t o a n y  st u d y  e n d p oi nt at t he e n d of t he st u d y  
are n ot c o nsi dere d t o ha ve disc o nti n ue d fr o m t he st u d y .
A pat ie nt  w h o wi t h dra ws c o nse nt a n d clearl y i n dicates t hat t here will be n o f urt her c o ntact of a n y 
ki n d wit h t he site will be c o nsi dere d t o ha ve disc o nt i n ue d fr o m t h e st u d y .
Pri or t o earl y  st u d y  di sc o nti n uati o n, t he pati e nt ma ydisc o nt i n ue st u d y  dr u g a n d will ha ve 
e n d -of -st u d y  pr oce d ures ( E T vi si t) p erf or m e d as s h o w n i n t he Sc he d ule of Act i vit ies ( Secti o n 2).  
D uri n g t he E T visit, t he patie nt will n ot i nit iate a n y ne w gl uc ose -l o weri n g t h era p y .  Visi t 8 0 1 
(safet y f o ll o w- u p visit) s h o ul d be perf or m e d a p pr o xi matel y  [ADDRESS_1239753] u d y  visi t. 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239754] u d y  pr e m at urel y f or a n y  reas o n s h o ul d c o m plete a d verse e ve nt 
a n d ot her safet y f o ll o w- u p per Secti o n 2( Sc he d ule of Act i vit ies), Secti o n 9. 2 ( A d verse E ve nts) ,
a n d Sect i o n 9. 4 ( Safet y) of t his pr ot oc ol. 
8. 3. L o st t o F oll o w - U p 
A pat ie nt will be c o nsi dere d l ost t o f o ll o w- u p if he or s he re peate dl y  f ails t o ret ur n f or sc he d ule d 
visit s a n d is u na ble t o be c o n tacte d b y  t he s t u d y  si t e .  E ver y  att e m pt will  b e ma de t o mi ni mize 
t h e n u m ber of patie nts c o nsi dere d l ost t o f o ll o w- u p at t he e n d of t he st u d y .  P ati e nts will be 
i nf or m e d a b o ut t he i m p orta nce of c o m plet i n g t he st u d y  a n d pr o vi di n g u p date d c o ntact 
i nf or m at i o n t o t he st u d y  s it e w he n necessar y .
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239755] u d y  pr oce d ures a n d t heir ti mi n g (i ncl u di n g 
t ol era nce li mit s f or ti mi n g). 
A p pe n di x [ADDRESS_1239756] u d y  Sc he d ule (see Secti o n 2). 
Mea n c ha n ge i n b o d y w ei g ht 
Pr o p orti o n of  patie nts ac hie vi n g a tar get H b A 1c < 7 . 0 % ( 5 3 m m o l/ m o l) ,≤ 6. 5 % ( 4 8 
m m o l/ m o l) , a n d < 5. 7 % ( 3 9 m m o l/ m o l) 
Mea n c ha n ge i n F S G val ues meas ure d i n t he ce ntral la b orat or y 
Mea n c ha n ge i n dail y  a vera ge 7-p oi nt S M B G pr ofiles 
Pr o p orti o n of  patie nts w h o ac hie ve d wei g ht l oss ≥ 5 %, ≥ 1 0 %, a n d ≥ 1 5 % 
9. 1. 3. E x pl or at or y A s s e s s m e nt s a n d Pr o c e d ur e s 
T he f o ll o wi n g sec o n dar y  efficac y meas ures will be cal c ulate d base d o n data c o llecte d at t he 
ti mes s h o w n i n t he St u d y  Sc he d ule (see Sect i o n 2). 
Mea n c ha n ge i n wa ist ci rc u mfere nce 
C ha n ge s f r o m  baseli ne i n mea n B MI 
Mea n c ha n ge i n li pi [INVESTIGATOR_805] (t otal c h olester ol, hi g h -de nsit y li p o pr otei n , l o w- de nsit y 
li p o pr otei n , v er y  l o w -de nsit y li p o pr otei n , a n d tri gl yceri des )
Bi o m ar kers 
A P P A D L sc ores 
E Q - 5 D- 5 L sc ores 
I W -S P sc ores 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239757] ci rc u mfere nce will be m eas ure d at pre s pecifie d ti me p o i nt s (see Sc he d ule 
of  Act i vit ies [Secti o n 2]. 
Eac h patie nt’s wei g ht s h o ul d be meas ure d acc or di n g t o a sta n dar dize d pr ot oc ol a n d rec or de d o n 
t h e e C R F t o t he nearest o ne- te nt h k g .Waist circ u mfere nce s h o ul d be meas ure d at mi d p o i nt , 
bet wee n l o wer m ar gi n o f least p al pa ble ri b a n d t o p of iliac crest (a p pr o xi matel y 1 i nc h ( 2. 5 4 c m) 
a b o ve t he na vel) , ( A p pe n di x 7 ). 
B o d y  m ass i n de x will be c o m p ute d fr o m t h e pati e nt’s wei g ht a n d hei g ht. B o d y  m ass i n de x 
s h o ul d be r o u n de d t o t he nearest w h ole n u m ber f or p ur p oses of I ncl usi o n C ri t eri o n [ 4]
( Secti o n 6. 1 ). 
9. 1. 5. A p pr o pri at e n e s s of A s s e s s m e nt s 
Efficac y a n d safet y assess me nts i ncl u de d i n t his st u d y  are ge nerall y  re gar de d as relia ble a n d 
acc urate wit h res pect t o t he efficac y a n d safet y assess me nts i n i n di vi d uals a n d p o p ulat i o ns wit h 
T [ADDRESS_1239758] i gat or re mai ns res p o nsi ble f or f o ll o wi n g, t hr o u g h a n a p pr o priate healt h care o pti o n :
A Es t hat are seri o us or ot her wise me dicall y i m p orta nt, c o nsi dere d r el ate d t o t he i n vest i gat i o nal 
pr o d uct or t he st u d y , or t hat ca use d t he pati e nt t o disc o nti n ue t he i n vest i gat i o nal pr o d uct bef ore 
c o m plet i n g t he st u d y.  T he pati e nt s h o ul d b e f ol l o we d u nt il t he e ve nt res ol ves a n d sta bilizes wit h 
a p pr o priate dia g n ostic e val u ati o n .T he fre q ue nc y of f o ll o w- u p e val uat i o ns o f t h e A E i s left t o 
t h e discret i o n of t he i n vest i gat or. 
Lac k of dr u g effect is n ot a n A E i n cli nical st u dies, beca use t he p ur p ose of t he cli nical st u d y is t o 
esta blis h treat me nt effect. 
After t he I C F is si g ne d, st u d y  si te pers o n nel will rec or d via e C R F t h e occ urre nce a n d nat ure of 
eac h pati e nt ’s pree xist i n g c o n dit i o ns, i ncl u di n g cli nicall y si g nifica nt si g ns a n d s y m pt o ms of t he 
di sease u n der treat me nt i n t he st u d y .  I n a d dit i o n, si te pers o n nel  will rec or d a n y  c ha n ge i n t he 
c o n di ti o n(s) a n d a n y  ne w c o n d iti o ns as A Es .F or eac h A E, t he o nset a n d d urati o n, t he 
seri o us ness a n d se verit y,  a n d t he act i o ns ta ke n wit h res pect t o st u d y treat me nt will be rec or de d. 
I n vest i gat ors s h o ul d rec or d t heir assess me nt of t he p ote n ti al  relate d ness of eac h A E t o pr ot oc ol 
pr oce d ure a n d i n vesti gati o nal pr o d uct via a n e C R F .
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239759] u d y  pr oce d ure, ta ki n g i nt o acc o u nt t he 
di sease, c o nc o mita nt treat me nt, or pat h ol o gies. 
A “reas o na ble p ossi bilit y” mea ns t hat t here is a ca use a n d effect relat i o ns hi p bet wee n t he 
i n vesti gat i o nal pr o d uct, st u d y  de vice a n d/ or st u d y  pr oce d ure ,a n d t he A E. 
T he i n vest i gat or a ns wers yes/ n o w he n ma ki n g t his assess me nt. 
Pl a n ne d s ur geries a n d n o ns ur gical i nter ve nt i o ns s h o ul d n ot be re porte d as A Es u nless t he 
u n derl yi n g me dical c o n dit i o n has w orse ne d d uri n g t he c o urse of t he st u d y .
If a patie nt ’s i n vesti gati o nal pr o d uct is disc o nt i n ue d as a res ult of a n A E, st u d y  si te pers o n nel  
m ust re p ort t his t o Lill y or its desi g nee via a n e C R F , cl arif yi n g ,if p ossi ble, t he circ u msta nces 
lea di n g t o a n y  d os a ge m o dificati o ns or disc o nt i n uati o ns of treat me nt. 
9. 2. 1. S eri o u s A d v er s e E v e nt s 
A n S A E is a n y  A E f r o m  t his st u d y  t hat res ul ts i n o ne of t he f o ll o wi n g o utc o m es: 
deat h 
i nit ial or pr ol o n ge d i n patie nt h os pi[INVESTIGATOR_90730] i o n
a life -t h reate ni n g e x perie nce ( t h at is , i m me diate ri s k of d yi n g) 
persiste nt or si g nifica nt disa bilit y/ i nca pacit y
c o n ge nital a n o ma l y/ birt h defect 
i m p orta nt me dical e ve nts t hat ma y n ot be i m me diatel y life -t h reate ni n g or res ult i n 
deat h or h os pi[INVESTIGATOR_417381] i o n b ut m a y je o par di ze t he patie nt or m a y  re q uire i nter ve nt i o n 
t o pre ve nt o ne of t he ot her o utc o mes liste d i n t he defi nit i o n a b o ve.   E xa m ples of 
s uc h m e dical e ve nts i ncl u de aller gic br o nc h os pas m re q uiri n g i nte nsi ve treat me nt 
i n a n e m er ge nc y r o o m  or at h o m e, bl o o d d y scrasias or c o n v ulsi o ns t hat d o n ot 
res ul t i n i n pat ie nt  h os pi [INVESTIGATOR_90730] i o n, or t he de vel o p me nt of dr u g de pe n de nc y  or dr u g 
a b use. 
All A Es occ urri n g after si g ni n g t he I C F are rec or de d i n t he e C R F a n d assesse d f or seri o us 
cri teria.  T he S A E re p orti n g t o t he s p o ns or be gi ns after t he pati e nt has si g ne d t he I C F a n d has 
recei ve d i n vest i gat i o nal pr o d uct.  H o we ver, if a n S A E occ urs afte r si g ni n g t he I C F, b ut pri or t o 
recei vi n g i n vest i gat i o nal pr o d uct, t he S A E s h o ul d be re p orte d t o t he s p o ns or as per S A E -
re p orti n g re q ui re me nts a n d t i meli nes (see Sect i o n 9. 2 ) if it is c o nsi dere d reas o na bl y p ossi bl y 
r el ate d t o st u d y  pr oce d ure. 
St u d y  si te pers o n nel  m ust al ert Lill y or i ts desi g n e e of  a n y S A E wit hi n [ADDRESS_1239760] i gat or 
a ware ness o f t h e e ve nt via a s p o ns or -a p pr o ve d met h o d.  If alert s are iss ue d via tele p h o ne, t he y 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239761] u d y -s pecific S A E f or ms.  T his 2 4 -
h o ur n otificat i o n re q uire me nt refers t o t he i nit ial S A E i nf or mat i o n a n d all f o ll o w- u p S A E 
i nf or m at i o n. Patie nts wi t h  a seri o us he pat ic A E s h o ul d ha ve a d di ti o nal data c ollecte d usi n g t he 
e C R F .
Pre g na nc y ( d uri n g mat er nal or pater nal e x p os ure t o i n vest i gat i o nal pr o d uct) d oes n ot meet t he 
defi nit i o n o f a n A E.  H o we ver, t o f ulfill re g ulat or y re q uire me nts ,a n y pre g na nc y s h o ul d be 
re p orte d f o ll o wi n g t he S A E pr ocess t o c ollect data o n t he o utc o me f or b ot h m ot her a n d fet us. 
I n vest i gat ors are n ot o bli gate d t o acti vel y  see k A Es or S A Es i n pat ie nt so nce t he y  ha ve 
di sc o nti n ue d a n d/ or c o m plete d t he st u d y  (t he pati e nt dis p osit i o n C R F has bee n c o m plete d).  
H o we ver, if t he i n vest i gat or lear ns of a n y S A E, i ncl u di n g a deat h, at a n y ti me after a pati e nt has 
bee n disc har ge d fr o m t he st u d y  a n d he/s he c o nsi ders t he e ve nt reas o na bl y p ossi bl y  relate d t o t he 
st u d y  tr e at m e n t or st u d y  p arti ci pat i o n, t he i n vest i g at or m ust pr o m ptl y n otif y Lill y .
9. 2. 1. 1. S u s p e ct e d U n e x p e ct e d S eri o u s A d v er s e R e a cti o n s 
S us pecte d u ne x pecte d seri o us a d verse react i o ns ( S U S A Rs) are seri o us e ve nts t hat are n ot liste d 
i n t he I B a n d t hat t he i n vesti gat or i de nt if ies as relate d t o i n vesti gati o nal pr o d uct or pr oce d ure.  
U nite d States [ADDRESS_1239762] i ve 2 0 0 1/ 2 0/ E C a n d t he 
ass oci ate d detaile d g ui da nces or nati o nal re g ulat or y  re q uire me nts i n parti ci pat i n g c o u ntries 
re q ui re t he re p orti n g of S U S A Rs.  Lill y has pr oce d ures t hat will be f oll o we d f or t he 
i de nt ificat i o n, rec or di n g ,a n d e x pe dite d re p orti n g of S U S A Rs t hat are c o nsiste nt wit h gl o bal 
re g ul at i o ns a n d t he ass ociate d detaile d g ui da nces. 
9. 2. 2. A d v er s e E v e nt of S p e ci al I nt er e st 
9. 2. 2. 1. H y p o gl y c e mi a 
P ati e nts will  c ollect i nf or m at i o n o n e pi s o des of h y p o gl yce mia starti n g fr o m Visit [ADDRESS_1239763] u d y  visi t ( F oll o w -u p Vi si t or E T Visit).  F or t hat p ur p ose, patie nts will be trai ne d a b o ut si g ns 
a n d s y m pt o ms of h y p o gl yce mia, h o w t o treat h y p o gl yce mia, a n d h o w t o c ollect a p pr o priate 
i nf or m at i o n f o r eac h e pis o de of h y p o gl yce mia i n t he st u d y  acc or di n g t o t he Sc he d ule of 
Act i vit ies ( Sect i o n 2).  Si te pers o n nel will e nter t his i nf or mat i o n i nt o t he e C R F at eac h visit. 
I n vest i gat ors s h o ul d use t he f o ll o wi n g defi nit i o ns a n d criteria w he n dia g n osi n g a n d cate g orizi n g 
a n e pis o de c o nsi dere d t o be relate d t o h y p o gl yce mia (t he pl as ma gl uc ose [P G ]val ues i n t his 
sect i o n refer t o val ues deter mi ne d b y a la b orat or y  or I nter nati o nal  F e derat i o n of Cli nical 
C he mistr y  a n d La b orat or y  Me dici ne plas ma -e q ui val e nt gl uc ose m eters a n d stri ps) ( AD A 2 0 1 7, 
A D A 2 0 1 8 ): 
Gl uc ose Alert V al ue ( Level 1): 
D oc u me nte d s y m pt o m atic h y p o gl yce mi a is defi ne d as a n y ti me a pat ie nt  f eels 
t h at he or s he is e x perie nci n g s y m pt o ms a n d/ or si g ns ass ociate d wit h 
h y p o gl yce mia, a n d has a P G l e vel of ≤ 7 0 m g/ d L ( ≤ 3. 9 m m o l/ L) .
D oc u me nte d as y m pt o m atic h y p o gl yce mi a is defi ne d as a n y e ve nt n ot 
acc o m pa nie d b y t y p ical s y m pt o ms of h y p o gl yce mia, b ut wit h a meas ure d P G 
≤ 7 0 m g/ d L (≤ 3. 9 m m o l/ L) .
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e 5 0 
L Y 3 2 9 8 1 7 6 D oc u me nte d u ns pecifie d h y p o gl yce mi a is defi ne d as a n y  e v e nt wi t h  n o 
i nf or m at i o na b o ut s y m pt o ms of h y p o gl yce mia a vaila ble, b ut wit h a meas ure d P G 
≤ 7 0 m g/ d L (≤ 3. 9 m m o l/ L) .
Cli nic ally Si g nific a nt Hy p o glyce mi a ( Level 2): 
D oc u me nte d s y m pt o m atic h y p o gl yce mi a is defi ne d as a n y ti me a pat ie nt  f eels 
t h at he or s he is e x perie nci n g s y m pt o ms a n d/ or si g ns ass ociate d wit h 
h y p o gl yce mia, a n d has a P G l e vel of < 5 4 m g/ d L ( < 3. 0 m m o l/ L) .
D oc u me nte d as y m pt o m atic h y p o gl yce mi a is defi ne d as a n y e ve nt n ot 
acc o m pa nie d b y t y p ical s y m pt o ms of h y p o gl yce mia, b ut wit h a meas ure d P G 
< 5 4 m g/ d L ( < 3. 0 m m o l/ L) .
D oc u me nte d u ns pecifie d h y p o gl yce mi a is defi ne d as a n y  e v e nt wi t h  n o 
i nf or m at i o na b o ut s y m pt o ms of h y p o gl yce mia a vaila ble, b ut wit h a meas ure d P G 
< 5 4 m g/ d L ( < 3. 0m m o l/ L) .
Severe hy p o glyce mi a ( Level 3): 
Se vere h y p o gl yce mi a is defi ne d as a n e pis o de wit h se vere c o g nit i ve i m pair me nt 
re q ui ri n g t he assista nce of a n ot her pers o n t o acti vel y  a d mi nister car b o h y drate, 
gl uca g o n, or ot her res uscitati ve act i o ns.  T hese e pis o de s ma y be ass ociate d wit h 
s ufficie nt ne ur o gl yc o pe nia t o i n d uce seiz ure or c o ma. Bl o o d gl uc ose 
meas ure me nts ma y  n ot be a vaila ble d uri n g s uc h a n e ve nt, b ut ne ur ol o gical 
rec o ver y  attri b uta ble t o t he rest orati o n of B G t o n or mal is c o nsi dere d s ufficie nt 
e vi de nc e t hat t he e ve nt was i n d uce d b y  a l o w B G c o nce ntrati o n. 
Ot her hy p o glyce mi a c ate g ories: 
N oct ur n al h y p o gl yce mi a is defi ne d as a n y h y p o gl yce mic e ve nt t hat occ urs 
bet wee n be dt i me a n d wa ki n g. 
If a h y p o gl yce mic e ve nt meets t he criteria of se vere, it nee ds t o be rec or de d as seri o us o n t he A E 
C R F a n d re p orte d t o Lill y as a n S A E. 
T o a v oi d d u plicate re p orti n g, all c o nsec uti ve B G val ues ≤ 7 0 m g/ d L ( 3. 9 m m o l/ L) occ urri n g 
wi t hi n 1 -h o ur peri o d ma y be c o n si dere d t o be a si n gle h y p o gl yce mic e ve nt ( Wei n ber g et al. 2 0 1 0; 
Da n ne et al. 2 0 1 3).  
I n eac h case of s us pecte d or c o nfir me d h y p o gl yce mia, it is i m p orta nt t hat t he e ve nt be pr o perl y 
cate g ori ze d, t he effect of t he i nter ve nti o n be assesse d, a n d t he fre q ue nc y of h y p o gl yce mia be 
e val uate d.  T he r ole of dietar y  c ha n ges a n d p h ysical  e xercise ( or a n y  ot her c o ntri b ut i n g fact or) i n 
t h e de vel o p me nt of a n e ve nt s h o ul d be esta blis he d.  T he patie nt s h o ul d recei ve a d dit i o nal 
e d ucati o n, if dee me d a p pr o priate.  Pl ease ref er t o S ecti o n 7. 8. 2. [ADDRESS_1239764] e nt H y p er gl y c e mi a 
Se vere, persiste nt h y per gl yce mia will be c ollecte d d uri n g t he trial t o assess t he ris k of e xtre m e 
i m bala nce i n gl yce mic c o ntr ol. 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239765] i n all trials wit h ti rze pat i de i ncl u di n g t his trial.  
Ac ute pa ncreat it is is a n ac ute i nfla m mat or y  pr ocess of t he pa ncreas t hat ma y  als o i n v ol ve 
p eri pa ncreat ic tiss ues a n d/ or re m ote or ga n s y ste ms ( Ba n ks a n d Free ma n 2 0 0 6).  T he dia g n osis of 
ac ute pa ncreatit is re q uires 2 of t he f o ll o wi n g 3 feat ures: 
a b d o mi nal pa i n, c haracterist ic of ac ute pa ncreat itis  ( ge nerall y l ocate d i n t he 
e pi g astri u m a n d ra di ates t o t he bac k i n a p pr o xi matel y half t he cases 
[Ba n ks a n d Free ma n 2 0 0 6; K o iz u mi et al . 2 0 0 6]; t he pai n is ofte n ass oc iate d wit h 
na usea a n d v o mit i n g) 
ser u m  a m ylase (t ot al a n d/ or pa ncreatic) a n d/ or li pase ≥ 3 XU L N 
c haracterist ic fi n di n gs of ac ute pa ncreat it is o n c o m p ute d t o m o gra p h y  ( C T) sca n or 
ma g net ic res o na nce i ma gi n g ( M RI) 
If ac ute pa ncreat it is is s us pecte d, a p pr o priate la b orat or y  tests (i ncl u di n g le vels of pa ncreat ic 
a m ylase [ p -a m ylase] a n d li pase) s h o ul d be o btai ne d via t he ce ntral la b orat or y  (a n d l ocall y, if 
nee de d).  I ma gi n g st u dies, s uc h as a b d o mi nal C T sca n wit h or wit h o ut c o ntrast, M RI, or 
gall bla d der ultras o u n d, s h o ul d be perf or me d.  If la b orat or y val ues a n d/ or a b d o mi nal i ma gi n g 
s u p p ort t he dia g n osis of ac ute pa ncreat it is, t he patie nt m ust disc o nt i n ue t hera p y wit h 
i n vesti gat i o nal pr o d uct(s) ,b ut will c o nt i n ue i n t he st u d y  o n a n ot her gl uc ose -l o weri n g re gi me n 
( details o n resc ue i nter ve nt i o n will be pr o vi de d).  T he m o st a p pr o priate dia betes t hera pe utic 
re gi me n will be deci de d b y t he i n vest i gat or, base d o n t he patie nt’s cli nical stat us.  A re vie w of 
t h e pati e nt’s c o nc o mita nt me dicat i o ns s h o ul d be c o n d ucte d t o assess a n y p ote ntial ca usal 
r el at i o ns hi p wit h pa ncreat it is. 
Eac h case o f a n A E of pa ncreat it is m ust be re p orte d.  If t y pi[INVESTIGATOR_126147] g ns a n d/ or s y m pt o ms of 
pa ncreat it is are prese nt a n d c o nfir me d b y la b orat or y val ues (li pase or a m ylase [t otal a n d/ or 
pa ncreat ic]) a n d i ma gi n g st u dies, t he e ve nt m ust be re p orte d as a n S A E. F or a p ote ntial case t hat 
d oes n ot m eet all of t hese criteria, it is u p t o t he i n vesti gat or t o deter mi ne t he seri o us ness of t he 
case ( A E or S A E) a n d t he relate d ness o f t h e e ve nt t o st u d y  dr u g(s). 
Eac h patie nt will ha ve meas ure me nts of  p -a m ylas e a n d li pase (assesse d at t he ce ntral la b orat or y ) 
as s h o w n o n t he Sc he d ule o f Act i vit ies ( Secti o n 2)t o assess t he effects of  t he i n vesti g ati o n al  
d oses of ti rze pati d e o n pa ncreat ic e nz y me le vels. S eri al  m eas ures of pa ncreat ic e nz y mes ha ve 
li mite d cli nical val ue f or pre dict i n g e pis o des of ac ute pa ncreatit is i n as y m pt o mat ic pat ie nt s 
( Na uc k et al. 2 0 1 7; Stei n ber g et al. 2 0 1 7a , 2 0 1 7 b). T h us, f urt her dia g n ostic f o ll o w- u p of  cases 
of  as y m pt o m atic pa ncreat ic h y pere nz y me mia (li pase a n d/ or p -a m ylase ≥ 3 XU L N) is n ot 
ma n date d b ut ma y be perf or me d base d o n t he i n vesti gat or’s cli nical j u d g me nt a n d assess me nt of 
t h e pati e nt’s o verall cli ni c al  c o n di ti o n .O nl y cases of pa ncreat ic h y pere nz y me mia t hat u n der g o 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e 5 2 
L Y 3 2 9 8 1 7 6 a d di ti o nal  di a g n osti c f ol l o w- u p a n d/ or are acc o m pa nie d b y s y m pt o ms s u g gest i ve of pa ncreat it is 
will be s u b mitte d f or a dj u dicat i o n. 
All s us pecte d cases of ac ute or c hr o nic pa ncreat itis  will be a dj u dicate d b y  a n i n de pe n de nt 
cli nical e n d p o i nt  c o m mittee ( C E C).  I n ad di ti o n, A Es of se vere or seri o us a b d o mi nal pai n o f 
u n k n o w n et i ol o g y  will  als o be s u b mitte d t o t he a dj u dicat i o n c o m mit tee t o assess f or p ossi ble 
pa ncreat it is or ot her pa ncreatic dise ase. Rele va nt data fr o m patie nts wit h ac ute or c hr o nic 
pa ncreat it is a n d t h ose wit h se vere or seri o us a b d o mi nal pai n will be e ntere d i nt o a s pecificall y 
desi g ne d e C R F pa ge b y st u d y  si te or Lill y  st aff .T he a dj u dicat i o n c o m mittee re prese ntati ve will 
e nter t h e res ul ts of  a dj u dicat i o n i n a c orres p o n di n g e C R F pa ge. 
9. 2. 2. 4. T h yr oi d M ali g n a n ci e s a n d C -C ell H y p er pl a si a 
I n di vi d uals wit h pers o nal or fa mil y hist or y  of  M T C a n d/ or M E N- [ADDRESS_1239766] as ms .
Tir ze pati d e s h o ul d be disc o nt i n ue d (after first c o nfir mi n g t he val ue) if p os tra n d o mizat i o n 
cal ci t o ni n val ue is ≥ 3 5 n g/ L a n d has i ncrease d at least 5 0 % o ver baseli ne.  A c o ns ultat i o n wi t h  a 
t h y r oi d s pecialist (if n ot a vaila ble, a n e n d ocri n o l o gist) s h o ul d be o btai ne d. If t he i ncrease d 
cal ci t o ni n val ue ( ≥ 3 5 ng/ L a n d i ncreases b y ≥ 5 0 % c o m pare d wi t h baseli ne) is o bser ve d i n a 
pati e nt w h o has a d mi nistere d a me dicat i o n t hat i s k n o w n t o i ncrease ser u m calcit o ni n, t his 
me dicat i o n s h o ul d be st o p pe d a n d calcit o ni n le vels s h o ul d b e m eas ure d after a n a p pr o priate 
was h o ut peri o d.  If t he c o nfir me d calcit o ni n val ue is < 3 5 ng/ L, ti rze pat i de s h o ul d be restarte d 
w he n it i s s af e t o d o s o.  
9. 2. 2. 5. M aj or A d v er s e C ar di o v a s c ul ar E v e nt s 
Deat hs a n d n o nfatal C V A Es will be a dj u dicate d b y a c o m mittee of p h ysicia ns e xter nal t o Lill y 
wi t h  car di ol o g y  e x pertise.  T he n o nfatal  C V A Es t o be a dj u dicate d i ncl u de t h e f ol l o wi n g:   
m y ocar dial  i nfarct i o n
h os pi [INVESTIGATOR_1314] o n f or u nsta ble a n gi na 
h os pi [INVESTIGATOR_1314] o n f or heart fail ure 
c or o nar y  i nt er ve nt i o ns (s uc h as c or o nar y  arter y  b y pass graft or perc uta n e o us c or o nar y  
i nt er ve nt i o n) 
cere br o vasc ular e ve nts, i ncl u di n g cere br o vasc u lar acci de nt (str o ke ) a n d tra nsie nt 
isc he mic attac k 
9. 2. 2. 6. S u pr a v e ntri c ul ar Arr hyt h mi a s a n d C ar di a c C o n d u cti o n Di s or d er s 
Treat me nt -e mer ge nt car diac c o n d ucti o n dis or ders will be f urt her e val uate d.  Patie nts w h o 
de vel o p a n y e ve nt fr o m t h is gr o u p of di s or ders s h o ul du n der g o a n E C G w hic h s h o ul d be 
s u b mitte d t o t he ce ntral rea di n g ce nter. A d dit i o nal dia g n ostic tests t o deter mi ne e xact dia g n osis 
s h o ul d be perf or m e d, as nee de d. T he s pecific dia g n osis will be rec or de d as a n A E. E ve nts t hat 
meet criteria f or seri o us c o n di ti o ns as descri be d i n Secti o n 9. 2. [ADDRESS_1239767] be re p orte d as S A Es .
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239768] u g(s) vi a a C R F create d f or t his p ur p ose.  A d dit i o nal sa m ples s h o ul d als o be c o llecte d as 
o utli ne d i n Sect i o n 9. 4. [ADDRESS_1239769] u g(s) s h o ul d be te m p oraril y i nterr u pte d i n a n y i n di vi d ual 
s us pecte d of ha vi n g a se vere or seri o us aller gic reacti o n t o t h e st u d y  dr u g(s).  St u d y  dr u g(s) m a y 
be restarte d w he n/if it is safe t o d o s o, i n t he o pi [INVESTIGATOR_9384] o n of t he i n vest i gat or.  If st u d y dr u g(s) is 
p er m a ne nt l y disc o nt i n ue d, t he patie nt will recei ve a n ot her gl uc ose -l o weri n g treat m e nt, j u d ge d b y 
t h e i n vest i gat or t o be a p pr o priate base d o n t he patie nt’s cli nical stat us, a n d will c o nt i n ue i n t he 
tri al  t o c ollect all pla n ne d ef ficac y a n d safet yme as ure m e nts. 
9. 2. 2. 7. 1. I nj e cti o n Sit e R e a cti o n s 
I nject i o n site reacti o ns will be c o llecte d o n t he e C R F se parate fr o m t he h y perse nsit i vit y react i o n 
e C R F.  At t he ti me o f A E occ urre nce i n t he tirze pati de gr o u p, sa m ples will be c o llecte d f or 
meas ure me nt of tirze pat i de a nt i- dr u g b o dies ( A D A s) a n d tirze pat i de c o nce ntrati o n. 
9. 2. 2. 7. 2. A nti -Dr u g A nti b o di e s 
T he occ urre nce of A D A f or mat i o n will be assesse d as o utli ne d i n Secti o n 9. 4. 4 .
9. 2. 2. 8. Di a b eti c R eti n o p at h y C o m pli c ati o n s 
Dilate d reti nal f u n d os c o pi [INVESTIGATOR_126148] i o n will be perf or me d b y  a q ualifie d e ye care pr ofessi o nal 
( o p ht hal m o l o gist or o pt o metrist) f or all patie nts bet wee n Visit 2 a n d Visit 3 t o e xcl u de patie nts 
wi t h  pr oliferat i ve ret i n o pat h y  a n d/ or m a c ul o p at h y .  T he res ul ts f r o m  t his e xa mi nat i o n will be 
rec or de d o n a s pecific reti n o pat h y  e C R F as a baseli ne meas ure of reti n o pat h y .  
A f o ll o w- u p dilate d f u n d os c o pi [INVESTIGATOR_126148] i o n s h o ul d be perf o r m e d w he n cli nicall y  i n dicate d b y  
a n y A E s us pecte d of w orse ni n g reti n o pat h y , a n d t he fi n di n gs s h o ul d be rec or de d o n t he 
reti n o pat h y  e C R F.  
9. 2. 2. 9. H e p at o bili ar y Di s or d er s 
All e ve nts of T E biliar y  c olic, c h ol ec yst it is, or ot h er s us pecte d e ve nts relate d t o gall bla d der 
dis ease s h o ul d be e val uate d a n d a d dit i o nal dia g n ostic tests perf or me d, as nee de d. I n cases of 
el e vate d li ver m ar kers, he pati c m o ni t ori n g s h o ul d be i nit iate d as o utli ne d i n Sect i o n 9. 4. 5. 1 a n d 
A p pe n di x 4 .
9. 2. 2. 1 0. S e v er e G a str oi nt e sti n al A d v er s e E v e nt s 
Ti rze pati d e ma y ca use se ver e GI A Es, s uc h as na usea, v o mit i n g, a n d diarr hea.  I nf or mat i o n 
a b o ut se vere GI A Es as well as a ntie metic/a nti diarr heal use will be c o llecte d i n t he e C R F/ A E 
f o r m .  F or detaile d i nf or mati o n c o ncer ni n g t he ma na ge m ent  of  GI A Es, please refer t o 
Secti o n 7. 8. 2. [ADDRESS_1239770] i ve o f ac ute or w o rse ni n g of c hr o nic re nal fail ure .Gastr oi ntesti nal 
A Es ha ve bee n re p orte d wit h ti rze pat i de , i ncl u di n g na usea, diarr hea, a n d v o mit i n g.  T hese are 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e 5 4 
L Y 3 2 9 8 1 7 6 c o nsiste nt wit h ot her G L P -1 rece pt or a g o nists ( Ar o da a n d Rat ner 2 0 1 1).  T he e ve nts ma y lea d t o 
de h y drat i o n, w hic h c o ul d ca use a deteri orati o n i n re nal f u ncti o n, i ncl u di n g ac ute re nal fail ure.  
P ati e nts s h o ul d be a d vise d t o n otif y i n vest i gat ors i n case of se vere na usea, fre q ue nt v o mit i n g, or 
s y m pt o ms of de h y drat i o n. 
9. 2. 2. 1 2. M et a b oli c A ci d o si s, In cl u di n g Di a b eti c K et o a ci d o si s 
Ket oaci d osis, a seri o us life -t h reate ni n g c o n dit i o n re q uiri n g ur ge nt h os pi[INVESTIGATOR_90730] i o n, has bee n 
re p orte d rarel y  i n patie nts wi t h  T 2 D M.  Pati e nts w h o prese nt wit h si g ns a n d s y m pt o ms c o nsiste nt 
wi t h  se vere meta b olic aci d osis s h o ul d be assesse d f or ket oac i d osis re gar dless of prese nt i n g B G 
le vels, as ket oaci d osis ma y be prese nt e ve n if B G le vels are less t ha n 2 5 0 m g/ d L.  Treat me nt of 
ket oaci d osis ma y  re q uire i ns uli n, fl ui d ,a n d car b o h y drate re place me nt.   R o ut i ne bicar b o nate 
assess me nt will be perf or me d d uri n g t he c o urse of t he st u d y .  If  l act ic aci d osis is s us pecte d, 
met f o r mi n s h o ul d be te m p oraril y disc o nt i n ue d u ntil t he res o l ut i o n of t he e ve nt. 
9. 2. 2. 1 3. A m p ut ati o n/ P eri p h er al R e v a s c ul ari z ati o n 
All cases of a m p utati o n a n d peri p heral re vasc ularizati o n s h o ul d be re p orte d as a n A E. 
9. 2. 2. 1 4. M aj or D e pr e s si v e Di s or d er/ S ui ci d al I d e ati o n 
T he pre vale nce of de pressi ve s y m pt o ms a n d dis o r ders is i ncrease d i n patie nts wi t h T 1 D M or T 2 D M 
( A D A 2 0 1 7).  A n y A E of maj or de pressi ve dis or der or s uici dal i deati o n s h o ul d be re p orte d. 
9. 2. 3. C o m pl ai nt H a n dli n g 
Lill y c o llects pr o d uct c o m plai nts o n i n vest i gat i o nal pr o d ucts a n d dr u g deli ver y s yste ms use d i n 
cli nical st u dies i n or der t o e ns ure t he safet y of  st u d y  p arti ci pa nts, t o m o nit or q ualit y,  a n d t o 
facilitate pr ocess a n d pr o d uct i m pr o ve me nts. 
P ati e nts will be i nstr ucte d t o c o ntact t he i n vesti gat or as s o o n as p ossi ble if he or s he has a 
c o m plai nt or pr o bl e m wi t h  t he i n vest i gat i o nal pr o d uct s o t hat t he sit uati o n ca n be assesse d. 
9. 3. Tr e at m e nt of O v er d o s e 
St u d y  dr u g o ver d ose ( m ore t ha n t he s pecifie d n u m ber of i njecti o ns) will be re p orte d as a n A E.  
I n t he e ve nt of o ver d ose, ref er t o t he I B f or tirze pati de. 
9. 4. S af et y 
9. 4. 1. El e ctr o c ar di o gr a m s 
F or eac h patie nt, E C Gs s h o ul d be c o llecte d acc or di n g t o t he Sc he d ule of Acti vit ies ( Secti o n 2).  
E C G ss h o ul d be p erf or me d af t er vi t al  si g ns are c ollecte d a n d pri or t o t he c o llect i o n of bl o o d 
sa m ples f or la b orat or y  testi n g if t he pat ie nt  is n ot a d versel y affecte d b y  t h e f asti n g c o n dit i o n.  
P ati e nts s h o ul d be s u pi [INVESTIGATOR_050] f or a p pr o xi matel y  [ADDRESS_1239771] u d y -s pecific rec o m me n dati o ns .  
Electr ocar di o gra ms will i nit iall y  b e i nter prete d b y  a q ualifie d p h ysicia n (t he i n vesti gat or or 
q ualifie d desi g nee) at t he site as s o o n after t he ti me of E C G c ollecti o n as p ossi ble, a n d i deall y  
w hile t he pati e nt i s st il l prese nt, f or i m me diate patie nt ma na ge me nt, s h o ul d a n y cli nicall y 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239772] i gat i o nal tr eat m e nt 
s h o ul d be re p orte d t o Lill y or its desi g nee as a n A E via t he e C R F. 
All di gital E C Gs will be o btai ne d usi n g ce ntrall y pr o vi de d E C G mac hi nes a n d will be 
el e ctr o ni call y tra ns mitte d t o a desi g nate d ce ntral E C G la b orat or y .T he ce ntral E C G la b orat or y  
wi ll perf or m a basic q ualit y c o ntr ol  c hec k ( f o r e xa m ple , d e m o gra p hics a n d st u d y  details) a n d 
t h e n st ore t he E C Gs i n a data base. At  a f ut ure ti me, t he st ore d E C G data ma y be o verrea d b y a 
car di ol o gi st at t he ce ntral  E C G l a b orat or y  f or f urt her e val uat i o n of m ac hi ne -rea d meas ure me nts 
or t o m eet re g ul at or y  r e q ui re me nts. T he m ac hi ne -rea d E C G i nter vals a n d heart rate ma y be use d 
f o r data a nal ysis a n d re p ort writ i n g p ur p oses, u nless a car di ol o gist o verrea di n g of t he E C Gs is 
c o n d ucte d pri or t o c o m plet i o n of t he fi n al  st u d y  re p ort (i n w hic h case, t he o verrea d data w o ul d 
be use d). 
9. 4. 2. Vit al Si g n s 
Vi t al  si g n m eas ure me nts s h o ul d be ta ke n bef ore o btai ni n g a n E C G traci n g a n d bef ore c ollect i o n 
of  bl o o d s a m pl es f or l a b orat or y  testi n g, at vi si ts w here re q ui re d.  T he parti ci pa nt s h o ul d si t 
q ui et l y f o r [ADDRESS_1239773] i vit ie s ( Secti o n 2) a n d 
f o ll o wi n g t he st u d y -s peci fic rec o m me n dati o ns .
An y cli nicall y  si g nifica nt fi n di n gs fr o m vital si g n meas ure me nt st h at res ul t i n a dia g n osi s a n d 
t h at occ ur after t h e pati e nt recei ves t he first d ose of st u d y  tr e at m e nt s h o ul d be re p orte d t o Lill y or 
it s desi g nee as a n A E via e C R F. 
9. 4. 3. L a b or at or y T e st s 
F or eac h patie nt, la b orat or y  tests detaile d i n A p pe n di x [ADDRESS_1239774] i vit ies ( Secti o n 2). 
Wit h t he e xce pti o n o f la b orat or y  test res ul ts t hat ma y  u n bli n d t he st u d y , Lill y or i ts desi g nee will  
pr o vi de t he i n vest i gat or wit h t he res ults of la b orat or y  tests a nal yze d b y  a ce ntral ve n d or if a 
ce ntral ve n d or i s use d f or t he cli nical trial.  
A n y cli nicall y  si gnifica nt fi n di n gs fr o m la b orat or y tests t hat res ult i n a dia g n osis a n d t hat occ ur 
af ter t he pati e nt recei ves t he first d ose of i n vest i gati o nal pr o d uct s h o ul d be re p orte d t o Lill y or its 
desi g nee as a n A E via e C R F. 
9. 4. 4. I m m u n o g e ni cit y A s s e s s m e nt s 
W here l ocal re g ulat i o ns a n d E R Bs all o w, bl o o d sa m ples f or i m m u n o ge nicit y testi n g will be 
c ollecte d t o deter mi ne a nt i b o d y  pr o d ucti o n a gai nst ti rze pat i de as s pecifie d i n t he Sc he d ule of 
Act i vit ies ( Secti o n 2). 
At  t he visit s a n d t i mes s pecifie d i n t he Sc he d ule of Act i vit ie s ( Secti o n 2), ve n o us bl o o d sa m ple s 
will be c o llecte d t o deter mi ne a nt i b o d y  pr o d ucti o n a gai nst ti rze pat i de .  T o i nt er pret t he res ults of 
i m m u n o ge nicit y,  a P K sa m ple will be c o llecte d at t he sa me t i me p oi nts as t he i m m u n o ge nicit y 
sa m ple .  All sa m ples f or i m m u n o ge nicit y s h o ul d be ta ke n bef or ed ose w he n a p plica ble a n d 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239775] u g h y perse nsi ti vi t y  r e a cti o ns (i m me diate or n o n i m me diate ), 
a d di ti o nal  sa m ples will  b e c ollecte d (i ncl u di n g A D A, P K, a n d e x pl orat or y  i m m u ne safet y 
sa m ple) as cl ose t o t he o nset of t he e ve nt as p ossi ble , at t he res ol uti o n of  t he e ve nt, a n d [ADDRESS_1239776] i o n a n d ha n dli n g of bl o o d sa m ples 
will be pr o vi de d b y t he s p o ns or.  Sa m ple c o llecte d at Visit 8 0 1 will assess i m m u n o ge nicit y at 
was h o ut of ti rze pat i de ( [ADDRESS_1239777] e n d of treat me nt). 
Treat me nt -e mer ge nt A D As are defi ne d i n Sect i o n 1 0. 3. 6 .
S a m ples wi t h  ti rze pat i de A D A detecte d will be titere d a n d e val uate d f or t heir a bilit y t o ne utralize 
t h e acti vit y of  assi g ne d treat m e nt ( ti rze pati d e -ne utralizi n g a nt i b o dies).  Sa m ples wi t h  ti rze pat i de 
A D A detecte d will als o be teste d f or cr oss -reacti ve bi n di n g t o nati ve GI P a n d G L P -1, a n d, if 
s uc h i s detecte d, t he n f or ne utralizi n g a nt i b o dies a gai nst nati ve GI P a n d G L P - 1. 
S a m ples will  b e retai ne d f or a m a xi m u m  of  [ADDRESS_1239778] u d y  pati e nt e x perie nces ele vate d A L T ≥ 3 XU L N, A L P ≥ 2 XU L N, or el e vate d T B L ≥ 2 X
U L N, li ver testi n g ( A p pe n di x 4 ) s h o ul d be re peate d wi t hi n [ADDRESS_1239779] u d y  m e dical m o nit or. M o nit ori n g of A L T, A S T, T B L ,a n d A L P s h o ul d 
c o nti n ue u ntil le vels n or malize or ret ur n t o a p pr o xi mate baseli ne le vels. 
He p atic S afet y D at a C ollecti o n 
A d dit i o nal safet y data s h o ul d be c o llecte d via t he eC R F if 1 or m ore of t he f o ll o wi n g c o n di ti o ns 
occ ur: 
Ele vat i o n of ser u m A L T t o ≥ 5 XU L N o n 2 or m ore c o nsec uti ve bl o o d tests 
Ele vat i o n of ser u m  T B L t o ≥ 2 XU L N (e xce pt f or cases of k n o w n Gil bert’s 
s y n dr o me )
Ele vat i o n of ser u m A L P t o ≥ 2 XU L N o n 2 or m ore c o nsec uti ve bl o o d tests 
Pati e nt disc o nt i n ue d fr o m treat me nt d ue t o a he patic e ve nt or a b n or m ali t y  of  
li ver tests 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e 5 7 
L Y 3 2 9 8 1 7 6 He pati c e ve nt c o nsi dere d t o be a nS A E 
9. 5. P h ar m a c o ki n eti c s 
P har mac o ki net ic sa m ples will be c o llecte d fr o m all patie nts. Pl as ma ti rze pat i de c o nce ntrati o ns 
will be deter mi ne d fr o m bl o o d sa m ples o btai ne d fr o m patie nts recei vi n g ti rze pat i de treat m e nt. 
Bl o o d sa m pl es f or P K assess me nt will be c ollecte d at Wee k 0, 7, [ADDRESS_1239780] u d y  Sc he d ule or at E T (see Secti o n 2). 
All patie nts will ha ve a si n gle P K sa m ple c o llecte d f o ll o wi n g t he fi rst d ose at Wee k 0. T hi s P K 
sa m ple ca n be c o llecte d a n y t i me af ter t his first d ose o n t he da y  of  dr u g a d mi nistrati o n. 
A d dit i o nall y , eac h pat ie nt  will be assi g ne d via I W R S t o o ne of t he sa m pli n g P K ti me wi n d o ws of 
[ADDRESS_1239781] u d y  Sc he d ule or at E T (see Secti o n 2).  T he P K sa m ple after t he last d ose of  
st u d y  dr u g a d mi nistere d at Wee k 3 9 will be c ollecte d at Visit 1 4 ( Wee k 4 0). 
T he date a n d ti me of t he m ost rece nt S C i nject i o n a d mi nistere d pri or t o c ol lect i n g t he sa m ple 
m ust be rec or de d o n t he e C R F fr o m t h e st u d y  di aries. T he act ual date a n d ti me at w hic h eac h 
sa m ple was dra w n m ust be rec or de d o n t he la b orat or y  re q ui si ti o n  f or m .I nstr ucti o ns f or t he 
c ollect i o n a n d ha n dli n g of bl o o d sa m ples will be pr o vi de d b y t he s p o ns or .  
C o nce ntrati o ns of ti rze pat i de will  b e assa ye d usi n g a vali date d li q ui d c hr o mat o gra p h y  m ass 
s pectr o metr y  m et h o d. Bi o a nal yt ical  s a m ples c ollecte d t o m eas ure ti rze pat i de c o nce ntrati o ns will 
be retai ne d f or a ma xi m u m o f [ADDRESS_1239782] i gati ve 
si tes or bli n de d pers o n nel ( u nt il t he st u d y  has bee n u n bli n de d). 
9. 6. P h ar m a c o d y n a mi c s 
S a m ple st o assess t he P D pr o perties of ti rze pat i de are i ncl u de d i n t he efficac y meas ures a n d n ot 
a p plica ble i n t his sect i o n. 
9. 7. P h ar m a c o g e n o mi c s 
9. 7. 1. W h ol e Bl o o d S a m pl e ( s) f or P h ar m a c o g e n eti c R e s e ar c h 
A w h o le bl o o d sa m ple will  b e c ollecte d f or p har mac o ge net ic a nal ysis as s pecifie d i n t he 
Sc he d ule of Ac ti vit ies ( Secti o n 2)w here l ocal re g ulat i o ns all o w .  
S a m ples will  n ot be use d t o c o n d uct u ns pecifie d disease or p o p ulat i o n ge net ic researc h eit her 
n o w or i n t he f ut ure.  Sa m ples will be use d t o i n vesti gate varia ble res p o nse t o ti rze pat i de a n d t o 
i n vesti gate ge net ic varia nts t h o u g h t t o pl a y a r ol e i n T [ADDRESS_1239783] i gat or site pers o n nel .  
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239784] u d y or f or a s h orter peri o d if l o cal  re g ulat i o ns a n d/ or 
E R Bs /I R Bs i m p ose s h orter ti me li mits.  T his rete nti o n peri o d e na bles use of ne w tec h n o l o gi es, 
res p o nse t o re g ulat or y  q uest i o ns, a n d i n vest i gat i o n of varia ble res p o nse t hat ma y n ot be o bser ve d 
u nt il later i n t h e de vel o p me nt of ti rze pat i de or af t er ti rze pat i de bec o me(s) c o m merciall y 
a vaila ble .
M olec ular tec h n o l o gi es ar e e x pecte d t o i m pr o ve d uri n g t he [ADDRESS_1239785] i o n, varia bilit y of  p ati e nt res p o nse (i ncl u di n g safet y ), a n d 
cli nical o utc o me.  Sa m ple c o llect i o n is i nc or p orate d i nt o cli nical st u dies t o e na ble e xa mi nat i o n of 
t h ese q uest i o ns t hr o u g h meas ure me nt of bi o m o lec ul es ,i ncl u di n g D N A, R N A, pr otei ns, li pi [INVESTIGATOR_805], 
a n d ot her cell ular ele me nts. 
S er u m  a n d plas ma sa m ples f or bi o m ar ker researc h will be c o llecte d at t he ti mes s pecifie d i n t he 
Sc he d ule of Act i vit ies ( Secti o n 2)w here l ocal re g ulat i o ns all o w. 
S a m ples will  b e use d f or researc h o n t he dr u g tar get, disease pr ocess, varia ble res p o nse t o 
ti rze pat i de , pat h wa ys ass ociate d wit h T 2 D M , m ec ha nis m o f acti o n of ti rze pat i de , a n d/ or researc h 
met h o d or i n vali dat i n g dia g n ost ic t o ols or assa y(s) relate d t o T [ADDRESS_1239786] io n nai res will be c o m plete d b y t he pati e nts at s pecific cli nic visit s acc or di n g 
t o t he Sc he d ule of E ve nts ( Secti o n 2). At t hese visits, t he q uesti o n naires s h o ul d be c o m p lete d 
bef ore t he patie nt has disc usse d t heir me dical c o n dit i o n or pr o gress i n t he st u d y  wi t h  t he 
i n vesti gat or a n d/ or site staff a n d bef ore a n y ot her st u d y  pr oce d ures if t he pat ie nt  is n ot a d versel y 
affecte d b y  t heir fast i n g c o n dit i o n. 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239787] of W ei g ht o n S elf -P er c e pti o n Q u e sti o n n air e 
T he I W -S P q uesti o n naire c o ntai ns 3 ite ms t hat assess h o w ofte n t he patie nts’ b o d y  w ei g ht affects 
h o w ha p p y  t h e y are wi t h  t h ei r a p peara nce a n d h o w ofte n t he y  f eel self -c o nsci o us w he n o ut i n 
p u blic ( Ha yes a n d De L ozier 2 0 1 5).  Eac h ite m is rate d o n a 5 -p oi nt scale ra n gi n g fr o m “al wa ys” 
t o “ ne ver.”  T otal sc ores f or t he I W -S P are deri ve d b y  s u m mi n g t he i t e m  sc ores a n d di vi di n g b y  
t h e n u m ber of ite ms.  T he sc ore ca n als o be tra nsf or me d t o a ra n ge fr o m 0t o 1 0 0.  Hi g her I W -S P 
sc ores c orres p o n d t o better self -perce pt i o n ( Ha y es a n d De L ozi er 2 0 1 5). 
9. 9. 2. A bilit y t o P erf or m P h y si c al A cti viti e s of D ail y Li vi n g 
T he A P P A D L q uest i o nnaire c o ntai ns [ADDRESS_1239788] i vit ies c o nsi dere d t o be i nte gral t o n or mal dail y life, s uc h as wal ki n g, sta n di n g ,a n d 
cli m bi n g stairs ( H a y es et al . 2 0 1 2).  Ite m s are sc ore d o n a 5 -p oi nt n u meric r ati n g scale, w here 
5 = “ n o t at all diffic ult” a n d 1 =“ u na ble t o d o.”  A ra w o verall sc ore is calc ulate d b y si m pl y 
s u m mi n g t he sc ores of t he [ADDRESS_1239789] i vit ies o f dail y li vi n g.  
9. 9. 3. E ur o p e a n Q u alit y of Lif e 
Ge neric heal t h -r el ate d q uali t y  of  l ife will be assesse d usi n g t he E Q - 5 D- 5 L 
(E ur o Q o L Gr o u p 2 0 1 5).  T he E Q - 5 D- 5 L is a sta n dar dize d 5-it e m  i nstr u me nt f or use as a 
meas ure of healt h o utc o me.  It pr o vi des a si m ple descri pt i ve pr ofile a n d a si n gle i n de x val ue f or 
healt h stat us t hat ca n be use d i n t he cli nical a n d ec o n o mic e val uat i o n of healt h care as well as 
p o p ul at i o n healt h s ur ve ys.  T he E Q - 5 D- 5 L c o m prises 5 di me nsi o ns of healt h ( m o bilit y, self -care, 
us ual act i vit ies, pai n/ disc o mf o rt, a n d a n xiet y/ de pressi o n ).  T he 5 L versi o n, i ntr o d uce d i n 2 0 0 5, 
sc ores eac h di me nsi o n at 5 le vels ( n o pr o ble ms, sli g ht pr o bl e ms, m o derate pr o ble ms, se vere 
pr o bl e ms, a n d u na ble t o perf or m/e xtre me pr o ble ms), f or a t otal of 3 12 5 p ossi ble healt h states.  I n 
a d di ti o n t o t he healt h pr ofile, a si n gle healt h state i n de x val ue ca n be deri ve d base d o n a f or m ula 
t h at attac hes w ei g hts t o eac h of t he le vels i n eac h di me nsi o n. T his i n de x val ue ra n ges bet wee n 
less t ha n 0 ( w here 0is a healt h state e q ui vale nt t o deat h; ne gati ve val ues are val ue d as w orse 
t h a n dea d) a n d 1 ( perfect healt h).   I n a d diti o n, t he E Q Vis ual A nal o g Scale rec or ds t he 
res p o n de nt ’s self -rate d heal t h  stat us o n a verti cal gra d uate d ( 0 t o 1 0 0) vis ual a n al o g scale.  I n 
c o nj u nct i o n wi t h  t he heal t h  state data ,it  pr o vi d es a c o m p osi te pi[INVESTIGATOR_886107] t he res p o n de nt’s healt h 
stat us. 
T he E Q - 5 D- 5 L is use d w orl d wi de a n d is a v aila ble i n m ore t ha n 1 20 differe nt la n g ua ges.  Details 
o n t he i nstr u me nt, a n d sc ori n g, or ga nizi n g, a n d prese nti n g t he data c ollecte d ca n be f o u n d i n t he 
E Q - 5 D- 5 L User G ui de ( E ur o Q o L Gr o u p 2 0 1 5). 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239790] e Si z e D et er mi n ati o n 
P ati e nts will  b e ra n d o mize d i n a 1: 1: 1: [ADDRESS_1239791] b o i n 
parallel relat i ve t o mea n c ha n ge fr o m baseli ne i n H b A 1c at 4 0 wee ks u n der t he f o ll o wi n g 
ass u m pt i o ns: 
use of [ADDRESS_1239792] t o c o m pare treat m e nt m ea ns utilizi n g H b A 1c data c ollecte d bef ore 
i nit iat i o n of a n y resc ue me dicat i o n a n d pre mat ure tre at m e nt disc o nt i n uat i o n; 
u p t o 2 5 % patie nts i n tirze pat i de ar ms a n d u p t o 3 5 % patie nts i n place b o ar m i nit iat i n g 
a n y resc ue me dicat i o n or pre mat ure treat me n t di sc o nti n uat i o n; 
at l east 0. 6 5 % ( place b o a dj uste d) mea n re d ucti o n i n H b A 1c f or t he ti rze pat i de d oses; a n d 
a c o m m o n sta n dar d de viat i o n ( S D) of 1. 1 %. 
O n t he basis of t hese ass u m pt i o ns, ra n d o mizi n g 4 7 2 patie nts usi n g a 1: 1: 1: 1 ra n d o mizat i o n rati o 
t o ti rze pat i de 5 m g ( 1 1 8 patie nts), tirze pati de 1 0 m g ( 1 1 8 patie nts), tirze pat i de 1 5 m g ( 1 1 8 
pati e nts), a n d pl ace b o ( 1 1 8 pati e nts ) will pr o vi de at l east 9 0 % p o wer t o esta blis h s u peri orit y  f or a 
ti rze pat i de d ose c o m pare d t o pl ace b o at a [ADDRESS_1239793] 9 0 % p o wer f or t he H b A 1c s u peri orit y  e val uat i o n utilizi n g all 
a vaila ble H b A 1c data at 4 0 wee ks wit h missi n g data i m p ute d wit h a c o nser vati ve m ult i ple 
i m p utati o n m et h o d (as descri be d i n t he E fficac y A nal yse s [ S ecti o n 1 0. 3. 3 ]bel o w ), pr o vi de d t hat 
t h e mea n re d ucti o n i n H b A 1c f or t he ti rze pat i de d oses is at least 0. 6 5 % ( place b o a dj uste d) a n d 
S D i ncreases t o n o m ore t ha n 1. 3 % d ue t o t he i ncl usi o n of data o n resc ue me d icat i o ns, i ncl usi o n 
of  data after pre mat ure treat me nt disc o nt i n uat i o n, a n d missi n g data i m p utati o n. 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e 6 1 
L Y 3 2 9 8 1 7 6 1 0. 2. P o p ul ati o n s f or A n al y s e s 
F or p ur p oses of a nal ysis, t he f oll o wi n g a nal ysis sets are defi ne d i n Ta ble G P G K . 4 .
T a bl e G P G K . 4. D e s cri pti o n of A n al y si s P o p ul ati o n a n d D at a S et s 
A n al ysis Set Descri pti o n 
Scree ne d patie nts All partici pa nts w h o si g n i nf or me d c o nse nt 
Ra n d o mize d patie nts All patie nts w h o are ra n d o ml y assi g ne d a treat me nt ar m 
m o difie d i nte nt -t o -treat ( mI T T) 
p o p ulati o nAll ra n d o ml y assi g ne d partici pa nts w h o are e x p ose d t o at least [ADDRESS_1239794] u g.  I n t he e ve nt of a treat me nt err or, partici pa nts will be a nal yze d acc or di n g 
t o t he treat me nt t he y were ra n d o mize d. 
Efficac y a nal ysis set ( E A S) Data o btai ne d d uri n g St u d y Peri o d II fr o m t he mI T T p o p ulati o n , e xcl u di n g 
data after i nitiati n g resc ue a nti h y per gl yce mic me dicati o n or st o p pi n g st u d y 
dr u g. 
F ull a nal ysis set ( F A S)  Data o btai ne d d uri n g St u d y Peri o d II fr o m t he mI T T p o p ulati o n , re gar dless of 
a d here nce t o st u d y dr u g or i nitiati o n of resc ue a nti h y per gl yce mic me dicati o n 
Safet y a nal y sis set ( S S) Data o btai ne d d uri n g St u d y Peri o dII or III fr o m t he mI T T p o p ulati o n , 
re gar d less of a d here nce t o st u d y dr u g or i nitiati o n of resc ue a nti h y per gl yce mic 
me dicati o n. 
[ADDRESS_1239795] ical a nal ysis pla n ( S A P) or t he cli nical st u d y  re p ort.  A d di ti o nal  e x pl or at or y  a nal yses o f t h e 
data ma ybe c o n d ucte d as dee me d a p pr o priate. 
U nless ot her wise n ote d, all tests of treat me nt effects will be c o n d ucte d at a 2 -si de d al p ha le vel of  
0. 0 5, a n d t he c o nfi de nce i nter val will be calc ulate d at 9 5 %, [ADDRESS_1239796] esti ma n d, t he “efficac y” esti ma n d, re prese nts efficac y pri or t o disc o nt i n uat i o n of st u d y  dr u g 
wi t h o ut c o nf o u n di n g effects of a nt i h y per gl yce mic resc ue t hera p y .  Sec o n d esti ma n d, t he 
“t reat m e nt -re gi me n” est i ma n d, re prese nts t he efficac y irres pect i ve of a d he re nce t o st u d y  dr u g or 
i nit iat i o n of resc ue a nti dia betic dr u gs. 
T he pri mar y  efficac y  assess me nt, g ui de d b y t he “efficac y” est i ma n d, will be c o n d ucte d usi n g t he 
efficac y  a n al ysis set ( E A S).  T he pri mar y  efficac y assess me nt, g ui de d b y  t he 
“t reat m e nt -re gi me n” est i ma n d, will be c o n d ucte d usi n g t he f ull a nal ysis set.  As t he y are 
i nt e n de d f or differe nt p ur p oses, n o m ult i plicit y a dj ust m e nts will be m a de f or c o n d ucti n g [ADDRESS_1239797] i ma n ds .
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239798] u g or i nit iat i o n of 
a nt i h y per gl yce mic resc ue t hera p y.  T h us, safet y a nal ysis will be c o n d ucte d usi n g t he safet y 
a nal ysis set ( S S ).   Selecte d safet y a nal yses ma y be c o n d ucte d after e xcl u di n g data o n resc ue 
t h era p y or data after starti n g a n ot her a nti h y per gl yce mic me dicat i o n. 
S u m mar y  statistics f or c o nti n u o us m eas ures will  i n cl u de sa m ple size, mea n, S D, me dia n, 
mi ni m u m, a n d ma xi m u m.  T he a nal ysis m o del t o ma ke c o m par is o ns a m o n g treat me nt gr o u ps 
r el at i ve t o c o nti n u o us meas ure me nts assesse d o ver ti me will be a mi xe d m o del f or re peate d 
meas ures ( M M R M) wit h ter ms: 
treat m e nt, 
visit, 
treat m e nt - b y- visit i nteracti o n, 
c o u ntr y , 
a n y past pri or use ( y es or n o) of a n y  or al  a nt i d ia betic me dicat i o n, 
baseli ne H b A 1c cate g or y [ ≤ 8. 5 % ( ≤ 6 9 m m o l/ m o l) or >8. 5 % ( > 6 9 m m o l/ m o l)] , 
a n d baseli ne meas ure me nt as a c o variate.  
F or a nal yses wi t h H b A 1c, t he baseli ne H b A 1c cate g or y  will  n ot be i ncl u de d i n t he m o d el . A n 
u nstr uct ure d c o varia nce str uct ure will m o del t he relat i o ns hi p of wit hi n -pat ie nt  err ors. 
T he Ka pla n -Meier m et h o d will be use d f or esti mati o n of c u m ulati ve e ve nt -free s ur vi val rates 
over ti me, a n d c o x pr o p orti o nal hazar ds re gressi o n a nal ysis will be use d t o c o m pare hazar d rates 
a m o n g treat m e nts. 
S u m mar y  statistics f or cate g orical meas ures (i ncl u di n g cate g orize d c o nti n u o us meas ures) will 
i ncl u de sa m ple size, fre q ue nc y, a n d perce nta ges. Fis her’s e xact test will be use d t o e xa mi ne t he 
treat m e nt differe nce i n cate g orical o utc o mes.  L o gistic re gressi o n ma y  be use d t o e xa mi ne t he 
treat m e nt differe nce i n bi nar y  efficac y  o utc o mes .  T he ne gati ve bi n o mial re gressi o n m o d el  will 
be use d f or t he tr eat me nt c o m paris o n of discrete c o u nt meas ures if dee me d a p pr o priate .
Ot her stati st ical met h o ds ma y be use d, as a p pr o priate, a n d details will be d oc u me nte d i n t he 
S A P. 
[ADDRESS_1239799] u d y ; pre mat urel y  disc o nti n ui n g t he st u d y i ncl u di n g t he 
reas o n f or pre mat ure disc o nt i n uat i o n; a n d pr e m at urel y  disc o nti n ui n g st u d y  dr u g i ncl u di n g t he 
reas o n f or pre mat ure disc o nt i n uat i o nof  st u d y  dr u g will be prese nte d b y tr eat m e nt gr o u ps.  A 
Ka pla n -Meier a nal yse s of ti me fr o m ra n d o mizat i o n t o pre m at ure di sc o nti n uat i o nfr o m st u d y  a n d 
pr e m at ure di sc o nti n uati o n f r o m  st u d y  dr u g b y treat me nt gr o u p will be pr o vi de d. 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239800] 7 5 % of re q uire d 
i nject i o ns o f st u d y  dr u gs.  Fre q ue nc y c o u nts a n d perce nta ges of pat ie nt s c o m plia nt t o st u d y  dr u g 
will be s u m marize d b y  tr e at m e nt ar ms usi n g t he mI T T p o p ulat i o n. 
1 0. 3. 3. Effi c a c y A n al y s e s 
1 0. 3. 3. 1. Pri m ar y A n al y s e s 
As i n dicate d i n Secti o n 1 0. 3. 1 , t here will be 2 pri mar y  efficac y a nal yses c o n d ucte d t o esta blis h 
s u peri ori t y of  ti rze pat i de 5m g, a n d/ or 1 0 m g,a n d / or [ADDRESS_1239801] b o relat i ve t o mea n c ha n ge 
i n H b A 1c val ues fr o m baseli ne t o t he 4 0 -wee k visit. 
F or t he F D A a n d p ossi bl y ot her re g ulat or y  a ge ncies , t he pri mar y  efficac y  a nal ysis will  b e g ui de d 
b y t he “treat me nt -re gi me n” est i ma n d defi ne d i n Secti o n 1 0. 3. 1 .  T his assess me nt will a nal yze 
c ha n ge i n H b A 1c val ues fr o m baseli ne o btai ne d at t he 4 0 -wee k visit usi n g a nal ysis o f c o vari a nce 
wi t h  t er m s: 
treat m e nt, 
c o u ntr y , 
a n y past pri or use ( y es or n o) of a n y  or al  a nt i d ia betic me dicat i o n, a n d 
baseli ne H b A 1c as a c o vari at e .  
Missi n g c ha n ge i n H b A [ADDRESS_1239802] u g a n d/ or 
i nit iat i o n of resc ue a nti h y per gl yce mic me dicat i o n.  A nal ysis will be c o n d ucte d wit h m ult i ple 
i m p utati o ns, a n d statistical i nfere nce o ver m ult i p le i m p utati o ns will be g ui de d b y  t he me t h o d 
pr o p ose d b y  R u bi n ( 1 9 8 7). 
F or t he P har mace uticals a n d Me dical De vices A ge nc y ( P M D A), t he pri mar y efficac y assess me nt 
will be g ui de d b y  t he “efficac y” est i ma n d, wit h c o ntr olli n g o verall fa mil y -wise t y pe [ADDRESS_1239803] ace b o i n H b A 1c c ha n ge fr o m baseli ne t o 4 0 wee ks. A d dit i o nal details will be pr o vi de d i n t he 
S A P. 
F or all ot her p ur p oses, t he pri mar y efficac y  a nal ysis will  b e g ui de d b y t he “efficac y” est i m a n d 
defi ne d i n Sect i o n 1 0. 3. 1 .  T his assess me nt will be c o n d ucte d usi n g E A S.  T he pri mar y a nal ysis 
m o d el  f or H b A 1c m eas ure me nts o ver ti me will be a M M R M.  T he res p o nse varia ble o f M M R M 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239804] pri or use ( y es or n o) of a n y oral a nt i d ia bet ic me dicat i o nas fi xe d 
effects, a n d baseli ne H b A 1c as a c o variate. 
Si nce t he y  are i nte n de d f or differe nt p ur p oses, eac h of t he [ADDRESS_1239805] t o t y pe 1 err or rate c o ntr ol are as f oll o ws: 
Su peri ori t y  of   ti rze pat i de d ose (s )t o place b o relati ve t o mea n c ha n ge i n b o d y wei g ht 
fr o m baseli ne t o t he 4 0 -wee k visit 
Su peri ori t y  of   ti rze pat i de d ose (s) t o place b o relati ve t o pr o p orti o n of pat ie nt s ac hie vi n g 
t h e tar get val ue of H b A 1c < 7 % ( < 5 3 m m o l/ m o l)  at t he 4 0 -wee k visit 
S u peri ori t y  of   ti rze pa ti de d ose (s) t o pl ace b o relati ve t o mea n c ha n ge i n F S G (ce ntral 
la b orat or y )at t h e 4 0 -wee k visit 
S u peri ori t y  of   ti rze pat i de d ose (s) t o pl ace b o relati ve t o pr o p orti o n of pat ie nt s ac hie vi n g 
t h e tar get val ue of H b A 1c < 5. 7 % ( < 3 9 m m o l/ m o l)  at t he 4 0 -wee k visi t
T he t y pe 1err or -c o nt r olle d strate g y f or t he pri mar y a n d sec o n dar y e n d p oi nts will be descri be d i n 
t h e S A P.  All t y pe I err or -c o ntr olle d sec o n dar y efficac y a nal yses will be c o n d ucte d relati ve t o 
b ot h esti ma n ds, t he “efficac y” est i ma n d a n d t he “treat me nt -re gi me n” est i ma n d se paratel y .
A nal ysis of c ha n ge fr o m baseli ne i n b o d y  wei g ht a n d F S G at t he 4 0 - wee k visit will be c o n d ucte d 
i n a m a n ner si milar t o t he pri mar y efficac y a nal yses wit h baseli ne H b A 1 C cate g or y  [ ≤ 8. 5 % ( ≤ 6 9 
m m o l/ m o l) or >8. 5 % ( > 6 9 m m o l/ m o l)] a d de d i n t he m o del , a n d baseli ne of  t he c orres p o n di n g 
varia ble as a c o variate .T he M M R M a nal yses were descri be d i n Sect i o n 1 0. 3. 1 . 
C o m paris o ns a m o n g treat m e nts relati ve t o t he pr o p orti o n of patie nts ac hie vi n g t he H b A 1c tar get 
val ue of  < 7. 0 % ( <5 3 m m o l/ m o l) a n d < 5. 7 % ( < 3 9 m m o l/ m o l) at t he 4 0 -wee k visit will be 
c o n d ucte d usi n g a l o gistic re gressi o n a nal ysis wit h ter ms :treat m e nt , c o u ntr y , a n d baseli ne 
H b A 1c as a c o variate.  I n t he a nal ysis of pat ie nt s ac hie vi n g t he H b A 1c tar get val ue relat i ve t o t he 
“efficac y” est i ma n d, patie nts wi t h  m issi n g val ues at t he 4 0 -wee k visit will be e xcl u de d.  I n t he 
a nal ysis of pat ie nt s ac hie vi n g t he H b A 1c tar get val ue re lati ve t o t he “treat me nt -re gi me n” 
esti ma n d, missi n g val ues at t he [ADDRESS_1239806] u g a n d/ or i nit iat i o n of resc ue me dicat i o n.  T he a nal ysis will be 
c o n d ucte d wit h m ult i ple i m p utati o ns a n d statist ic al i nfere nce o ver m ult i ple i m p utati o ns will be 
g ui de d b y  t he met h o d pr o p ose d b y  R u bi n ( 1 9 8 7). 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e 6 5 
L Y 3 2 9 8 1 7 6 1 0. 3. 3. 3. T erti ar y/ E x pl or at or y A n al y s e s 
All e x pl or at or y  effic ac y a nal yses will be g ui de d b y t he “efficac y” esti ma n d a n d will be 
c o n d ucte d usi n g t he E A S.  Details will be pr o vi de d i n t he S A P. 
[ADDRESS_1239807] i vit ies ( Me d D R A) a n d re p orte d wit h preferre d ter ms a n d s yste m or ga n class.  Selecte d
n ota bl e A Es of i nterest ma y be re p orte d u si n g hi g h -le vel ter ms or Sta n dar dize d Me d D R A 
Q ueri es.  S u m mar y  statistics will be pr o vi de d f or i nci de nce of T E A Es, S A Es, st u d y  
di sc o nti n uat i o n d ue t o A Es, st u d y  dr u g di sc o nt i n uati on d ue t o A Es, deat hs, a n d ot her C V 
e n d p o i nt s.  C o u nts a n d pr o p orti o ns of pat ie nt se x p eri e nci n g A Es will be re p orte d f or eac h 
treat m e nt gr o u p, a n d Fis her’s e xact test will be use d t o c o m pare t he treat me nt gr o u ps. 
[ADDRESS_1239808] ure will m o del 
r el at i o ns hi p of wit hi n -pat ie nt  err ors. 
T he perce nta ges of pat ie nt s wi t h T E a b n or mal, hi g h, or l o w la b orat or y  m eas ures at a n y  ti me will 
be s u m marize d a n d c o m pare d bet wee n treat me nt gr o u ps b y  usi n g Fis her’s e xact test.  A T E 
a b n or mal val ue i s defi ne d as a c ha n ge fr o m n or mal val ue at bas eli ne t o a val ue greater t ha n t he 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239809] u d y  P eri o ds II a n d III.   T he hi g h a n d l o w li mit s will be pr o vi de d i n t he S A P. 
1 0. 3. 5. P h ar m a c o ki n eti c/ P h ar m a c o d y n a mi c A n al y s e s 
Ti rze pati d e c o nce ntrati o n data will be a nal yze d usi n g a p o p ulat i o n P K a p pr oac h via n o n li near 
mi xe d -effects m o deli n g wi t h  t he N O N M E M s oft ware. T he relati o ns hi ps bet wee n ti rze pat i de 
d ose a n d/ or c o nce ntrati o n a n d efficac y , t ol era bili t y , a n d safet y e n d p o i nt s will be c haracterize d.   
A d dit i o nall y , t he i m pact of i ntri nsic a n d e xtri nsic patie nt fa ct ors s uc h as a ge, wei g ht, ge n der, a n d 
re nal f u nct i o n o n P K a n d/ or P D para meters ma y be e xa mi ne d as nee de d. If A D A ti ters are 
detecte d fr o m i m m u n o ge nicit y testi n g, t he n t he i m pact of i m m u n o ge nicit y ti t ers o n ti rze pat i de 
P K or a n y  r el e va nt P D para m et ers m ay als o be e xa mi ne d. 
[ADDRESS_1239810] i n g A D A, wit h T E A D A, a n d wit h 
ne utralizi n g T E A D A t o ti rze pat i de will be ta b ulate d b y  ti rze pat i de d ose . Treat me nt -e m er ge nt 
A D As are defi ne d as t h ose wit h a ti t er 2 -f o l d ( 1 dil uti o n) greater t ha n t he mi ni m u m re q uire d 
dil ut i o n if n o A D As were detecte d at baseli ne (treat me nt -i n d uce d A D A) or t h ose wit h a 4 -f o l d ( 2 
dil ut i o ns) i ncrease i n t it er c o m pare d t o baseli ne if A D As were detecte d at baseli ne 
(treat me n t- b o oste d A D A).  F or t he pati e nts wi t h TE A D A ,t h e di stri b uti o n of  m a xi m u m  ti ters 
will be descri be d.  The fre q ue nc y of ne utralizi n g a nt i b o dies t o ti rze pat i de a n d/ or cr oss -reacti ve 
a n d ne utralizi n g a nt i b o dies t o e n d o ge n o us c o u nter parts will be ta b ulate d i n pat ie nt s wi t h  T E 
A D A .
The relat i o ns hi p bet wee n t he prese nce of a nt i b o dies a n d ti rze pati d e P K a n d P D res p o nse 
i ncl u di n g safet y a n d efficac y t o ti rze pati d e ma ybe assesse d. 
[ADDRESS_1239811] ual a n d c ha n ge fr o m baseli ne i n patie nt -re p orte d o utc o me ( P R O) sc ores will be 
c o n d ucte d usi n g li near m o d el s wi t h  baseli ne P R O sc ores, treat me nt ,a n d ot her fact ors t hat ma y 
be c o nsi dere d rele va nt.  T hese varia bles will be s pecifie d i n t he S A P. 
1 0. 3. 7. 2. S u b gr o u p A n al y s e s 
S u b gr o u p a nal yses of mea n c ha n ge i n H b A 1c val ues fr o m baseli ne t o Visit 1 4will be pr o vi de d 
b y 
a ge, 
race, 
et h nicit y,  
ge n der, 
d urati o n of  di a betes, a n d 
baseli ne H b A 1c [( ≤ 8. 5 % ( ≤ 6 9 m m o l/ m o l) a n d >8. 5 % ( > 6 9 m m o l/ m o l) ]. 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239812] or, or desi g nee, will be c o ns ulte d t o 
deter mi ne w het her it is necessar y  t o a m e n d t he pr ot oc ol ( o nl y  f or u n pla n ne d efficac y  re vie w) .
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e 6 8 
L Y 3 2 9 8 1 7 6 1 1. R ef er e n c e s 
[ A D A] A merica n Dia betes Ass ociat i o n. 3 3. C o m pre he nsi ve Me dical E val uat i o n a n d 
Assess me nt of C o m or bi dit ies : sta n dar ds of m e dical Care i n dia betes 2 0 1 7. Di a betes C are. 
2 0 1 7; 4 0(s u p pl 1): S 2 5-S 3 2 .
[ A D A] A merica n Dia betes Ass ociat i o n. 6. Gl yce mic tar gets : s ta n dar ds of me dical Care i n 
dia betes —2 0 1 8 . Di a betes C are . 2 0 1 8; 4 1(s u p pl 1): S 5 5 -S 6 4. 
Al bert i K G, Zi m met P Z. Defi nit i o n, di a g n osis a n d cl assificat i o n of dia betes mellit us a n d its 
c o m plicat i o ns. Part 1: dia g n osis a n d classificat i o n of dia betes mellit us pr o visi o nal re p ort of a 
W H O c o ns ultati o n. Di a bet Me d. 1 9 9 8; 1 5( 7): 5 3 9 -5 5 3. 
Ar o da V R, Rat ner R. T he safet y a n d t ol era bilit y of G L P -1 rece pt or a g o nists i n t he treat me nt of 
t y pe 2 di a betes: a re vie w. Di a betes Met a b Res Rev 2 0 1 1 ;2 7( 6): [ADDRESS_1239813] of GI P re g ulati n g a di p ose tiss ue meta b o lis m i n h u ma ns. J Cli n 
E n d ocri n ol Met a b 2 0 1 6; 1 0 1: 3 1 5 5 - 3 1 6 2. 
Ba n ks P A, Free ma n M L. Practice g ui deli nes i n ac ute pa ncreatit is. A m J G astr oe nter ol. 
2 0 0 6; 1 0 1( 1 0): [ADDRESS_1239814] K B, C ui X, Briere D A, 
Ca brera O, R oell W C, K uc hi b h ot la U, M o yers J S, Be ns o n C T, Gi me n o R E, D’ Alessi o D A, 
Ha u pt A. L Y [ADDRESS_1239815] f or t h e treat m e nt of t y pe 2 
di a betes m elli t us: fr o m  disc o ver y  t o cli nical  pr o of  of  c o nce pt. M olec ul ar Met a b . 2 0 1 8 ; 1 8: [ADDRESS_1239816] o n P. A ra n d o mize d trial 
c o m pari n g t he rate of h y p o gl yce mia – assesse d usi n g c o nti n u o us gl uc ose m o nit ori n g – i n 1 2 5 
presc h o ol c hil dre n wit h t y pe 1 dia betes treate d wit h i ns uli n glar gi ne or N P H i ns uli n (t he 
P R E S C H O O L st u d y ). Pe di atr Di a betes . 2 0 1 3; 1 4( 8): 5 9 3 -6 0 1. 
Da vies MJ, D ’Alessi o D A, Fra d ki n J, Ker na n W N , Mat hi e u C, Mi n gr o ne G, R ossi n g P, Tsa pas 
A, We xler DJ, B use J B. Ma na ge me nt of hy per gl yce mia i n ty pe 2 dia betes, 2 0 1 8. A co nse ns us 
re p ort b y  t he A merica n Dia betes Ass ociat i o n ( A D A) a n d t he E ur o pea n Ass ociat i o n f o r t he 
St u d y of  Dia betes ( E A S D). Di a betes C are . 2 0 1 8 ; 4 1( 1 2): 2 6 6 9 -2 7 0 1. 
E ur o Q o L Gr o u p. E Q - 5 D- 5 L User g ui de: basic i nf o r m at i o n o n h o w t o use t he E Q - 5 D- 5 L 
i nstr u m e nt. Versi o n 2. 1. A vaila ble at: htt ps://e ur o q ol. or g/ w p -c o nt e nt/ u pl oa ds/ 2 0 1 6/ 0 9/ E Q - [ADDRESS_1239817], i n pat ie nt s wi t h  t y pe 2 di a betes: a ra n d o mise d, pl ace b o -c o ntr olle d a n d act i ve 
c o m p ar at or -c o nt r olle d p hase 2 trial. L a ncet. 2 0 1 8; 3 9 2( 1 0 1 6 0): [ADDRESS_1239818] of  Wei g ht o n 
Self -Perce pt i o ns Q uesti o n naire (I W -S P) i n i n di vi d uals wit h t y pe 2 dia betes a n d o besit y.  
Di a betes Tec h n ol T her . 2 0 1 5; 1 7( 3): 2 1 0 -2 1 4. 
H a y es R P, Nel s o n D R, Mel da hl M L, C urtis B H. A bilit y t o perf or m  dail y  p h ysical  a cti vi ti es i n 
i n di vi d uals wit h t y pe 2 di a betes a n d m o derate o besit y: a preli mi nar y vali dati o n o f t h e I m p a ct 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239819] i o n nai re. Di a betes Tec h n ol T her . 
2 0 1 1; 1 3( 7): [ADDRESS_1239820] i o n naire i n 
i n di vi d uals wit h t y pe 2 di a betes a n d o besit y.  Di a betes Tec h n ol T her . 2 0 1 2; 1 4( 1 2): 1 1 1 8 -1 1 2 5. 
I nz ucc hi S E, Ber ge nstal R M, B use J B, Dia ma nt M, Ferra n ni ni E, Na uc k M, Peters A L, Tsa pas 
A, We n der R, Matt he ws D R. Ma na ge me nt of h y per gl yce mia i n t y pe 2 dia betes, 2 0 1 5: a 
pati e nt -ce ntere d a p pr oac h: u p date t o a p osit i o n state m e nt of  t he A meri ca n Dia betes 
Ass oci at i o n a n d t he E ur o pea n Ass ociat i o n f o r t he St u d y  of  Dia betes. Di a betes C are. 
2 0 1 5; 3 8( 1): 1 4 0 - 1 4 9. 
K o iz u mi M, Ta ka da T, Ka wara da Y, Hirata K, Ma y u mi T, Y os hi da M, Se ki m ot o M, Hir ota M, 
Ki m ura Y, Ta ke da K, Isaji S, Ots u ki M, Mats u n o S; J P N. J P N G ui deli nes f or t he ma na ge me nt 
of  ac ute pa ncreatit is: dia g n ostic criteria f or ac ute pa ncreat it is. J He p at o bili ary P a ncre at S u r g .
2 0 0 6; 1 3( 1): 2 5 - 3 2. 
Na uc k M. I ncreti n t hera pi[INVESTIGATOR_014]: hi g hli g ht i n g c o m m o n feat ures a n d differe nces i n t he m o des of 
acti o n of  gl uca g o n -li ke pe pti de -1 a g o nists a n d di pe pti d yl pe pti dase -4 i n hi bit ors. Di a betes 
O bes Met a b. 2 0 1 6; 1 8( 3): 2 0 3 -2 1 6. 
Na uc k M A, Meier JJ. I ncret i n h or m o nes: their r ole i n healt h a n d disease. Di a betes O bes Met a b. 
2 0 1 8: 2 0( su p pl 1): 5 - 2 1. 
Na uc k M A, Meier JJ, Sc h mi dt W E. I ncreti n -base d gl uc ose -l o weri n g me dicat i o ns a n d t he ris k o f 
ac urte pa ncreatit is a n/ or pa ncreatic ca ncer: r e ass uri n g data fr o m car di o -vasc ular o utc o m e 
tri als. Di a betes O bes Met a b . 2 0 1 7; 1 9( 9): 1 3 2 7 -1 3 2 8. 
R u bi n D B. M ulti ple Im p ut ati o n f or No nres p o nse i n Surveys . Ne w Y or k: J o h n Wile y & S o ns I nc.; 
1 9 8 7. 
Stei n ber g W M, B use J B, G h or ba ni M L M, Ørste d D D , Na uc k M A; L E A D E R Steeri n g 
C o m mittee; L E A D E R Tri al I n vest i gat ors. A m ylase, li pase, a n d ac ute pa ncreat it is i n pe o ple 
wi t h  t y pe 2 dia betes treate d wit h lira gl ut i de: res ult s f r o m  t he L E A D E R ra n d o mize d tri al . 
Di a betes C are. 2 0 1 7a; 4 0( 7): [ADDRESS_1239821] of 
lir a gl ut i de o n a m ylase, li pase, a n d ac ute pa ncreat it is i n part ic i pa nts wi t h  o ver wei g ht/ o besi t y  
a n d n or m o gl yce mia, pre dia betes, or t y pe 2 di a betes: sec o n dar y  a nal yses of p o ol e d data fr o m 
t h e S C A L E cli nical de vel o p me nt pr o gra m . Di a betes C are. 2 0 1 7 b; 4 0( 7): 8 3 9 - 8 4 8 .
Wei n ber g M E, Bacc hetti P, R us ha k off RJ. Fre q ue nt l y re peate d gl uc ose m eas ure me nts 
o veresti mate t he i nci de nce of i n patie nt h y p o gl yce mia a n d se vere h y per gl yce mia. J Di a betes 
Sci Tec h n ol . 2 0 1 0; 4( 3): 5 7 7 - 5 8 2. 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e 7 0 
L Y 3 2 9 8 1 7 6 1 2. A p p e n di c e s 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239822] u g a nti b o d y 
A E a d verse e ve nt :  A n y u nt o war d me dical occ urre nce i n a patie nt or cli nical i n vesti gati o n 
patie nt a d mi nistere d a p har mace utical pr o d uct t hat d oes n ot necessaril y ha ve a ca usal 
relati o ns hi p wit h t his treat me nt.  A n a d verse e ve nt ca n t heref ore be a n y u nfa v ora ble a n d 
u ni nte n de d si g n (i ncl u di n g a n a b n or mal la b orat or y fi n di n g), s y m pt o m, or disease 
te m p oral l y  ass ociate d wit h t he use of a me dici nal (i n vesti gati o nal) pr o d uct, w het her or 
n ot relate d t o t he me dici nal (i n vesti gati o nal) pr o d uct. 
A L P al kali ne p h os p hatase 
A L T ala ni ne a mi n otra nsferase 
A N C O V A a nal y sis of c o varia nce 
A P P A D L A bilit y t o Perf or m P h ysical Acti vities of Dail y Li vi n g 
A S T as partate a mi n otra nsferase 
B G bl o o d gl uc ose 
bli n di n g/ m a s ki n g A d o u ble -bli n d st u d y is o ne i n w hi c h neit her t he patie nt n or a n y of t he i n vesti gat or or 
s p o ns or staff w h o are i n v ol ve d i n t he treat me nt or cli nical e val uati o n of t he patie nts are 
a ware of t he treat me nt recei ve d. 
B M I bo d y mass i n de x 
C E C cli nical e n d p oi nt c o m mittee 
C H F c o n gesti ve heart fail ure 
c o m pl ai nt A c o m plai nt is a n y writte n, electr o nic, or oral c o m m u nicati o n t hat alle ges deficie ncies 
relate d t o t he i de ntit y, q ualit y, p urit y, d ura bilit y, relia bilit y, safet y or effecti ve ness, or 
perf or ma nce of a dr u g or dr u g deli ver y s yste m. 
c o m pli a n c e A d here nce t o all st u d y -relate d g o o d cli nical practice ( G C P) a n d a p plica ble re g ulat or y 
re q uire me nts. 
C O VI D -1 9 C or o na vir us Disease 2 0 1 9 
C R P cli nical researc h p h ysicia n: I n di vi d ual res p o nsi ble f or t he me dical c o n d uct of t he st u d y.  
Res p o nsi bilities of t he C R P ma y be perf or me d b y a p h ysicia n, cli nical researc h 
scie ntist, gl o bal safet y p h ysicia n or ot her me dical officer. 
C T c o m p ute d t o m o gra p h y 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239823] u d y are 
t h ose w h o ha ve bee n assi g ne d t o a treat me nt. 
E Q -5 D -5 L E ur o pea n Q ualit y of Life -Di me nsi o ns 
E R B et hical re vie w b oar d 
E T earl y  ter mi nati o n 
F B G fasti n g bl o o d gl uc ose 
F S G fasti n g ser u m gl uc ose 
F S H f ollicle -sti m ulati n g h or m o ne 
GI gastr oi ntesti nal 
GI P gl uc ose -de pe n de nt i ns uli n otr o pic p ol y pe pti de 
G L P - 1 gl uca g o n -li ke pe pti de - 1 
H b A 1 c he m o gl o bi n A 1c 
I B I n vesti gat or’s Br oc h ure 
I C F i nf or me d c o nse nt f or m 
I nf or m e d c o n s e nt A pr ocess b y w h ic h a patie nt v ol u ntaril y c o nfir ms his or her willi n g ness t o partici pate 
i n a partic ular st u d y, after ha vi n g bee n i nf or me d of all as pects of t he st u d y t hat are 
rele va nt t o t he patie nt’s decisi o n t o partici pate.  I nf or me d c o nse nt is d oc u me nte d b y 
mea ns of a writte n, si g ne d, a n d date d i nf or me d c o nse nt f or m. 
i n v e sti g ati o n al 
pr o d u ct A p har mace utical f or m of a n acti ve i n gre die nt or place b o bei n g teste d or use d as a 
refere nce i n a cli nical trial, i ncl u di n g pr o d ucts alrea d y o n t he mar ket w he n use d or 
asse m ble d (f or m ulate d or pac ka ge d) i n a wa y differe nt fr o m t he a ut h orize d f or m, or 
mar kete d pr o d ucts use d f or a n u na ut h orize d i n dicati o n, or mar kete d pr o d ucts use d t o 
gai n f urt her i nf or mati o n a b o ut t he a ut h orize d f or m. 
I T T i nte nt t o treat:  T he pri nci ple t hat asserts t hat t he effect of a treat me nt p olic y ca n be best 
assesse d b y e val uati n g o n t he ba sis of t he i nte nt t o treat a patie nt (t hat is, t he pla n ne d 
treat me nt re gi me n) rat her t ha n t he act ual treat me nt gi ve n.  It has t he c o nse q ue nce t hat 
patie nts all o cate d t o a treat me nt gr o u p s h o ul d be f oll o we d u p, assesse d, a n d a nal yze d as 
me m bers of t hat gr o u p irres pecti ve of t heir c o m plia nce t o t he pla n ne d c o urse of 
treat me nt. 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239824] of Wei g ht o n Self -Perce pti o n 
M e d D R A Me dical Dicti o nar y f or Re g ulat or y Acti vities 
M E N 2 m ulti ple e n d ocri ne ne o plasia t y pe 2 
mI T T m o difie d i nte nt -t o -treat 
M M R M mi xe d m o del f or re peate d meas ures 
M RI ma g netic res o na nce i ma gi n g 
M T C me d ullar y t h yr oi d carci n o ma 
N A F L D n o nalc o h olic fatt y li ver disease 
O A M or al a nti h y per gl y ce mic me dicati o ns 
O T C o ver t he c o u nter 
p- a m yl a s e pa ncreatic a m ylase 
P G plas ma gl uc ose 
P K/ P D p har mac o ki netics/ p har mac o d y na mics 
P R O/ e P R O patie nt -re p orte d o utc o mes/electr o nic patie nt -re p o rte d o utc o mes 
Q W o nce wee kl y 
S A D si n gle asce n di n g d ose 
S A E seri o us a d verse e ve nt 
S A P statistical a nal ysis pla n 
S A R S -C o V - [ADDRESS_1239825] u d y. 
S D sta n dar d de viati o n 
S D P si n gle -d ose pe n 
S M B G self -m o nit ori n g of bl o o d gl uc ose 
S S safet y a nal ys is set 
S U S A R s s us pecte d u ne x pecte d seri o us a d verse reacti o ns 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e 7 4 
L Y 3 2 9 8 1 7 6 T 1 D M t y pe 1 dia betes mellit us 
T 2 D M t y pe 2 dia betes mellit us 
T B L t otal bilir u bi n le vel 
T E A E Treat me nt -e mer ge nt a d verse e ve nt:  A n u nt o war d me dical occ urre nce t hat e mer ges 
d uri n g a defi ne d treat me nt peri o d, ha vi n g bee n a bse nt pretreat me nt, or w orse ns relati ve 
t o t he pretreat me nt state, a n d d oes n ot necessaril y ha ve t o ha ve a ca usal relati o ns hi p 
wit h t his treat me nt. 
U L N u p per li mit of n or mal 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239826] s 
Cli nic al L a b or at or y Te sts a
He m at ol o g y Cli nic al C he mistr y 
He m o gl o bi n Ser u m C o nce ntr ati o ns of 
He mat ocrit S o di u m 
Er y t hr oc y te c o u nt ( R B C )
Mea n cell v ol u me P otassi u m 
Bicar b o nate 
Mea n cell he m o gl o bi n c o nce ntrati o n T otal bilir u bi n 
Le u k oc ytes ( W B C) Direct bilir u bi n 
Ne utr o p hils, se g me nte d Al kali ne p h os p hatase 
L y m p h oc y t es Ala ni ne a mi n otra nsferase ( A L T) 
M o n oc ytes As partate a mi n otra nsferase ( A S T) 
E osi n o p hils Bl o o d urea nitr o ge n ( B U N) 
Bas o p hils Creati ni ne 
Platelets Ur ic aci d 
Calci u m 
Gl uc ose , fasti n g b
Uri n al ysis 
Al b u mi n 
Creati ni ne Pre g n a nc y Test (fe males o nl y) c
F ollicle -sti m ulati n g h or m o ne ( F S H) d
Estra di ol c
H b A 1c 
E n d ocri ne e G F R (calc ulate d b y C K D -E PI e q uati o n) e
Fasti n g plas ma gl uca g o n 
Fasti n g ser u m Ins uli n 
Calcit o ni n 
Fasti n g C- pe pti de 
I m m u n o ge nicit y 
Tirze pati de a nti -dr u g a nti b o d y 
P K sa m ple f or i m m u n o ge nicit y P a ncre as (e x ocri ne) 
Ser u m pa ncreatic a m ylase 
Ser u m li pase 
N o n p h ar m ac o ge netic St ore d S a m ples 
E D T A plas ma 
Ser u m 
P [ADDRESS_1239827] ore d S a m ples 
S a m ples f or P h ar m ac o ki netic A n a l ysis Li pi d P a nel (f asti n g) 
T otal c h olester ol 
L D L 
H D L 
V L D L 
Tri gl yceri d es 
A b bre viati o ns :  C K D -E PI =C hr o nic Ki d ne y Disease -E pi [INVESTIGATOR_32450] o g y; E D T A =et h yle ne dia mi netetraacetic aci d; 
e G F R =esti mate d gl o mer ular filtrati o n rate; H b A 1c =he m o gl o bi n A 1c; H D L =hi g h -de nsit y li p o pr otei n; 
L D L =l o w -de nsit y  li p o pr otei n; R B C =re d bl o o d cells; V L D L =ver y l o w -de nsit y  li p o pr otei n; W B C =w h ite 
bl o o d cells. 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239828] u g(s) f o r w o me n of c hil d beari n g p ote ntial o nl y.  A d diti o nal pre g na nc y tests will be perf or me d at 
Visits 7, 1 2, a n d 1 4. Pr e g na nc y tests ma y be perf or me d at t he i n vesti gat or’s discreti o n d uri n g t he st u d y.  If re q uire d 
per l ocal re g ulati o ns a n d/ or i nstit uti o nal g ui d eli nes, pre g na nc y testi n g ca n als o occ ur at ot her ti mes d uri n g t he st u d y 
treat me nt peri o d 
dF ollicle -sti m ulati n g h or m o ne test perf or me d at Visit [ADDRESS_1239829] me n o pa usal state ( F S H ≥ 4 0 mI U/ m L a n d estra di ol 
< 3 0 p g/ m L). 
eEsti mate d gl o mer ular filtrati o n rate will be calc ulate d b y t he ce ntral la b ora t or y  a n d i ncl u de d i n la b or at or y res ult 
re p orts. 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239830] u d y  G o v er n a n c e C o n si d er ati o n s 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239831] i gat or is res p o nsi ble f or 
e ns uri n g t hat t he pati e nt u n dersta n ds t h e nat ure of t he st u d y , t he p ote ntial 
ri s ks a n d be nefits of partici pat i n g i n t he st u d y , a n d t hat t hei r p arti ci pat i o n is 
v o l u nt ar y .
e ns uri n g t hat i nf or me d c o nse nt is gi ve n b y eac h pati e nt or le gal 
re prese ntati ve.  T his i ncl u des o btai ni n g t he a p pr o priate si g nat ures a n d dates 
o n t he i nf or me d c o nse nt f or m ( I C F) pri or t o t he perf or ma nce o f a n y pr ot oc ol 
pr oce d ures a n d pri or t o t he a d mi nistrati o n of i n vesti gat i o nal pr o d uct. 
a ns weri n g a n y q uest i o ns t he pati ent  ma y ha ve t hr o u g h o ut t he st u d y  a n d 
s hari n g i n a t i mel y ma n ner a n y  n e w i nf or mat i o n t hat m a y  b e rele va nt t o t he 
pati e nt ’s willi n g ness t o c o nti n ue his or her partici pati o n i n t he st u d y .
e ns uri n g t hat a c o p y  of  t he I C F is pr o vi de d t o t he partici pa nt or t he 
part ic i pa nt’s le gal re prese ntati ve a n d is ke pt o n file. 
e ns uri n g t hat t he me dical rec or d i ncl u des a state me nt t hat writte n i nf or me d 
c o nse nt was o btai ne d bef ore t he partici pa nt was e nr olle d i n t he st u d y  a n d t he 
date t he writte n c o nse nt was o btai ne d. T he a ut h or ize d pers o n o btai ni n g t he 
i nf or m e d c o nse nt m ust al s o si g n t he I C F. 
A p p e n di x 3. 1. [ADDRESS_1239832] i gat or (or a n a p pr o pri ate l o c al  re prese ntati ve )m u st gi ve ass ura nce t hat t he et hical 
re vie w b oar d ( E R B) was pr o perl y  c o nsti t ute d a n d c o n ve ne d as re q uire d b y I nter nat i o nal C o u ncil 
f o r H ar m o nisat i o n (I C H) g ui deli nes a n d ot her a p plica ble la ws a n d re g ulati o ns. 
D oc u m e nt ati o n of  E R B a p pr o val  of  t he pr ot oc ol a n d t he I C F m u st be pr o vi de d t o Lill y  b ef ore t he 
st u d y  m a y  be gi n at t he i n vesti gati ve si te(s).  Lill y  or i ts re prese ntati ves m ust a p pr o ve t he I C F, 
i ncl u di n g a n y  c ha n ges ma de b y t he E R Bs, bef ore it is use d at t he i n vest i gat i ve site(s).  All I C Fs 
m ust be c o m plia nt wi t h  t he I C H g ui deli ne o n G o o d Cli nical Pract ice ( G C P ). 
T he st u d y  si te’s E R B(s) s h o ul d be pr o vi de d wi t h  t h e f ol l o wi n g: 
t h epr ot oc ol a n d relate d a me n d me nts a n d a d de n da ,c urre nt I n vest i gat or 
Br oc h ure ( I B ), a n d u p dates d uri n g t he c o urse of t he st u d y 
i n f o r m e d c o nse nt f or m  
ot her rele va nt d oc u m e nts ( f o r e xa m ple , c urri c ula vi t a e , a d verti se me nts) 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239833] u d y  will  be c o n d ucte d i n acc or da nce wit ht h e pr ot oc ol a n d wit h t h e
c o nse ns us et hics pri nci ples deri ve d fr o m i nt er n at i o nal et hics g ui deli nes, i ncl u di n g 
t h e Decl arat i o n of Helsi n ki a n d C o u ncil f o rI nter nati o nal Or ga nizati o ns of 
Me dical Scie nces (CI O M S ) I nter nati o nal Et hi c al G ui deli nes 
a p plica ble I C H G C P gui deli nes 
a p plica ble la ws a n d re g ulati o ns 
S o m e of  t he o bli gat i o ns of  t he s p o ns or will be assi g ne d t o a t hir d part y .
A p p e n di x 3. 1 . 5. I n v e sti g at or I nf or m ati o n 
P h ysicia ns wit h a s pecialt y i n dia betes/e n d ocri n ol o g y , i nter nal  m e dici ne, fa mil y  m e dici ne, 
ge neral me dici ne , or a n y  ot her s peci al t y  p h ysicia n w h o ha ve e x perie nce tre at i n g T [ADDRESS_1239834] u d y .
A p p e n di x 3. 1. 6. Pr ot o c ol Si g n at ur e s 
T he s p o ns or’s res p o nsi ble me dical o fficer will a p pr o ve t he pr ot oc ol, c o nfir mi n g t hat, t o t he best 
of  his or her k n o wle d ge, t he pr ot oc ol acc uratel y descri bes t he pla n ne d desi g n a n d c o n d uct of t he 
st u d y .
After rea di n g t he pr ot oc ol, eac h pri nci pal i n vest i gat or will si g n t he pr ot oc ol si g nat ure pa ge a n d 
se n d a c o p y  of  t he si g ne d pa ge t o a Lill y re prese ntati ve. 
A p p e n di x [ADDRESS_1239835] u d y  R e p ort ( C S R) c o or di nat i n g i n vesti gat or will si g n t he fi nal C S R f or t his st u d y, 
i n dicat i n g a gree me nt t hat, t o t he best of his or her k n o wle d ge, t he re p ort acc uratel y descri bes t he 
c o n d uct a n d res ults of t he st u d y. 
A q ualifie d i n vest i gat or will ser ve as t he C S R c o or di nat i n g i n vest i gat or.  If t his i n vest i gat or is 
u na ble t o f ulfill t his f u nct i o n, a n ot her i n vest i gat or will be c h ose n b y Lill y t o ser ve as t he C S R 
c o or di nat i n g i n vesti gat or. 
T he s p o ns or’s res p o nsi ble me dical o fficer a n d statisticia n will  a p pr o ve t he fi nal C S R f or t his 
st u d y , c o nfir mi n g t hat, t o t he best of his or her k n o wle d ge, t he re p ort acc uratel y descri bes t he 
c o n d uct a n d res ults of t he st u d y .
A p p e n di x 3. 2. D at a Q u alit y A s s ur a n c e 
T o e ns ure acc urate, c o m plete, a n d relia ble data, Lill y or its re prese ntati ves will d o t he f o ll o wi n g: 
pr o vi de i nstr ucti o nal materi al t o t he st u d y  si tes, as a p pr o priate 
pr o vi de s p o ns or start -u p trai ni n g t o i nstr uct t he i n vesti gat ors a n d st u d y  
c o or d i nat ors.  T his trai ni n g will gi ve i nstr ucti o n o n t he pr ot oc ol, t he c o m plet i o n 
of  t he C R Fs, a n d st u d y  pr oce d ures. 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e 8 0 
L Y 3 2 9 8 1 7 6 ma ke peri o dic visit s t o t he st u d y  si t e 
be a vaila ble f or c o ns ultati o n a n d sta y  i n c o ntact wit h t he st u d y  si te pers o n nel b y  
mail, tel e p h o ne, a n d/ or f a x 
re vie w a n d verif y  data re p orte d t o detect p ote ntial err ors 
I n a d dit i o n, Lill y or its re prese ntati ves will peri o dicall y c hec k a sa m ple of t he patie nt data 
rec or de d a gai nst s o urce d oc u me nts at t he st u d y  si t e .  T he st u d y  m a y  b e a u di t e d b y  Lill y or i ts 
re prese ntati ves a n d/ or re g ulat or y  a ge ncies at a n y  ti me.  I n vest i gat ors will be gi ve n n otice bef ore 
a n a u dit occ urs. 
T he i n vest i gat or will kee p rec or ds of all ori gi nal s o urce data.  T his mi g ht i ncl u de la b orat or y 
tests, m e dical rec or ds, a n d cli nical n otes. If re q ueste d, t he i n vest i gat or will pr o vi de t he s p o ns or, 
a p plica ble re g ulat or y  a ge ncies, a n d a p plica ble E R Bs wit h direct access t o ori gi nal s o urce 
d oc u m e nts. 
A p p e n di x 3. 2. 1. D at a C a pt ur e S y st e m 
T he i n vest i gat or is res p o nsi ble f or e ns uri n g t he acc urac y, c o m p lete ness, le gi bilit y,  a n d ti meli ness 
of  t he data re p orte d t o t he s p o ns or. 
A n electr o nic data ca pt ure s y st e m  ( E D C) will be use d i n t his st u d y  f or t he c ollect i o n of C R F 
data.  T he i n vesti gat or mai ntai ns a se parate s o urce f or t he data e ntere d b y  t he i n vest i gat or or 
desi g nee i nt o t he s p o ns or -pr o vi de d E D C s yste m.  T he i n vest i gat or is res p o nsi ble f or t he 
i de nt ificat i o n of a n y data t o be c o nsi dere d s o urce a n d f or t he c o nfir mat i o n t hat data re p orte d are 
acc urate a n d c o m plete b y  si g ni n g t he C R F .
A d dit i o nall y , cli nical  o ut c o m e assess me nt data (scales, self -re p orte d di ar y  data) will  be c ollecte d 
b y t he patie nt/i n vesti gat or site pers o n nel, via a pa per s o urce d oc u me nt ,a n d will be tra nscri be d 
b y t he i n vesti gat or site pers o n nel i nt o t he E D C s yste m. 
Data c ollecte d via t h e s p o ns or -pr o vi de d data ca pt ure s yste m (s) will be st ore d at t hir d parties. 
T he i n vest i gat or will ha ve c o nt i n u o us access t o t he data d uri n g t he st u d y a n d u nt il 
dec o m missi o ni n g of t he data ca pt ure s y st e m s.  Pri or t o dec o m missi o ni n g, t he i n vest i gat or will 
recei ve a n arc hi val c o p y  of  perti ne nt data f or rete nti o n. 
Data m a na ge d b y  a ce ntral  ve n d or, s uc h as la b orat or y  test data, will be st ore d electr o nicall y  i n 
t h e ce ntral  ve n d or’s data base s yste m ,a n d electr o nic tra nsfers will be pr o vi de d t o t he i n vest i gat or 
for re vie w a n d rete nt i o n.  Data will s u bse q ue ntl y be tra nsferre d fr o m t h e ce ntral  ve n d or t o t he 
Lill y data ware h o use. 
Data fr o m c o m p lai nt f or ms s u b mitte d t o Lill y will be e nc o de d a n d st ore d i n t he gl o bal pr o d uct 
c o m plai nt m a na ge me nt s y st e m .
A p p e n di x 3. 3. St u d y a n d Sit e Cl o s ur e 
A p p e n di x 3. 3. 1. Di s c o nti n u ati o n of St u d y Sit e s 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239836] u d y  I 8 R -M C -G P G K is descri be d i n t h e Cli nical Trial A gree me nt. 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239837] bilir u bi n He patitis E a nti b o d y, I g M 
Al kali ne p h os p hatase 
A L T A nti -n ucle ar a nti b o d y a
A S T 
G G T Al k ali ne ph os p h at ase is oe nz y mes a
C P K 
A nti -s m o ot h m uscle a nti b o d y ( or a nti -acti n a nti b o d y) a
A b bre viati o ns:  A L T = ala ni ne a mi n otra nsferase; A S T = as pi[INVESTIGATOR_337] a mi n otra nsferase; C P K = creati ni ne 
p h os p h o ki nase; G G T = ga m ma -gl uta m yl tra nsferase; I g = i m m u n o gl o b uli n; I N R = i nter nati o nal n or mali ze d 
rati o; R B C = re d bl o o d cells; W B C = w hite bl o o d cells 
aAssa y e d b y Lill y -desi g nate d or l ocal la b orat or y 
bRefle x/c o nfir mati o n de pe n de nt o n re g ulat or y re q uire me nts a n d/ or testi n g a vaila bilit y 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e 8 3 
L Y 3 2 9 8 1 7 6 A p p e n di x 5. W orl d H e alt h Or g a ni z ati o n 
Cl a s sifi c ati o n of Di a b et e s a n d Di a g n o sti c Crit eri a 
T y pe 1 Di a betes:   T y pe 1 di a betes is j u d ge d t o be prese nt w he n t he classical s y m pt o ms of 
di abetes (t hi rst, p ol y uri a, wast i n g a n d st u p or, or c o ma) are ass ociate d wit h rea dil y detecta ble 
c o nce ntrati o ns of gl uc ose a n d ket o ne b o dies i n t he bl o o d a n d uri ne.  I ns uli n treat me nt is 
necessar y  n ot o nl y t o c o ntr ol  h y per gl yce mia b ut als o t o pre ve nt s p o nta ne o us ket osis a n d deat h. 
T y pe 2 Di a betes:   T y pe 2 di a betes, al t h o u g h ofte n as y m pt o mat ic, ma y als o prese nt wit h 
cl assical h y per gl yce mic s y m pt o ms (t hirst, p ol y uria, wei g ht l oss), b ut des pi[INVESTIGATOR_040] h y per gl yce mia, 
ket o ne b o di es are prese nt i n o nl y l o w c o nce ntrati o ns i n t h e bl o o d a n d uri ne.  C o m a i s rare i n t y p e 
2 dia betes ,b ut m a y  r es ul t f r o m  e xtre m e h y per gl yce mia a n d h y per os m o larit y; la ctic aci d osis or 
ket oaci d osis ca n als o occ ur i n f ul mi nat i n g ill ness (f or e xa m ple, se vere i nfect i o n or m ese nteri c 
arter y  t hr o m b osis) d ue t o a n ac ute i ncrease i n i ns uli n re q uire me nts, b ut s p o nta ne o us ket osis d oes 
n ot occ ur.  S o me patie nts wit h t y pe 2 dia betes later pr o gress t o a state of a bs o l ut e i ns uli n 
deficie nc y ( Al bert i a n d Zi m met 1 9 9 8). 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e 8 4 
L Y 3 2 9 8 1 7 6 A p p e n di x 6. Cl a s sifi c ati o n of C o ntr a c e pti v e 
M et h o d s 
Hi g hl y Effecti ve Met h o ds of C o ntr ace pti o n: 
C o m bi ne d oral c o ntrace pti ve pi[INVESTIGATOR_4382] a n d mi ni pi[INVESTIGATOR_4382] 
N u va Ri n g 
I m pla nta ble c o ntrace pti ves 
I njecta ble c o ntrace pti ves (s uc h as De p o -Pr o vera ®)
I ntra uteri ne de vice (s uc h as Mire na ®a n d Para Gar d ®)
C o ntrace pti ve patc h –O N L Y w o me n < 1 9 8 p o u n ds or 9 0 k g 
T ot al  a bsti ne nce (if t his is t heir preferre d a n d us ual lifest yle) or i n a sa me -se x rel at i o ns hi p 
wi t h  n o se x ual  r el ati o ns hi p wi t h  m ales (as part of t heir preferre d a n d us ual lifest yle).  
N ote:  peri o dic a bst i ne nce ( f o r e xa m ple , c al e n dar, o v ul at i o n, s y m pt ot her mal, 
p ost o v ulat i o n met h o ds), declarat i o n of a bst i ne nce j ust f or t he d urati o n of a trial, a n d 
wi t h dra wal  are n ot acce pta bl e met h o ds of c o ntrace pti o n 
Vasect o m y  – f o r m e n i n cli nical st u dies 
Effecti ve Met h o ds of C o ntr ace pti o n ( m ust use c o m bi n ati o n of 2 met h o ds): 
Male c o n d o m wit h s per mici de 
Fe male c o n d o m wi t h  s per mici de 
Di a p hra g m  wi t h  s per mici de 
Cer vical s p o n ge 
Cer vical ca p wit h s per mici de 
Me n, re gar dless of t heir fertilit y stat us, wit h n o n pre g na nt w o me n of c hil d beari n g p ote ntial 
part ners m ust a gree t o eit her re mai n a bsti ne nt (if t his is t heir preferre d a n d us ual lifest yle) or use 
c o n d o ms pl us 1a d di ti o nal hi g hl y  effect i ve (less t ha n 1 % fail ure rate) m et h o d of c o ntrace pti o n 
(s uc h as c o m bi nat i o n oral  c o ntrace pti ves, i m pla nte d c o ntrace pti ves, or i ntra uteri ne de vice) or 
effect i ve met h o d of c o ntrace pti o n (s uc h as dia p hra g ms wit h s per mici de or cer vical s p o n ge) f or 
t h e d urati o n of t he st u d y  a n d f or at l east [ADDRESS_1239838] i mate d rele va nt p ote ntial e x p os ure i n w o me n of c hil d beari n g p ote ntial. 
Me n w h o are i n e xcl u si vel y sa me se x relat i o ns hi ps (as t heir preferre d a n d us ual lifest yle) are n ot 
re q ui re d t o use c o ntrace pti o n. 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239839] c u mf er e n c e 
T he f o ll o wi n g i nf or m at i o n has bee n a da pte d fr o m sta n dar dize d p h ysical meas ure me nt pr ot oc ols 
f o r t h e W orl d Healt h Or ga nizati o n’s S T E P wise a p pr oac h t o S ur veilla nce ( S T E P S) ( W H O 2 0 0 8) 
(A vaila ble at: htt p:// w w w. w h o.i nt/c h p/ste ps/ Part 3 _ Secti o n 3. p df ) Accesse d N o ve m ber 05, 2 0 1 8. 
Me as uri n g Hei g ht 
Ste p 1 .As k t he pati e nt t o re m o ve t heir f o ot wear a n d a n y hea d gear (li g ht hea d gear w or n f or 
reli gi o us reas o ns ca n re mai n, b ut t his s h o ul d be w or n b y t he patie nt at e ver y cli nic visit w he n 
t h ei r hei g ht is m eas ure d). 
Ste p 2 .As k t he pati e nt t o sta n d o n t he cali brate d hei g ht meas uri n g b oar d (sta di o met er) or a gai nst 
a wall wit h t heir feet t o get her a n d t heir k nees strai g ht wit h t heir heels a gai nst t he bac k b oar d ,t h e 
sta di o m eter or t he wall .
Ste p 3 .As k t he pati e nt t o l o o k strai g ht a hea d wi t h o ut til ti n g t heir hea d u p. 
Ste p 4 .As k t he pati e nt t o breat he i n a n d sta n d tall.  If usi n g a sta di o meter or fi xe d meas uri n g 
de vice, m o ve t he de vice’s meas ure me nt ar m ge nt l y d o w n o nt o t he t o p of t he patie nt’s hea d. 
Rec or d t he patie nt’s hei g ht i n ce nt i meters (c m). 
Me as uri n g Wei g ht 
B o d y wei g ht meas ure me nts s h o ul d be d o ne i n a c o nsiste nt ma n ner usi n g a cali brate d 
el e ctr o ni c scale ca pa ble of meas uri n g wei g ht i n kil o gra ms. 
All wei g hts f or a gi ve n patie nt s h o ul d be meas ure d usi n g t he sa me scale, w he ne ver p ossi ble, 
at a p pr o xi matel y t he sa me ti me i n t he m or ni n g after e vac uat i o n of bla d der c o nte nts .  
P ati e nts s h o ul d be li g ht l y cl ot h e d b ut n ot weari n g s h oes w hile t heir wei g ht is meas ure d. 
Ste p 1 .As k t he pati e nt t o re m o ve t heir f o ot wear, o uter wear (c oat, jac ket, etc), a n d a n y hea d gear 
(l i g ht  h ea d gear w or n f or reli gi o us reas o ns ca n re mai n, b ut t his s h o ul d be w or n b y  t he pat ie nt  at 
e ver y cli nic visit w he n wei g ht is meas ure d). 
Ste p [ADDRESS_1239840] d o n a fir m, flat, e ve n s urface ( n ot o n car pet ,o n a sl o pi n g 
s urface ,or a r o u g h, u ne v e n s urface). 
Ste p 3 .As k t he pati e nt t o ste p o n t o t he scal e wi t h  1 f o ot o n eac h si de of t he scale. 
Ste p 4 .As k t he pati e nt t o sta n d still wit h ar ms b y si des a n d t he n rec or d wei g ht i n kil o gra ms ( k g) 
t o t he nearest o ne- te nt h k g. 
Me as uri n g W aist Circ u mfere nce 
Waist circ u mfere nce s h o ul d be meas ure d at mi d p oi nt, bet wee n l o wer mar gi n o f le ast 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239841] (a p pr o xi matel y  1 i nc h ( 2. 5 4 c m ) a b o ve t he na vel). 
P ati e nts s h o ul d be li g ht l y cl ot h e d. 
Ste p 1 . As k t he patie nt t o sta n d wit h t heir feet cl ose t o get her, a n d ar m s at t hei r si de wi t h  t heir 
b o d y  wei g ht e ve nl y distri b ute d. 
Ste p 2 . As k patie nt t o rela x 
Ste p 3 . Meas ure me nts s h o ul d be rec or de d at t he e n d of a n or mal e x pi[INVESTIGATOR_20325] i o n. 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e [ADDRESS_1239842] o me c or o na vir us 2 ( S A R S -C o V - 2 ), t he vir us t h at ca uses t h e n o vel 
C O VI D -[ADDRESS_1239843] a 
pati e nt’s a bilit y a n d/ or willi n g ness t o atte n d t heir o nsite st u d y  visi t as ori gi nall y  sc he d ule d.  I n 
s uc h a sit uati o n, pl ease f o ll o w t he g ui da nce bel o w: 
1) P ati e nts s h o ul d c o m e f or t he pri mar y  e n d p oi nt visit ( Vi si t 1 4) at t he ori gi nall y pla n ne d 
4 0 - wee k ( ± 7 da ys) sc he d ule w he ne ver p ossi ble a n d safe t o d o s o, at t he i n vest i gat or's 
di scre ti o n.  H o we ver, i n or der t o ma xi mize t he a bilit y f o r o nsi te visi ts  f or Vi si t [ADDRESS_1239844] u d y, t he visit wi n d o w 
f o r Vi si t 1 4 m a y be br o u g ht f or war d n o s o o ner t ha n 1 4 da ys ( Wee k 3 8) or e xte n de d u p t o 
2 8 d a y s ( Wee k 4 4).  T he s u bse q ue nt safet y f o ll o w- u p visit ( Visit 8 0 1) s h o ul d ta ke place 
4wee ks ± 7 da y s after Vi si t 1 4.  
2) F or pati e nts re q ui ri n g a n e xte nsi o n f o r Visit [ADDRESS_1239845] u g u ni nterr u pte d d uri n g t he e xte n de d 
treat m e nt peri o d, t o e ns ure patie nt safet y, a n d t o mai ntai n t he o verall i nte grit y of  t h e tri al . 
3) A d dit i o nal c o nse nt fr o m t h e pati e nt per l o c al  re g ulati o ns will  b e o btai ne d f or t h ose 
pati e nts w h o will be dis pe nse d a d dit io nal I P d uri n g t he e xte n de d treat me nt peri o d. 
4) T he sites will nee d t o i de nt if y a n d d oc u me nt t he details of h o w all pat ie nt s a n d visits 
were affecte d b y C O VI D -[ADDRESS_1239846] i o ns. 
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e 8 8 
L Y 3 2 9 8 1 7 6 A p p e n di x 9. Pr ot o c ol A m e n d m e nt I 8 F -M C -G P G K( b) 
A R a n d o mi z e d, D o u bl e -bli n d , Pl a c e b o C o ntr oll e d Tri al 
C o m p ari n g t h e Effi c a c y  a n d S af et y  of T hr e e Tir z e p ati d e 
D o s e s v er s u s Pl a c e b o i n P ati e nt s wit h T y p e 2 Di a b et e s, 
I n a d e q u at el y  C o ntr oll e d wit h Di et a n d E x er ci s e A l o n e 
( S U R P A S S - 1) 
O v er vi e w 
Pr ot oc ol  I 8 F -M C -G P G K ti tl e d “ A Ra n d o mize d, D o u ble -bli n d, Pl ace b o -C o ntr olle d Trial 
C o m pari n g t he Efficac y a n d Safet y of  T hree Ti rze pati de D oses vers us Place b o i n Patie nts wit h 
T y pe 2 Di a betes, I na de q uatel y  C o ntr olle d wi t h  Diet a n d E xercise Al o ne ( S U R P A S S - 1) ” has 
bee n a me n de d.  T he ne w pr ot oc ol is i n dicate d b y  a m e n d me nt ( b) a n d will be use d t o c o n d uct t he 
st u d y  i n place of a n y prece di n g versi o n of t he pr ot oc ol. 
T he o verall c ha n ges a n d rati o nale f or t he c ha n ges ma de t o t his pr ot oc ol are descri be d i n t he 
f o ll o wi n g ta ble.   
I 8 F -M C -G P G K( b) Cli ni c al Pr ot o c ol P a g e 8 9 
L Y 3 2 9 8 1 7 6 A m e n d m e nt S u m m ar y f or Pr ot o c ol I 8 F -M C -G P G K A m e n d m e nt ( b) 
Secti o n # a n d N a me Descri pti o n of C h a n ge Brief R ati o n ale 
Secti o n [ADDRESS_1239847] u d y 
Pr oce d ures d ue t o 
the C O VI D -1 9 
Pa n de mic A n a p pe n di x was a d de d t o pr o vi de 
g ui da nce f or Visit 1 4 o n: 
1) A dj usti n g t he Visit 1 4 wi n d o w t o 
be br o u g ht f or war d n o s o o ner 
t ha n 1 4 da y s ( Wee k 3 8) or 
e xte n de d u p t o 2 8 da ys ( Wee k 
4 4), 
2) A d diti o nal I P dis pe nse d f or Visit 
1 4, a n d 
3) C o nse nt fr o m t he patie nts f or t he 
a d diti o nal I P nee de d f or Visit [ADDRESS_1239848] t he ti mi n g of Visit 1 4 ( pri mar y 
e n d p oi nt) a n d t o e ns ure patie nt safet y a n d trial 
i nte grit y. 
L e o  D o c u m e n t  I D  =  8 8 3 3 f 2 4 f - 6 d a 0 - 4 8 f f - b c 6 4 - c c 8 d 1 2 c c 1 b b 3 
A p p r o v e r :  
A p p r o v a l  D a t e  &  T i m e :  1 5 - A p r - 2 0 2 0  2 0 : 1 6 : 0 0  G M T 
S i g n a t u r e  m e a n i n g :  A p p r o v e d 
A p p r o v e r :  
A p p r o v a l  D a t e  &  T i m e :  1 5 - A p r - 2 0 2 0  2 2 : 0 4 : 0 1  G M T 
S i g n a t u r e  m e a n i n g :  A p p r o v e d P P D 
P P D 